10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the quarterly period ended February 1, 2025

or

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the transition period from ______ to ______

Commission file number 001-33731

METHODE ELECTRONICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	36-2090085
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
8750 West Bryn Mawr Avenue, Suite 1000, Chicago, Illinois	60631-3518
(Address of principal executive offices)	(Zip Code)

(Registrant’s telephone number, including area code) (708) 867-6777

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.50 Par Value	MEI	New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☒
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

At March 3, 2025, the registrant had 35,690,749 shares of common stock outstanding.

METHODE ELECTRONICS, INC.

INDEX

		Page
PART I.	FINANCIAL INFORMATION
Item 1.	Financial Statements
	Condensed Consolidated Statements of Operations (unaudited) - Three and Nine Months Ended February 1, 2025 and January 27, 2024	2
	Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) - Three and Nine Months Ended February 1, 2025 and January 27, 2024	3
	Condensed Consolidated Balance Sheets as of February 1, 2025 (unaudited) and April 27, 2024	4
	Condensed Consolidated Statements of Shareholders’ Equity (unaudited) - Three and Nine Months Ended February 1, 2025 and January 27, 2024	5
	Condensed Consolidated Statements of Cash Flows (unaudited) - Nine Months Ended February 1, 2025 and January 27, 2024	7
	Notes to Condensed Consolidated Financial Statements	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	27
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	36
Item 4.	Controls and Procedures	36
PART II.	OTHER INFORMATION
Item 1	Legal Proceedings	38
Item 1A.	Risk Factors	38
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	38
Item 5.	Other Information	38
Item 6.	Exhibits	40
SIGNATURES		41

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

METHODE ELECTRONICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

(in millions, except per share data)

	Three Months Ended						Nine Months Ended
	February 1, 2025			January 27, 2024			February 1, 2025			January 27, 2024
	(13 Weeks)			(13 Weeks)			(40 Weeks)			(39 Weeks)
Net sales	$	239.9		$	259.5		$	791.0		$	837.2
Cost of products sold		198.6			222.5			647.2			693.9
Gross profit		41.3			37.0			143.8			143.3
Selling and administrative expenses		37.7			33.9			126.5			119.3
Goodwill impairment		—			—			—			56.5
Amortization of intangibles		5.8			6.1			17.6			18.0
Loss from operations		(2.2	)		(3.0	)		(0.3	)		(50.5	)
Interest expense, net		5.5			5.0			16.5			12.2
Other expense, net		0.5			2.5			2.9			2.3
Pre-tax loss		(8.2	)		(10.5	)		(19.7	)		(65.0	)
Income tax expense		6.2			1.1			14.6			1.0
Net loss	$	(14.4	)	$	(11.6	)	$	(34.3	)	$	(66.0	)
Loss per share:
Basic	$	(0.41	)	$	(0.33	)	$	(0.97	)	$	(1.86	)
Diluted	$	(0.41	)	$	(0.33	)	$	(0.97	)	$	(1.86	)
Cash dividends per share	$	0.14		$	0.14		$	0.42		$	0.42

See notes to condensed consolidated financial statements.

2

METHODE ELECTRONICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)

(in millions)

	Three Months Ended						Nine Months Ended
	February 1, 2025			January 27, 2024			February 1, 2025			January 27, 2024
	(13 Weeks)			(13 Weeks)			(40 Weeks)			(39 Weeks)
Net loss	$	(14.4	)	$	(11.6	)	$	(34.3	)	$	(66.0	)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments		(15.5	)		13.7			(13.9	)		(9.0	)
Derivative financial instruments		2.0			(2.0	)		(0.6	)		(3.2	)
Other comprehensive (loss) income		(13.5	)		11.7			(14.5	)		(12.2	)
Comprehensive (loss) income	$	(27.9	)	$	0.1		$	(48.8	)	$	(78.2	)

See notes to condensed consolidated financial statements.

3

METHODE ELECTRONICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, except share and per share data)

	February 1, 2025			April 27, 2024
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	103.8		$	161.5
Accounts receivable, net		220.0			262.6
Inventories		218.8			186.2
Income tax receivable		4.2			4.0
Prepaid expenses and other current assets		22.7			18.7
Assets held for sale		2.7			4.7
Total current assets		572.2			637.7
Long-term assets:
Property, plant and equipment, net		208.6			212.1
Goodwill		167.4			169.9
Other intangible assets, net		235.7			256.7
Operating lease right-of-use assets, net		24.9			26.7
Deferred tax assets		34.3			34.7
Pre-production costs		40.0			44.1
Other long-term assets		21.5			21.6
Total long-term assets		732.4			765.8
Total assets	$	1,304.6		$	1,403.5
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	107.7		$	132.4
Accrued employee liabilities		29.4			38.0
Other accrued liabilities		42.3			46.0
Short-term operating lease liabilities		7.5			6.7
Short-term debt		0.2			0.2
Income tax payable		14.3			8.1
Total current liabilities		201.4			231.4
Long-term liabilities:
Long-term debt		327.7			330.7
Long-term operating lease liabilities		19.8			20.6
Long-term income tax payable		—			9.3
Other long-term liabilities		21.7			16.8
Deferred tax liabilities		29.7			28.7
Total long-term liabilities		398.9			406.1
Total liabilities		600.3			637.5
Shareholders' equity:
Common stock, $0.50 par value, 100,000,000 shares authorized, 37,004,282 shares and 36,650,909 shares issued as of February 1, 2025 and April 27, 2024, respectively		18.5			18.3
Additional paid-in capital		190.2			183.6
Accumulated other comprehensive loss		(51.2	)		(36.7	)
Treasury stock, 1,346,624 shares as of February 1, 2025 and April 27, 2024		(11.5	)		(11.5	)
Retained earnings		558.3			612.3
Total shareholders' equity		704.3			766.0
Total liabilities and shareholders' equity	$	1,304.6		$	1,403.5

See notes to condensed consolidated financial statements

4

METHODE ELECTRONICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (Unaudited)

(in millions, except share data)

	Three Months Ended February 1, 2025 (13 Weeks)
	Common stock shares		Common stock		Additional paid-in capital			Accumulated other comprehensive loss			Treasury stock			Retained earnings			Total shareholders' equity
Balance as of November 2, 2024		36,621,507	$	18.3	$	188.6		$	(37.7	)	$	(11.5	)	$	580.6		$	738.3
Issuance of restricted stock, net of tax withholding		382,775		0.2		(0.2	)		—			—			(3.0	)		(3.0	)
Stock-based compensation expense		—		—		1.8			—			—			—			1.8
Other comprehensive loss		—		—		—			(13.5	)		—			—			(13.5	)
Net loss		—		—		—			—			—			(14.4	)		(14.4	)
Dividends on common stock		—		—		—			—			—			(4.9	)		(4.9	)
Balance as of February 1, 2025		37,004,282	$	18.5	$	190.2		$	(51.2	)	$	(11.5	)	$	558.3		$	704.3

	Three Months Ended January 27, 2024 (13 Weeks)
	Common stock shares			Common stock			Additional paid-in capital			Accumulated other comprehensive loss			Treasury stock			Retained earnings			Total shareholders' equity
Balance as of October 28, 2023		37,034,050		$	18.5		$	183.8		$	(42.9	)	$	(11.5	)	$	697.0		$	844.9
Issuance of restricted stock, net of tax withholding		65,666			—			—			—			—			—			—
Cancellation of restricted stock		(144,000	)		(0.1	)		0.1			—			—			—			—
Purchases of common stock		(130,592	)		—			—			—			—			(3.0	)		(3.0	)
Stock-based compensation expense		—			—			(2.2	)		—			—			—			(2.2	)
Other comprehensive income		—			—			—			11.7			—			—			11.7
Net loss		—			—			—			—			—			(11.6	)		(11.6	)
Dividends on common stock		—			—			—			—			—			(4.8	)		(4.8	)
Balance as of January 27, 2024		36,825,124		$	18.4		$	181.7		$	(31.2	)	$	(11.5	)	$	677.6		$	835.0

See notes to condensed consolidated financial statements.

5

METHODE ELECTRONICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (Unaudited) (continued)

(in millions, except share data)

	Nine Months Ended February 1, 2025 (40 Weeks)
	Redeemable noncontrolling interest		Common stock shares			Common stock			Additional paid-in capital			Accumulated other comprehensive loss			Treasury stock			Retained earnings			Total shareholders' equity
Balance as of April 27, 2024	$	—		36,650,909		$	18.3		$	183.6		$	(36.7	)	$	(11.5	)	$	612.3		$	766.0
Issuance of restricted stock, net of tax withholding		—		568,698			0.3			(0.1	)		—			—			(3.5	)		(3.3	)
Cancellation of restricted stock		—		(79,325	)		—			—			—			—			—			—
Conversion of cash bonus to RSUs		—		—			—			2.1			—			—			—			2.1
Purchases of common stock		—		(136,000	)		(0.1	)		—			—			—			(1.5	)		(1.6	)
Stock-based compensation expense		—		—			—			4.6			—			—			—			4.6
Other comprehensive loss		—		—			—			—			(14.5	)		—			—			(14.5	)
Net loss		—		—			—			—			—			—			(34.3	)		(34.3	)
Dividends on common stock		—		—			—			—			—			—			(14.7	)		(14.7	)
Balance as of February 1, 2025	$	—		37,004,282		$	18.5		$	190.2		$	(51.2	)	$	(11.5	)	$	558.3		$	704.3

	Nine Months Ended January 27, 2024 (39 Weeks)
	Redeemable noncontrolling interest			Common stock shares			Common stock			Additional paid-in capital			Accumulated other comprehensive loss			Treasury stock			Retained earnings			Total shareholders' equity
Balance as of April 29, 2023	$	11.1			37,167,375		$	18.6		$	181.0		$	(19.0	)	$	(11.5	)	$	772.7		$	941.8
Issuance of restricted stock, net of tax withholding		—			255,120			0.1			(0.1	)		—			—			(3.8	)		(3.8	)
Cancellation of restricted stock		—			(144,000	)		(0.1	)		0.1			—			—			—			0.0
Purchase of redeemable noncontrolling interest		(11.1	)		—			—			—			—			—			—			—
Purchases of common stock		—			(453,371	)		(0.2	)		—			—			—			(10.6	)		(10.8	)
Stock-based compensation expense		—			—			—			0.7			—			—			—			0.7
Other comprehensive loss		—			—			—			—			(12.2	)		—			—			(12.2	)
Net loss		—			—			—			—			—			—			(66.0	)		(66.0	)
Dividends on common stock		—			—			—			—			—			—			(14.7	)		(14.7	)
Balance as of January 27, 2024	$	—			36,825,124		$	18.4		$	181.7		$	(31.2	)	$	(11.5	)	$	677.6		$	835.0

See notes to condensed consolidated financial statements.

6

METHODE ELECTRONICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

(in millions)

	Nine Months Ended
	February 1, 2025			January 27, 2024
	(40 Weeks)			(39 Weeks)
Operating activities:
Net loss	$	(34.3	)	$	(66.0	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization		42.5			43.3
Stock-based compensation expense		5.5			1.8
Amortization of debt issuance costs		0.8			0.5
Partial write-off of unamortized debt issuance costs		1.2			—
(Gain) loss on sale of assets		(0.3	)		0.6
Impairment of long-lived assets		0.4			0.7
Goodwill impairment		—			56.5
Change in deferred income taxes		(0.2	)		(4.0	)
Other		1.1			(0.2	)
Changes in operating assets and liabilities:
Accounts receivable		35.5			47.7
Inventories		(34.5	)		(47.1	)
Prepaid expenses and other assets		(0.4	)		(8.8	)
Accounts payable		(19.0	)		11.0
Other liabilities		(7.3	)		(13.4	)
Net cash (used in) provided by operating activities		(9.0	)		22.6
Investing activities:
Purchases of property, plant and equipment		(32.5	)		(41.1	)
Proceeds from settlement of net investment hedge		3.1			0.6
Proceeds from disposition of assets		2.7			1.5
Net cash used in investing activities		(26.7	)		(39.0	)
Financing activities:
Taxes paid related to net share settlement of equity awards		(3.5	)		(3.8	)
Repayments of finance leases		(0.2	)		(0.2	)
Debt issuance costs		(1.8	)		—
Purchases of common stock		(1.6	)		(10.8	)
Cash dividends		(15.3	)		(15.0	)
Purchase of redeemable noncontrolling interest		—			(10.9	)
Proceeds from borrowings		60.0			232.9
Repayments of borrowings		(54.2	)		(207.2	)
Net cash used in financing activities		(16.6	)		(15.0	)
Effect of foreign currency exchange rate changes on cash and cash equivalents		(5.4	)		(2.7	)
Decrease in cash and cash equivalents		(57.7	)		(34.1	)
Cash and cash equivalents at beginning of the period		161.5			157.0
Cash and cash equivalents at end of the period	$	103.8		$	122.9
Supplemental cash flow information:
Cash paid during the period for:
Interest	$	17.5		$	12.7
Income taxes, net of refunds	$	17.6		$	17.0
Operating lease obligations	$	6.9		$	6.9

See notes to condensed consolidated financial statements.

7

METHODE ELECTRONICS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

Note 1. Description of Business and Summary of Significant Accounting Policies

Description of business

Methode Electronics, Inc. (the “Company” or “Methode”) is a leading global supplier of custom engineered solutions with sales, engineering and manufacturing locations in North America, Europe, Middle East and Asia. The Company designs, engineers and produces mechatronic products for Original Equipment Manufacturers (“OEMs”) utilizing its broad range of technologies for user interface, light-emitting diode (“LED”) lighting system, power distribution and sensor applications.

The Company’s solutions are found in the end markets of transportation (including automotive, commercial vehicle, e-bike, aerospace, bus and rail), cloud computing infrastructure, construction equipment and consumer appliance.

Basis of presentation

The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). All intercompany balances and transactions have been eliminated in consolidation. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. These interim condensed consolidated financial statements include all adjustments (consisting of normal recurring adjustments, except as otherwise disclosed) that management believes are necessary for a fair presentation of the results of operations, financial position and cash flows of the Company for the interim periods presented. These financial statements should be read in conjunction with the consolidated financial statements included in the Company’s Form 10-K for the year ended April 27, 2024, filed with the SEC on July 11, 2024. Results may vary from quarter to quarter for reasons other than seasonality.

Financial reporting periods

The Company’s fiscal year ends on the Saturday closest to April 30 of the following year, typically resulting in a 52-week year, but occasionally giving rise to an additional week, resulting in a 53-week year. The current fiscal year ending May 3, 2025 is a 53-week fiscal year, with the additional week being included in the second fiscal quarter. The three months ended February 1, 2025 and January 27, 2024 were 13-week periods, while the nine months ended February 1, 2025 and January 27, 2024 were 40 and 39-week periods, respectively.

Use of estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. These estimates and assumptions are subject to an inherent degree of uncertainty and may change, as new events occur, and additional information is obtained. As a result, actual results may differ from previously estimated amounts, and such differences may be material to the condensed consolidated financial statements. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the period they occur.

Accounting pronouncements not yet adopted

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which requires entities to provide disclosures about their reportable segments’ significant expenses on an interim and annual basis. The updated standard is effective for the Company’s annual periods beginning in fiscal 2025 and interim periods beginning in the first quarter of fiscal 2026. Early adoption is permitted. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures.

In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU No. 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU No. 2023-09 will become effective for the Company in the first quarter of fiscal 2026 and will be applied on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on its financial statement disclosures.

In November 2024, the FASB issued ASU 2024-03, “Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures.” ASU 2024-03 requires public entities to disclose more detailed information about certain costs and expenses presented in the income statement, including inventory purchases, employee compensation, selling expenses and depreciation. ASU 2024-03 will become effective for the Company’s annual periods beginning in fiscal 2028. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on its financial statement disclosures.

8

There have been no other newly issued or newly applicable accounting pronouncements that have had, or are expected to have, a material impact on the Company’s condensed consolidated financial statements. Further, at February 1, 2025, there are no other pronouncements pending adoption that are expected to have a material impact on the Company’s condensed consolidated financial statements.

Summary of significant accounting policies

The Company’s significant accounting policies are described in Note 1, “Description of Business and Summary of Significant Accounting Policies,” to the consolidated financial statements included in the Company’s Form 10-K for the year ended April 27, 2024. There have been no material changes to the significant accounting policies in the nine months ended February 1, 2025.

Foreign currency translation.

The functional currencies of the majority of the Company’s foreign subsidiaries are their local currencies. The results of operations of these foreign subsidiaries are translated into U.S. dollars using average monthly rates, while the assets and liabilities are translated using period-end exchange rates. The resulting translation adjustments are recorded as a component of accumulated other comprehensive income (loss) (“AOCI”). Gains and losses arising from transactions denominated in a currency other than the functional currency, except certain long-term intercompany transactions, are included in the condensed consolidated statements of operations in other expense, net. Net foreign exchange loss was $1.3 million in the three months ended February 1, 2025, compared to $2.8 million in the three months ended January 27, 2024. Net foreign exchange loss was $3.6 million in the nine months ended February 1, 2025, compared to $2.2 million in the nine months ended January 27, 2024.

Note 2. Revenue

The Company generates revenue from manufacturing products for customers in diversified global markets under multi-year programs. Typically, these programs do not reach the level of a performance obligation until the Company receives either a purchase order and/or a materials release from the customer for a specific quantity at a specified price, at which point an enforceable contract exists. Contracts may also provide for annual price reductions over the production life of a program, and prices may be adjusted on an ongoing basis to reflect changes in product content/cost and other commercial factors. Sales and other taxes collected concurrent with revenue-producing activities are excluded from revenue.

The majority of the Company’s revenue is recognized at a point in time. The Company has determined that the most definitive demonstration that control has transferred to a customer is physical shipment or delivery, depending on the contractual shipping terms, except for consignment transactions. Consignment transactions are arrangements where the Company transfers product to a customer location but retains ownership and control of such product until it is used by the customer. Revenue for consignment arrangements is recognized upon the customer’s usage. The Company’s revenue also includes customer cost recoveries, which represent reimbursements the Company receives from customers for incremental costs associated with spot purchases of raw materials and premium freight incurred in fulfilling its performance obligation to the customer. Given these cost recoveries are generally negotiated after contract inception, the Company accounts for these cost recoveries as a modification to the existing contract. The Company recognizes cost recoveries as revenue when (or as) the remaining performance obligations per the contract are satisfied, or on the modification date if all performance obligations under the contract have been previously satisfied.

Revenue associated with products which the Company believes have no alternative use (such as highly customized parts), and where the Company has an enforceable right to payment, are recognized on an over time basis. Revenue is recognized based on progress to date, which is typically even over the production process through transfer of control to the customer.

The Company’s payment terms with its customers are typically 30-45 days from the time control transfers. As the Company’s standard payment terms are less than one year, the Company has elected the practical expedient under Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers” to not assess whether a contract has a significant financing component.

Contract balances

The Company receives payment from customers based on the contractual billing schedule and specific performance requirements established in the contract. Billings are recorded as accounts receivable when an unconditional right to the contractual consideration exists. A contract asset is an entity’s right to consideration in exchange for goods or services that the entity has transferred to a customer. A contract liability exists when an entity has received consideration, or the amount is due from the customer in advance of revenue recognition. Contract assets and contract liabilities are recognized in other current assets and other accrued liabilities, respectively in the condensed consolidated balance sheets and were immaterial as of February 1, 2025 and April 27, 2024.

9

Disaggregated revenue information

The following table represents a disaggregation of revenue from contracts with customers by segment and geographical location. Net sales are attributed to regions based on the location of production. Though revenue recognition patterns and contracts are generally consistent, the amount, timing and uncertainty of revenue and cash flows may vary in each reportable segment due to geographic and economic factors.

	Three Months Ended February 1, 2025 (13 Weeks)
(in millions)	Automotive		Industrial		Interface		Medical		Total
Geographic net sales:
North America	$	51.8	$	38.6	$	12.3	$	—	$	102.7
Europe, the Middle East & Africa ("EMEA")		55.9		41.4		—		—		97.3
Asia		8.0		31.9		—		—		39.9
Total net sales	$	115.7	$	111.9	$	12.3	$	—	$	239.9
Timing of revenue recognition:
Goods transferred at a point in time	$	111.8	$	111.9	$	12.3	$	—	$	236.0
Goods transferred over time		3.9		—		—		—		3.9
Total net sales	$	115.7	$	111.9	$	12.3	$	—	$	239.9

	Three Months Ended January 27, 2024 (13 Weeks)
(in millions)	Automotive		Industrial		Interface		Medical		Total
Geographic net sales:
North America	$	56.7	$	45.6	$	12.7	$	—	$	115.0
EMEA		52.0		37.5		—		—		89.5
Asia		31.0		24.0		—		—		55.0
Total net sales	$	139.7	$	107.1	$	12.7	$	—	$	259.5
Timing of revenue recognition:
Goods transferred at a point in time	$	136.6	$	107.1	$	12.7	$	—	$	256.4
Goods transferred over time		3.1		—		—		—		3.1
Total net sales	$	139.7	$	107.1	$	12.7	$	—	$	259.5

	Nine Months Ended February 1, 2025 (40 Weeks)
(in millions)	Automotive		Industrial		Interface		Medical		Total
Geographic net sales:
North America	$	187.8	$	133.8	$	40.2	$	—	$	361.8
EMEA		181.7		129.5		—		—		311.2
Asia		26.5		91.5		—		—		118.0
Total net sales	$	396.0	$	354.8	$	40.2	$	—	$	791.0
Timing of revenue recognition:
Goods transferred at a point in time	$	387.2	$	354.8	$	40.2	$	—	$	782.2
Goods transferred over time		8.8		—		—		—		8.8
Total net sales	$	396.0	$	354.8	$	40.2	$	—	$	791.0

	Nine Months Ended January 27, 2024 (39 Weeks)
(in millions)	Automotive		Industrial		Interface		Medical		Total
Geographic net sales:
North America	$	194.4	$	137.6	$	39.6	$	2.3	$	373.9
EMEA		153.9		131.4		—		—		285.3
Asia		104.0		73.9		—		0.1		178.0
Total net sales	$	452.3	$	342.9	$	39.6	$	2.4	$	837.2
Timing of revenue recognition:
Goods transferred at a point in time	$	440.7	$	342.9	$	39.6	$	2.4	$	825.6
Goods transferred over time		11.6		—		—		—		11.6
Total net sales	$	452.3	$	342.9	$	39.6	$	2.4	$	837.2

10

Note 3. Disposition

In the first quarter of fiscal 2024, the Company made the decision to initiate the discontinuation of the Dabir business in the Medical segment. In fiscal 2024, the Company sold certain assets and contracts of its Dabir business to a third party for consideration of $1.5 million and recorded a loss on the sale, including transaction costs, of $0.6 million. The discontinuation of the Dabir business does not qualify as a discontinued operation as it does not represent a strategic shift that will have a major effect on the Company’s operations or financial results.

Note 4. Income Taxes

For the three and nine months ended February 1, 2025, the Company utilized the discrete effective tax rate method, treating the year-to-date period as if it was the annual period to calculate its interim income tax provision, as allowed by ASC 740-270-30-18, “Income Taxes-Interim Reporting.” The Company concluded it could not use the estimated annual effective tax rate method as it could not calculate a reliable estimate of the annual effective tax rate due to it being highly sensitive to minor changes in the forecasted amounts, thus generating significant variability in the estimated annual effective tax rate and distorting the customary relationship between income tax expense and pre-tax income in interim periods.

The Company’s income tax expense and effective tax rate for the three and nine months ended February 1, 2025 and January 27, 2024 were as follows:

	Three Months Ended						Nine Months Ended
	February 1, 2025			January 27, 2024			February 1, 2025			January 27, 2024
($ in millions)	(13 Weeks)			(13 Weeks)			(40 Weeks)			(39 Weeks)
Pre-tax loss	$	(8.2	)	$	(10.5	)	$	(19.7	)	$	(65.0	)
Income tax expense		6.2			1.1			14.6			1.0
Effective tax rate		(75.6	)%		(10.5	)%		(74.1	)%		(1.5	)%

The effective tax rate for the three and nine months ended February 1, 2025 differs from the U.S. federal statutory tax rate of 21% primarily due to an increase in a valuation allowance for U.S. deferred tax assets and an unfavorable impact from global intangible low-tax income (“GILTI”), partially offset by the impact of income derived from foreign operations with lower statutory tax rates. The effective tax rate for the three months ended January 27, 2024 differs from the U.S. federal statutory tax rate of 21% primarily due to the impact of income derived from foreign operations with lower statutory tax rates and research deductions claimed in foreign jurisdictions, offset by GILTI. The effective tax rate for the nine months ended January 27, 2024 differs from the U.S. federal statutory tax rate of 21% primarily due to an impairment of goodwill which is non-deductible for tax purposes, income derived from foreign operations with lower statutory tax rates and research deductions claimed in foreign jurisdictions, offset by GILTI.

As of February 1, 2025, the Company determined that recovery of some of its U.S. deferred tax assets was not more likely than not, and recorded a valuation allowance to income tax expense of $6.5 million for the three months ended February 1, 2025 and $14.0 million for the nine months ended February 1, 2025. The valuation allowance was recorded based on the evaluation of all available evidence.

The Organization for Economic Cooperation and Development’s (“OECD”) Pillar II Initiative introduced a 15% global minimum tax for certain multinational groups exceeding minimum annual global revenue thresholds. Some countries in which the Company operates have enacted legislation adopting the minimum tax effective January 1, 2024. To date, the Company has determined that there is an immaterial global minimum tax liability as a result of Pillar II, as certain tax jurisdictions either will not have Pillar II enacted until after December 31, 2024, or have satisfied the safe harbor test to prevent any minimum tax under Pillar II. The Company continues to monitor its jurisdictions for any changes and include any appropriate minimum tax throughout the fiscal year.

The Company’s gross unrecognized income tax benefits were $4.5 million and $4.4 million as of February 1, 2025 and April 27, 2024, respectively. If any portion of the Company’s unrecognized tax benefits is recognized, it would impact the Company’s effective tax rate. The unrecognized tax benefits are reviewed periodically and adjusted for changing facts and circumstances, such as tax audits, the lapsing of applicable statutes of limitations and changes in tax law. The Company recognizes interest and penalties related to income tax uncertainties in income tax expense. Accrued interest and penalties were $0.6 million and $0.4 million as of February 1, 2025 and April 27, 2024, respectively.

11

Note 5. Balance Sheet Components

Cash and cash equivalents

Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less. Highly liquid investments include money market funds which are classified within Level 1 of the fair value hierarchy. As of February 1, 2025 and April 27, 2024, the Company had a balance of $0.2 million and $73.2 million, respectively, in money market accounts.

Accounts receivable and allowance for doubtful accounts

Accounts receivable are customer obligations due under normal trade terms and are presented net of an allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts based on the current expected credit loss impairment model. The Company applies a historical loss rate based on historic write-offs to aging categories. The historical loss rate is adjusted for current conditions and reasonable and supportable forecasts of future losses as necessary. The Company may also record a specific reserve for individual accounts when it becomes aware of specific customer circumstances, such as in the case of a bankruptcy filing or deterioration in the customer’s operating results or financial position. The allowance for doubtful accounts balance was $2.7 million and $1.4 million as of February 1, 2025 and April 27, 2024, respectively.

Inventories

Inventories are stated at the lower-of-cost or net realizable value. Cost is determined using the first-in, first-out method. Finished products and work-in-process inventories include direct material costs and direct and indirect manufacturing costs. The Company records reserves for inventory that may be obsolete or in excess of current and future market demand. A summary of inventories is shown below:

(in millions)	February 1, 2025		April 27, 2024
Finished products	$	47.1	$	45.6
Work in process		24.1		16.1
Raw materials		147.6		124.5
Total inventories	$	218.8	$	186.2

Assets held for sale

The Company classifies long-lived assets to be sold as held for sale in the period in which all of the required criteria under ASC 360 “Property, Plant, and Equipment” are met. The Company initially measures a long-lived asset that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Upon determining that a long-lived asset meets the criteria to be classified as held for sale, the Company ceases depreciation and reports long-lived assets as “Assets held for sale” on the condensed consolidated balance sheets. Assets held for sale at April 27, 2024 consisted of three non-core real estate assets, two of which were sold in the nine months ended February 1, 2025. The two non-core real estate assets had an aggregate carrying value of $2.0 million and the Company recognized a gain of $0.3 million from these sales. The Company has accepted an offer for the asset held for sale at February 1, 2025, and currently expects the sale to be completed prior to the end of its fourth quarter ending May 3, 2025. The Company expects to recognize an immaterial gain from the sale of this non-core real estate asset.

Property, plant and equipment

Property, plant and equipment is stated at cost. Maintenance and repair costs are expensed as incurred. Depreciation is calculated using the straight-line method using estimated useful lives of 5 to 40 years for buildings and building improvements and 3 to 15 years for machinery and equipment. A summary of property, plant and equipment is shown below:

(in millions)	February 1, 2025			April 27, 2024
Land	$	3.3		$	3.3
Buildings and building improvements		98.4			98.5
Machinery and equipment		395.4			394.6
Construction in progress		48.1			50.4
Total property, plant and equipment, gross		545.2			546.8
Less: accumulated depreciation		(336.6	)		(334.7	)
Property, plant and equipment, net	$	208.6		$	212.1

Depreciation expense was $8.3 million and $8.8 million in the three months ended February 1, 2025 and January 27, 2024, respectively. Depreciation expense was $24.9 million and $25.3 million in the nine months ended February 1, 2025 and January 27, 2024, respectively. As of February 1, 2025 and April 27, 2024, capital expenditures recorded in accounts payable totaled $2.3 million and $6.1 million, respectively.

12

Pre-production tooling costs related to long-term supply arrangements

The Company incurs pre-production tooling costs related to products produced for its customers under long-term supply arrangements. Engineering, testing and other costs incurred in the design and development of production parts are expensed as incurred, unless the costs are reimbursable by the customer. As of February 1, 2025 and April 27, 2024, the Company had $40.0 million and $44.1 million, respectively, of pre-production tooling costs related to customer-owned tools for which reimbursement is contractually guaranteed by the customer or for which the customer has provided a non-cancelable right to use the tooling.

Costs for molds, dies and other tools used in products produced for its customers under long-term supply arrangements for which the Company has title are capitalized in property, plant and equipment and amortized over the shorter of the life of the arrangement or the estimated useful life of the assets. As of February 1, 2025 and April 27, 2024, Company-owned tooling was $12.5 million and $14.0 million, respectively.

Note 6. Goodwill and Other Intangible Assets

Goodwill

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. All of the Company’s goodwill is in the Industrial segment. A summary of the changes in the carrying amount of goodwill is shown below:

(in millions)	Total
Balance as of April 27, 2024	$	169.9
Foreign currency translation		(2.5	)
Balance as of February 1, 2025	$	167.4

A summary of goodwill by reporting unit is as follows:

(in millions)	February 1, 2025		April 27, 2024
Grakon Industrial	$	123.2	$	124.4
Nordic Lights		42.6		43.9
Other		1.6		1.6
Total	$	167.4	$	169.9

The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis as of the beginning of the fourth quarter each fiscal year. In addition, the Company continuously monitors for events and circumstances that could negatively impact the key assumptions used in determining fair value and therefore require interim goodwill impairment testing, including long-term revenue growth projections, profitability, discount rates, volatility in the Company's market capitalization, and general industry, market and macroeconomic conditions. No impairment indicators were identified in the third quarter of fiscal 2025.

October 28, 2023 goodwill impairment

During the three months ended October 28, 2023, the Company identified an impairment triggering event associated with a sustained decrease in the Company’s publicly quoted share price, market capitalization and lower than expected operating results. These factors suggested that the fair value of one or more of the Company’s reporting units may have fallen below their carrying amounts. As a result, the Company performed an interim quantitative impairment test and recognized a non-cash goodwill impairment charge of $56.5 million for two reporting units in its Automotive segment.

Other intangible assets, net

Details of identifiable intangible assets are shown below:

	As of February 1, 2025
(in millions)	Gross		Accumulated amortization			Net		Weighted average remaining useful life (years)
Amortized intangible assets:
Customer relationships and agreements	$	303.0	$	(96.5	)	$	206.5		14.2
Trade names, patents and technology licenses		74.4		(47.0	)		27.4		6.5
Total amortized intangible assets		377.4		(143.5	)		233.9
Unamortized trade name		1.8		—			1.8
Total other intangible assets	$	379.2	$	(143.5	)	$	235.7

13

	As of April 27, 2024
(in millions)	Gross		Accumulated amortization			Net		Weighted average remaining useful life (years)
Amortized intangible assets:
Customer relationships and agreements	$	306.6	$	(84.7	)	$	221.9		14.8
Trade names, patents and technology licenses		75.3		(42.3	)		33.0		6.9
Total amortized intangible assets		381.9		(127.0	)		254.9
Unamortized trade name		1.8		—			1.8
Total other intangible assets	$	383.7	$	(127.0	)	$	256.7

Based on the current amount of intangible assets subject to amortization, the estimated aggregate amortization expense for each of the five succeeding fiscal years and thereafter is as follows:

(in millions)
Fiscal Year:
Remainder of 2025	$	5.7
2026		22.3
2027		21.6
2028		19.3
2029		18.1
Thereafter		146.9
Total	$	233.9

Note 7. Derivative Instruments and Hedging Activities

The Company is exposed to various market risks including, but not limited to, foreign currency exchange rates and market interest rates. The Company strives to control its exposure to these risks through our normal operating activities and, where appropriate, through the use of derivative financial instruments. Derivative financial instruments are measured at fair value on a recurring basis using various pricing models that incorporate observable market parameters, such as interest rate yield curves and foreign currency rates and are classified as Level 2 within the fair value hierarchy.

For a designated cash flow hedge, the effective portion of the change in the fair value of the derivative financial instrument is recorded in AOCI in the condensed consolidated balance sheets. When the underlying hedged transaction is realized, the gain or loss previously included in AOCI is recorded in earnings and reflected in the condensed consolidated statements of operations on the same line as the gain or loss on the hedged item attributable to the hedged risk. The gain or loss associated with changes in the fair value of derivatives not designated as hedges are recorded immediately in the condensed consolidated statements of operations on the same line as the associated risk. For a designated net investment hedge, the effective portion of the change in the fair value of the derivative financial instrument is recorded as a cumulative translation adjustment in AOCI in the condensed consolidated balance sheets.

Net investment hedges

The Company is exposed to the risk that adverse changes in foreign currency exchange rates could impact its net investment in non-U.S. subsidiaries. To manage this risk, the Company designates certain qualifying derivative and non-derivative instruments, including cross-currency swaps and foreign currency-denominated debt, as net investment hedges of certain non-U.S. subsidiaries.

The Company had a fixed-rate, cross-currency swap, with a notional value of $60.0 million (€54.8 million), that settled in December 2024 with a gross gain of approximately $3.1 million. The cross-currency swap was designated as a hedge of the Company’s net investment in a euro-based subsidiary. The gain will remain in AOCI until the hedged net investment is sold or substantially liquidated.

Hedge effectiveness is assessed at the inception of the hedging relationship and quarterly thereafter, under the spot-to-spot method. The Company recognizes the impact of all other changes in fair value of the derivative, which represents the interest rate differential of the cross-currency swap, through interest expense. For the three months ended February 1, 2025 and January 27, 2024, the Company recorded a loss of $0.1 million and zero, respectively, in interest expense, net in the condensed consolidated statements of operations. For the nine months ended February 1, 2025 and January 27, 2024, the Company recorded gains of $0.4 million and $1.1 million, respectively, in interest expense, net in the condensed consolidated statements of operations.

14

The Company has €275.0 million of long-term borrowings under its Amended Credit Agreement (see Note 8 “Debt”) which was designated as a net investment hedge of the foreign currency exposure of its investment in its euro-denominated subsidiaries. On December 18, 2024, the Company de-designated these long-term borrowings as a net investment hedge. As of December 18, 2024, the cumulative gain, net of tax, was $9.0 million which will remain in AOCI until there is a substantial liquidation of the Company’s net investment of its euro-denominated subsidiaries. Due to changes in the value of the euro-denominated long-term borrowings designated as a net investment hedge, in the three months ended February 1, 2025 (through the date of de-designation) and January 27, 2024, a gain, net of tax, of $7.7 million and loss, net of tax, of $5.9 million, respectively, were recognized within the currency translation section of other comprehensive income (loss). In the nine months ended February 1, 2025 (through the date of de-designation) and January 27, 2024, a gain, net of tax, of $4.8 million and $1.4 million, respectively, were recognized within the currency translation section of other comprehensive income (loss). Included in AOCI related to this net investment hedge were cumulative gains of $9.0 million and $4.2 million, respectively, as of February 1, 2025 and April 27, 2024. The Company is now managing the related foreign exchange risk of its €275.0 million of long-term borrowings not designated as a net investment hedge through certain Euro denominated financial assets.

Interest rate swaps

The Company utilizes interest rate swaps to limit its exposure to market fluctuations on its variable-rate borrowings. The interest rate swaps effectively convert a portion of the Company's variable rate borrowings to a fixed rate based upon a determined notional amount. The Company has an interest rate swap, maturing on October 31, 2027, with a notional value of $137.0 million (€132.0 million). The interest rate swaps are designated as cash flow hedges.

Hedge effectiveness is assessed at the inception of the hedging relationship and quarterly thereafter. The effective portion of the periodic changes in fair value is recognized in AOCI in the condensed consolidated balance sheets. Subsequently, the accumulated gains and losses recorded in AOCI are reclassified to income in the period during which the hedged cash flow impacts earnings, which are expected to be immaterial over the next 12 months. No ineffectiveness was recognized in the three or nine months ended February 1, 2025 and January 27, 2024.

Derivatives not designated as hedges

The Company uses short-term foreign currency forward contracts to reduce the earnings impact that exchange rate fluctuations have on non-functional currency balance sheet exposures. These forward contracts are not designated as hedging instruments. Gains and losses on these forward contracts are recognized in other expense, net, along with the foreign currency gains and losses on monetary assets and liabilities, in the condensed consolidated statements of operations.

As of February 1, 2025 and April 27, 2024, the Company held foreign currency forward contracts with a notional value of $152.8 million and $110.9 million, respectively. During the three and nine months ended February 1, 2025, the Company recognized a loss of $4.7 million and $4.2 million, respectively, related to foreign currency forward contracts in the condensed consolidated statements of operations. During the three and nine months ended January 27, 2024, the Company recognized a gain of $0.6 million and a loss of $2.1 million, respectively, related to foreign currency forward contracts in the condensed consolidated statements of operations.

Effect of derivative instruments on comprehensive income (loss)

The pre-tax effects of derivative financial instruments recorded in other comprehensive income (loss) were as follows:

	Three Months Ended					Nine Months Ended
	February 1, 2025		January 27, 2024			February 1, 2025			January 27, 2024
(in millions)	(13 Weeks)		(13 Weeks)			(40 Weeks)			(39 Weeks)
Net investment hedges	$	2.6	$	0.3		$	1.8		$	1.5
Interest rate swaps		0.1		(3.1	)		(2.6	)		(5.8	)
Total	$	2.7	$	(2.8	)	$	(0.8	)	$	(4.3	)

15

Fair value of derivative instruments on the balance sheet

The fair value of derivative instruments are classified as Level 2 within the fair value hierarchy and are recorded in the condensed consolidated balance sheets as follows:

		Asset/(Liability)
(in millions)	Financial Statement Caption	February 1, 2025			April 27, 2024
Derivatives designated as hedging instruments:
Net investment hedges	Prepaid expenses and other current assets	$	—		$	1.3
Interest rate swaps	Other long-term liabilities	$	(4.7	)	$	(2.1	)
Derivatives not designated as hedging instruments:
Foreign currency forward contracts	Other accrued liabilities	$	(0.8	)	$	(0.2	)

Note 8. Debt

A summary of debt is shown below:

(in millions)	February 1, 2025			April 27, 2024
Revolving credit facility	$	330.0		$	333.0
Other debt		1.3			1.5
Unamortized debt issuance costs		(3.4	)		(3.6	)
Total debt		327.9			330.9
Less: current maturities		(0.2	)		(0.2	)
Total long-term debt	$	327.7		$	330.7

Revolving credit facility

On October 31, 2022, the Company entered into a Second Amended and Restated Credit Agreement (the “Credit Agreement”) among the Company, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, and the Lenders and other parties named therein. On March 6, 2024, the Company entered into a First Amendment to Second Amended and Restated Credit Agreement (the “First Amendment”) and on July 9, 2024, the Company entered into a Second Amendment to Second Amended and Restated Credit Agreement and First Amendment to Second Amended and Restated Guaranty (the “Second Amendment”) among the Company, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, the other Lenders party thereto and other parties thereto.

Among other things, the Second Amendment (i) reduced the revolving credit commitments under the Credit Agreement from $750 million to $500 million, (ii) granted a security interest in substantially all of the personal property of the Company and its U.S. subsidiaries that are guarantors, including 100% of the equity interests of their respective U.S. subsidiaries and 65% of the equity interests of their respective foreign subsidiaries (or such greater amount to the extent such pledge could not reasonably cause adverse tax consequences), (iii) amended the consolidated interest coverage ratio covenant for each quarter in fiscal year 2025, (iv) amended the consolidated leverage ratio covenant for the quarter ending July 27, 2024 and each subsequent fiscal quarter, (v) amended certain interest rate provisions, (vi) added a requirement to provide monthly financial statements to the lenders through the period ending July 25, 2025, (vii) decreased the general basket exceptions to certain covenants restricting certain Company investments, liens and indebtedness for specified periods of time, (viii) increased, for fiscal year 2025, the general basket exception to a covenant restricting certain Company dispositions of property, (ix) added an “anti-cash hoarding” requirement, applicable during the period from the effective date of the Second Amendment until the earlier to occur of (a) the delivery of financial statements and a compliance certificate for the fiscal quarter ending July 25, 2025 and (b) the delivery of compliance certificates for two consecutive fiscal quarters demonstrating that the Company’s consolidated leverage ratio as of the last day of such fiscal quarters was less than 3.00:1.00, that if the Company has cash on hand (subject to certain exceptions) of more than $65 million for 10 consecutive business days, the Company shall prepay the indebtedness under the credit facility by the amount of such excess and (x) made certain other changes to the investment, restricted payment and indebtedness baskets. The Credit Agreement, as amended by the First Amendment and the Second Amendment, is referred to herein as the “Amended Credit Agreement.”

16

The Amended Credit Agreement provides for a secured multicurrency revolving credit facility of $500 million. In addition, the Amended Credit Agreement permits the Company to increase the revolving commitments and/or add one or more tranches of term loans under the Amended Credit Agreement from time to time by up to an amount equal to (i) $250 million plus (ii) an additional amount so long as the consolidated leverage ratio would not exceed 3.00:1.00 on a pro forma basis, subject to, among other things, the receipt of additional commitments from existing and/or new lenders. The Amended Credit Agreement matures on October 31, 2027.

The Second Amendment was accounted for as a debt modification, which resulted in a non-cash loss of $1.2 million in the nine months ended February 1, 2025 related to the partial write-off of unamortized debt issuance costs as a result of the reduction in the credit facility size. The non-cash loss was recognized in other expense, net in the Company’s condensed consolidated statement of operations. Additionally, the Company incurred debt issuance costs of approximately $1.8 million associated with the Second Amendment which were capitalized and, along with the current unamortized debt issuance costs, are being amortized to interest expense on a straight-line basis over remaining term of the Amended Credit Agreement.

Loans denominated in US dollars under the Amended Credit Agreement bear interest at either (a) an adjusted base rate or (b) an adjusted term Secured Overnight Financing Rate (“SOFR”) rate or term SOFR daily floating rate (in each case, as determined in accordance with the provisions of the Amended Credit Agreement in each case plus an applicable rate (the “Applicable Rate”) ranging between 0.375% and 1.75%, in the case of adjusted base rate loans, and between 1.375% and 2.75%, in the case of adjusted term SOFR rate loans and term SOFR daily floating rate loans. Loans denominated in euros will bear interest at the Euro Interbank Offered Rate plus an Applicable Rate ranging between 1.375% and 2.75%. The Applicable Rate is set based on the Company’s consolidated leverage ratio.

As of February 1, 2025, the outstanding balance under the revolving credit facility consisted of $285.0 million (€275.0 million) of euro-denominated borrowings and $45.0 million of US dollar denominated borrowings.

The weighted-average interest rate on outstanding US dollar and euro-denominated borrowings under the Amended Credit Agreement was approximately 7.4% and 5.7% as of February 1, 2025. The Amended Credit Agreement contains customary representations and warranties, financial covenants, restrictive covenants and events of default.

The Amended Credit Agreement contains various representations and warranties, financial covenants (including covenants requiring the Company to maintain compliance with a minimum consolidated interest coverage ratio and a maximum consolidated leverage ratio, in each case as of the end of each fiscal quarter), restrictive and other covenants, and events of default. The covenants in the Amended Credit Agreement include an “anti-cash hoarding” requirement, as discussed above. As of February 1, 2025, the Company was in compliance with all the covenants in the Amended Credit Agreement.

Other debt

One of the Company’s European subsidiaries has debt that consists of one note with a maturity in 2031. The weighted-average interest rate on this debt was approximately 1.8% as of February 1, 2025 and $0.2 million of the debt was classified as short-term.

Note 9. Shareholders’ Equity

Repurchases of Common Stock

On March 31, 2021, as subsequently amended on June 16, 2022, the Board of Directors authorized the purchase of up to $200.0 million of the Company’s outstanding common stock through June 14, 2024 (the “2021 Buyback Authorization”). On June 13, 2024, the Board of Directors approved a new share buyback authorization, commencing on June 17, 2024, for the purchase of up to $200.0 million of the Company’s outstanding common stock through June 17, 2026 (the “2024 Buyback Authorization”). Purchases may be made on the open market, including pursuant to purchase plans designed to comply with Rule 10b5-1 of the Securities Exchange Act of 1934, or in private transactions.

The following table summarizes activity under the 2021 Buyback Authorization:

	Three Months Ended				Nine Months Ended
	February 1, 2025		January 27, 2024		February 1, 2025		January 27, 2024
(in millions, except share and per share data)	(13 Weeks)		(13 Weeks)		(40 Weeks)		(39 Weeks)
Shares purchased		—		130,592		136,000		453,371
Average price per share	$	—	$	22.99	$	11.55	$	23.73
Total cost	$	—	$	3.0	$	1.6	$	10.8

17

Prior to its expiration, a total of 3,553,961 shares were purchased under the 2021 Buyback Authorization at a total cost of $134.6 million. All purchased shares were retired and are reflected as a reduction of common stock for the par value of shares, with the excess applied as a reduction to retained earnings. In the three and nine months ended February 1, 2025, there were zero and 136,000 shares purchased under the 2021 Buyback Authorization and no shares purchased under the 2024 Buyback Authorization. No further shares can be purchased under the 2021 Buyback Authorization. As of February 1, 2025, the dollar value of shares that remained available to be purchased by the Company under 2024 Buyback Authorization was $200.0 million.

Dividends

The Company paid dividends totaling $5.3 million and $4.9 million in the three months ended February 1, 2025 and January 27, 2024, respectively. The Company paid dividends totaling $15.3 million and $15.0 million in the nine months ended February 1, 2025 and January 27, 2024, respectively. Dividends paid in the three months ended February 1, 2025 include $0.6 million of dividend equivalent payments for restricted stock units that vested. Dividends paid in the nine months ended February 1, 2025 and January 27, 2024, include $0.8 million and $0.4 million of dividend equivalent payments for restricted stock units that vested.

Accumulated other comprehensive income (loss)

Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. A summary of changes in AOCI, net of tax is shown below:

	Three Months Ended February 1, 2025 (13 Weeks)									Nine Months Ended February 1, 2025 (40 Weeks)
(in millions)	Currency translation adjustments			Derivative instruments			Total			Currency translation adjustments			Derivative instruments			Total
Balance at beginning of period	$	(34.9	)	$	(2.8	)	$	(37.7	)	$	(36.5	)	$	(0.2	)	$	(36.7	)
Other comprehensive income (loss)		(13.3	)		2.7			(10.6	)		(12.5	)		(0.8	)		(13.3	)
Tax (expense) benefit		(2.2	)		(0.7	)		(2.9	)		(1.4	)		0.2			(1.2	)
Net other comprehensive income (loss)		(15.5	)		2.0			(13.5	)		(13.9	)		(0.6	)		(14.5	)
Balance at the end of period	$	(50.4	)	$	(0.8	)	$	(51.2	)	$	(50.4	)	$	(0.8	)	$	(51.2	)

	Three Months Ended January 27, 2024 (13 Weeks)									Nine Months Ended January 27, 2024 (39 Weeks)
(in millions)	Currency translation adjustments			Derivative instruments			Total			Currency translation adjustments			Derivative instruments			Total
Balance at beginning of period	$	(42.5	)	$	(0.4	)	$	(42.9	)	$	(19.8	)	$	0.8		$	(19.0	)
Other comprehensive income (loss)		11.7			(2.8	)		8.9			(8.6	)		(4.3	)		(12.9	)
Tax benefit (expense)		2.0			0.8			2.8			(0.4	)		1.1			0.7
Net other comprehensive income (loss)		13.7			(2.0	)		11.7			(9.0	)		(3.2	)		(12.2	)
Balance at the end of period	$	(28.8	)	$	(2.4	)	$	(31.2	)	$	(28.8	)	$	(2.4	)	$	(31.2	)

Stock-based compensation

The Company has granted stock options, restricted stock awards (“RSAs”), performance units (“PUs”), restricted stock units (“RSUs”), performance stock units (“PSUs”) and stock awards to employees and non-employee directors under the Methode Electronics, Inc. 2022 Omnibus Incentive Plan (“2022 Plan”), the Methode Electronics, Inc. 2014 Omnibus Incentive Plan (“2014 Plan”), the Methode Electronics, Inc. 2010 Stock Plan (“2010 Plan”), and the Methode Electronics, Inc. 2004 Stock Plan (“2004 Plan”). The Company can no longer make grants under the 2014 Plan, 2010 Plan and 2004 Plan.

Subject to adjustment as provided in the 2022 Plan and the 2022 Plan’s share counting provisions, the number of shares of the Company's common stock that will be available for all awards under the 2022 Plan is 5,550,000, less an amount to reflect shares, options or other awards granted under prior plans after April 30, 2022. As of February 1, 2025, there were approximately 3.6 million shares available for award under the 2022 Plan.

Restricted stock awards and performance units

As of February 1, 2025, the Company had 710,349 RSAs outstanding which may be earned based on the achievement of an earnings before net interest, taxes, fixed asset depreciation and intangible asset amortization (“EBITDA”) measure for fiscal 2025. The RSAs will vest ranging from 0% (for performance below threshold) to 100% (target performance) based on the achievement of the EBITDA performance measure and continued employment. In addition, if the target performance is exceeded, up to an additional 355,175 PUs can be earned that will be settled in cash.

18

The fair value of the RSAs was based on the closing stock price on the date of grant and the RSAs earn dividend equivalents during the vesting period, which are forfeitable if the RSAs do not vest. Compensation expense for the RSAs is recognized when it is probable the minimum threshold performance criteria will be achieved. Compensation expense for the PUs is recognized when it is probable that the target performance criteria will be exceeded. The Company assesses the probability of vesting at each balance sheet date and adjusts compensation costs based on the probability assessment. The cash-settled PUs represent a non-equity unit with a conversion value equal to the fair market value of a share of the Company’s common stock on the vesting date. The PUs are classified as liability awards due to the cash settlement feature and are re-measured at each balance sheet date. In accordance with ASC 718, “Compensation - Stock Compensation” based on projections of the Company’s current business portfolio, no compensation expense has been recognized for the RSAs or PUs to date, as the performance conditions are not probable of being met. Unrecognized stock-based compensation expense at target level of performance is $20.5 million as of February 1, 2025, which, subject to the performance conditions being met, will be recognized through fiscal 2025. The following table summarizes RSA activity:

	Restricted stock awards			Weighted average grant date fair value
Non-vested at April 27, 2024		789,674		$	28.81
Awarded		—		$	—
Vested		—		$	—
Forfeited		(79,325	)	$	28.28
Non-vested at February 1, 2025		710,349		$	28.87

Performance stock units

In the nine months ended February 1, 2025, the Company granted 208,661 PSUs which will vest upon the achievement of a total stockholder return (“TSR”) measure based on the growth in the Company’s stock price over a three-year performance period that ends April 30, 2027. The number of shares to be issued may range from 0% to a maximum of 200% of the PSUs granted. The Company estimated the grant date fair value of the PSUs using the Monte Carlo simulation model, as the TSR metric and changes in stock price are considered market conditions under ASC 718. The following table provides a summary of the weighted-average assumptions for the PSUs granted:

	Assumptions
Expected volatility		52.40	%
Risk free interest rate		4.07	%
Expected term (in years)		2.72
Grant date fair value	$	14.09

The PSUs earn dividend equivalents during the vesting periods, which are forfeitable if the PSUs do not vest. As of February 1, 2025, unrecognized share-based compensation expense for the PSUs was $2.5 million, which is expected to be recognized over a weighted average period of approximately three years. The following table summarizes PSU activity:

	Performance stock units		Weighted average grant date fair value
Non-vested at April 27, 2024		—	$	—
Awarded		208,661	$	14.09
Vested		—	$	—
Forfeited		—	$	—
Non-vested at February 1, 2025		208,661	$	14.09

19

Restricted stock units

RSUs granted vest over a pre-determined period of time, up to five years from the date of grant. The fair value of the RSUs granted are based on the closing stock price on the date of grant and earn dividend equivalents during the vesting periods, which are forfeitable if the RSUs do not vest. The following table summarizes RSU activity:

	Restricted stock units			Weighted average grant date fair value
Non-vested at April 27, 2024		941,640		$	26.43
Awarded		326,244		$	12.01
Conversion of cash bonus to RSUs		160,401		$	12.87
Vested		(396,744	)	$	28.29
Forfeited		(183,930	)	$	22.73
Non-vested at February 1, 2025		847,611		$	18.25

In the nine months ended February 1, 2025, 160,401 RSUs were awarded in exchange for cash bonuses earned by certain employees. These RSUs vest on March 7, 2025. As the expense associated with the cash bonuses was previously recognized in fiscal 2024, there is no incremental expense to be recognized for the RSUs. The Company reclassified $2.1 million from accrued employee liabilities to additional paid-in capital on its condensed consolidated balance sheets related to the conversion of the cash bonuses to RSUs.

Under the various stock plans, RSUs that have vested for certain executives, including Ronald L.G. Tsoumas, the Company’s former CFO, will not be delivered in common stock until the first day of the seventh month following the executive’s termination from the Company or upon a change of control. As of February 1, 2025, common stock to be delivered to these executives totaled 85,553 shares, of which 60,875 shares were delivered on February 4, 2025. The vested deferred RSUs are considered outstanding for earnings per share calculations. As of February 1, 2025, unrecognized share-based compensation expense for RSUs was $4.8 million which will be recognized over a weighted-average amortization period of 1.3 years.

Director awards

The Company grants stock awards to its non-employee directors as a component of their compensation. The stock awards vest immediately upon grant. Non-employee directors may elect to defer receipt of their shares under the Company’s non-qualified deferred compensation plan. The following table summarizes awards granted to non-employee directors:

	Non-employee director awards			Deferred non-employee director awards			Total			Weighted average grant date fair value
Outstanding at April 27, 2024		—			77,319			77,319		$	37.23
Awarded		56,680			90,725			147,405		$	9.92
Issued		(56,680	)		(23,756	)		(80,436	)	$	10.49
Outstanding at February 1, 2025		—			144,288			144,288		$	22.80

Stock options

The following table summarizes stock option activity:

	Stock options			Weighted average exercise price		Weighted- average life (years)		Aggregate intrinsic value (in millions)
Outstanding and exercisable at April 27, 2024		8,000		$	37.01		0.2	$	0.0
Exercised		—		$	—
Forfeited		(8,000	)	$	37.01
Outstanding and exercisable at February 1, 2025		—		$	—		0.0	$	0.0

20

Stock-based compensation expense

All stock-based awards to employees and non-employee directors are recognized in selling and administrative expenses on the condensed consolidated statements of operations. Awards subject to graded vesting are recognized using the accelerated recognition method over the requisite service period. The table below summarizes the stock-based compensation expense related to the equity awards:

	Three Months Ended					Nine Months Ended
	February 1, 2025		January 27, 2024			February 1, 2025		January 27, 2024
(in millions)	(13 Weeks)		(13 Weeks)			(40 Weeks)		(39 Weeks)
RSUs	$	1.5	$	(2.1	)	$	3.5	$	0.2
PSUs		0.3		—			0.5		—
Deferred non-employee director awards		—		—			0.9		1.0
Non-employee director awards		—		—			0.6		0.6
Total stock-based compensation expense	$	1.8	$	(2.1	)	$	5.5	$	1.8

Note 10. Loss per Share

Basic loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the applicable period, but excludes any contingently issued shares where the contingency has not been resolved. The weighted average number of common shares used in the diluted loss per share calculation is determined using the treasury stock method which includes the effect of all potential dilutive common shares outstanding during the period.

The following table sets forth the computation of basic and diluted loss per share:

	Three Months Ended						Nine Months Ended
	February 1, 2025			January 27, 2024			February 1, 2025			January 27, 2024
	(13 Weeks)			(13 Weeks)			(40 Weeks)			(39 Weeks)
Numerator:
Net loss (in millions)	$	(14.4	)	$	(11.6	)	$	(34.3	)	$	(66.0	)
Denominator:
Denominator for basic loss per share - weighted average shares outstanding and vested/unissued restricted stock units		35,182,166			35,327,995			35,370,099			35,562,513
Dilutive potential common shares		—			—			—			—
Denominator for diluted loss per share		35,182,166			35,327,995			35,370,099			35,562,513
Loss per share:
Basic	$	(0.41	)	$	(0.33	)	$	(0.97	)	$	(1.86	)
Diluted	$	(0.41	)	$	(0.33	)	$	(0.97	)	$	(1.86	)
Number of anti-dilutive potentially issuable shares excluded from diluted common shares outstanding		1,303,187			1,319,577			1,176,069			1,463,996

In the three and nine months ended February 1, 2025 and January 27, 2024, all potential common shares issuable for PSUs and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for PSUs and RSUs on the weighted-average number of common shares outstanding would have been approximately 362,000 and 503,000 common shares for the three months ended February 1, 2025 and January 27, 2024, respectively. The dilutive effect of potential common shares issuable for PSUs and RSUs on the weighted-average number of common shares outstanding would have been approximately 221,000 and 560,000 common shares for the nine months ended February 1, 2025 and January 27, 2024, respectively.

21

Note 11. Segment Information

An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and incur expenses, and about which separate financial information is regularly evaluated by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources. The CODM is the Company’s Chief Executive Officer (“CEO”).

The Automotive segment supplies electronic and electro-mechanical devices and related products to automobile OEMs, either directly or through their tiered suppliers. Products include integrated overhead and center consoles, hidden and ergonomic switches, transmission lead-frames, insert molded components, LED-based lighting and sensors, which incorporate magneto-elastic sensing and other sensing technologies that monitor the operation or status of a component or system.

The Industrial segment manufactures exterior and interior lighting solutions, industrial safety radio remote controls, braided flexible cables, current-carrying laminated busbars and devices, custom power-product assemblies, such as our PowerRail® solution, high-current high-voltage flexible power cabling systems and powder-coated busbars that are used in various markets and applications, including aerospace, commercial vehicles, data centers, industrial equipment, power conversion, military, telecommunications and transportation.

The Interface segment provides a variety of high-speed digital communication over copper media solutions for the data center and broadband markets, and interface panel solutions for the appliance market. Solutions include copper transceivers, distribution point units, and solid-state field-effect consumer touch panels.

The Medical segment was made up of the Company’s medical device business, Dabir Surfaces, with its surface support technology aimed at pressure injury prevention. In the first quarter of fiscal 2024, the Company made the decision to initiate the discontinuation of Dabir Surfaces. In the second quarter of fiscal 2024, the Company sold certain assets of its Dabir Surfaces business. See Note 3, “Disposition” for more information.

The tables below present information about the Company’s reportable segments:

	Three Months Ended February 1, 2025 (13 Weeks)
(in millions)	Automotive			Industrial			Interface		Medical		Eliminations/ Corporate			Consolidated
Net sales	$	120.1		$	119.3		$	12.3	$	—	$	(11.8	)	$	239.9
Transfers between segments		(4.4	)		(7.4	)		—		—		11.8			—
Net sales to unaffiliated customers	$	115.7		$	111.9		$	12.3	$	—	$	—		$	239.9
Income (loss) from operations	$	(9.0	)	$	22.6		$	2.2	$	—	$	(18.0	)	$	(2.2	)
Interest expense, net															5.5
Other expense, net															0.5
Pre-tax loss														$	(8.2	)

	Three Months Ended January 27, 2024 (13 Weeks)
(in millions)	Automotive			Industrial			Interface		Medical			Eliminations /Corporate			Consolidated
Net sales	$	142.4		$	117.1		$	12.7	$	—		$	(12.7	)	$	259.5
Transfers between segments		(2.7	)		(10.0	)		—		—			12.7			—
Net sales to unaffiliated customers	$	139.7		$	107.1		$	12.7	$	—		$	—		$	259.5
Income (loss) from operations	$	(11.0	)	$	18.9		$	1.5	$	(0.1	)	$	(12.3	)	$	(3.0	)
Interest expense, net																5.0
Other expense, net																2.5
Pre-tax loss															$	(10.5	)

22

	Nine Months Ended February 1, 2025 (40 Weeks)
(in millions)	Automotive			Industrial			Interface		Medical		Eliminations/ Corporate			Consolidated
Net sales	$	404.9		$	375.8		$	40.2	$	—	$	(29.9	)	$	791.0
Transfers between segments		(8.9	)		(21.0	)		—		—		29.9			—
Net sales to unaffiliated customers	$	396.0		$	354.8		$	40.2	$	—	$	—		$	791.0
Income (loss) from operations	$	(14.0	)	$	63.8		$	8.8	$	—	$	(58.9	)	$	(0.3	)
Interest expense, net															16.5
Other expense, net															2.9
Pre-tax loss														$	(19.7	)

	Nine Months Ended January 27, 2024 (39 Weeks)
(in millions)	Automotive			Industrial			Interface			Medical			Eliminations /Corporate			Consolidated
Net sales	$	461.5		$	367.7		$	39.7		$	2.4		$	(34.1	)	$	837.2
Transfers between segments		(9.2	)		(24.8	)		(0.1	)		—			34.1			—
Net sales to unaffiliated customers	$	452.3		$	342.9		$	39.6		$	2.4		$	—		$	837.2
Income (loss) from operations	$	(75.3	)	$	68.8		$	5.4		$	(3.0	)	$	(46.4	)	$	(50.5	)
Interest expense, net																	12.2
Other income, net																	2.3
Pre-tax loss																$	(65.0	)
Goodwill impairment	$	56.5		$	—		$	—		$	—		$	—		$	56.5

(in millions)	February 1, 2025		April 27, 2024
Identifiable assets:
Automotive	$	592.9	$	592.7
Industrial		583.4		604.5
Interface		66.6		67.1
Medical		—		0.2
Eliminations/Corporate		61.7		139.0
Total identifiable assets	$	1,304.6	$	1,403.5

Note 12. Contingencies

Certain litigation arising in the normal course of business is pending against us. The Company is, from time-to-time, subject to various legal actions and claims incidental to our business, including those arising out of alleged defects, breach of contracts, employment-related matters, environmental matters and intellectual property matters. The Company has established loss provisions for matters in which losses are deemed probable and reasonably estimable. The Company considers insurance coverage and third-party indemnification, among other things, when determining required accruals for pending litigation and claims. Although the outcome of potential legal actions and claims cannot be predicted with certainty, it is the Company's opinion, based on the information available, that it has adequate reserves for these liabilities. However, the ultimate outcome of any matter could require payment in excess of any amount that the Company may have accrued.

23

Hetronic Germany-GmbH Matters

For several years, Hetronic Germany-GmbH and Hydronic-Steuersysteme-GmbH (the “Fuchs companies”) served as our distributors for Germany, Austria and other central and eastern European countries pursuant to their respective intellectual property licenses and distribution and assembly agreements. The Company became aware that the Fuchs companies and their managing director, Albert Fuchs, had materially violated those agreements. As a result, the Company terminated all of its agreements with the Fuchs companies. On June 20, 2014, the Company filed a lawsuit against the Fuchs companies in the Federal District Court for the Western District of Oklahoma alleging material breaches of the distribution and assembly agreements and seeking damages, as well as various forms of injunctive relief. The defendants filed counterclaims alleging breach of contract, interference with business relations and business slander. On April 2, 2015, the Company amended its complaint against the Fuchs companies to add additional unfair competition and Lanham Act claims and to add additional affiliated parties.

A trial with respect to the matter began in February 2020. During the trial, the defendants dismissed their one remaining counterclaim with prejudice. On March 2, 2020, the jury returned a verdict in favor of the Company. The verdict included approximately $102 million in compensatory damages and $11 million in punitive damages. On April 22, 2020, the District Court entered a permanent injunction barring defendants from selling infringing products and ordering them to return Hetronic’s confidential information. Defendants appealed entry of the permanent injunction. On May 29, 2020, the District Court held defendants in contempt for violating the permanent injunction and entered the final judgment. Defendants appealed entry of the final monetary judgment as well. The appeal of the permanent injunction and the appeal of the final judgment were consolidated into a single appeal before the U.S. Court of Appeals for the Tenth Circuit. On August 24, 2021, the Tenth Circuit issued a decision affirming the lower court’s ruling with the exception that it instructed the District Court to modify the injunction from the entire world to all of the countries in which Hetronic sells its products. On April 20 and 21, 2022, the District Court held a hearing related to modifying the injunction pursuant to the Tenth Circuit’s opinion, and the parties have filed post-hearing briefs. The defendants also filed a petition for certiorari with the United States Supreme Court seeking to further appeal the extraterritorial application of the Lanham Act in this case. The Company opposed that petition. The Supreme Court requested the views of the Solicitor General on the petition for certiorari, and the Solicitor General recommended granting the petition. On November 4, 2022, the Supreme Court granted the petition. The Supreme Court heard arguments in this matter on March 21, 2023. On June 29, 2023, the Supreme Court vacated the Tenth Circuit’s August 2021 decision and remanded the matter back to the Tenth Circuit for further proceedings. On September 1, 2023, the Tenth Circuit requested supplemental briefing from the parties regarding the effect of the Supreme Court’s decision on the appeal and the proper course of further proceedings. That briefing was thereafter submitted, and the Tenth Circuit heard argument in this matter on January 24, 2024. On April 23, 2024, the Tenth Circuit issued an opinion affirming the District Court’s final judgment on the state law breach of contract and tort claims (this affirmed final judgment amount represents only approximately $22.5 million of the vacated original $113 million final judgment that had been entered in 2020) and remanding for further non-trial proceedings with respect to the appropriate remedies for the Lanham Act claims in light of the Supreme’s Court ruling that the Lanham Act does not apply extraterritorially. On August 5, 2024, the District Court entered an amended permanent injunction and amended final judgment. The amended permanent injunction limited the geographic reach of the permanent injunction barring defendants from selling infringing products so that it only applies in the United States and reaffirmed the court’s prior order requiring defendants to return Hetronic’s confidential information. The amended final judgment reaffirmed the final judgment of approximately $22.5 million plus interest for the state law breach of contract and tort claims and entered judgment in an amended amount of approximately $0.3 million plus interest for the infringing U.S. sales under the Lanham Act. The deadline for any appeals of the District Court’s orders was September 4, 2024 and no appeal of those orders was filed before that deadline.

The Company has not received payment of any portion of the judgment from the defendants. Like any judgment, particularly a judgment involving defendants outside of the United States, there is no guarantee that the Company will be able to collect all or any portion of the judgment. Furthermore, defendants Abitron Germany and Hetronic Germany filed for insolvency in German court in September and October 2023 respectively, and the Germany insolvency court then appointed a receiver. These insolvency proceedings could potentially adversely impact our ability to enforce or collect upon the judgment or portions of the judgment or otherwise pursue or enforce claims or rights against those defendants.

24

Stockholder Litigation

On August 26, 2024, a putative class action lawsuit on behalf of purchasers of Company common stock between June 23, 2022 and March 6, 2024, inclusive, entitled Marie Salem v. Methode Electronics, Inc. et al. was filed in the U.S. District Court for the Northern District of Illinois against the Company, a former Chief Executive Officer, President and director of the Company and a former Chief Financial Officer of the Company. The complaint alleges, among other things, that the defendants made false and/or misleading statements relating to the Company’s business, operations and prospects, including in respect of the Company’s transition to production of more specialized components for manufacturers of electric vehicles and the Company’s operations at its facility in Monterrey, Mexico, in violation of Sections 10(b) and 20 of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The complaint seeks, among other things, unspecified money damages along with equitable relief and costs and expenses, including counsel fees and expert fees. Another purported shareholder filed a substantially similar action in the U.S. District Court for the Northern District of Illinois on October 7, 2024 against the same defendants and a former Chief Operating Officer of the Company, in a case entitled City of Cape Coral Municipal General Employees Retirement Plan v. Methode Electronics, Inc., et al. The second securities class action was filed on behalf of a broader putative class of purchasers of Company common stock between December 2, 2021 and March 6, 2024. In addition, two purported shareholders filed derivative lawsuits on November 26, 2024 and February 4, 2025, respectively. The derivative lawsuits were filed on behalf of the Company in the U.S. District Court for the Northern District of Illinois against the current members of the Company’s Board of Directors, as well as certain former directors and executives, alleging that the defendants breached their fiduciary duties by allowing the Company to issue various statements that are alleged to have been false or misleading for the same reasons alleged in the securities class action complaints. The derivative lawsuits are entitled Ray Homsi v. Donald Duda, et al. and Kevin D. Murphy v. Mark D. Schwabero, et al. (collectively with the Salem and City of Cape Coral matters, the “Stockholder Actions”).

The Company disagrees with and intends to vigorously defend against the Stockholder Actions. The Stockholder Actions could result in costs and losses to the Company, including potential costs associated with the indemnification of the other defendants. At this time, given the current status of the Stockholder Actions, the Company is unable to reasonably estimate an amount or range of reasonably possible loss, if any, that may result from the Stockholder Actions.

SEC Investigation

The Company received a subpoena from the SEC dated November 1, 2024 seeking documents and information relating to, among other things, the Company’s operations in certain foreign countries, certain financial and accounting matters relating thereto, compliance with the Foreign Corrupt Practices Act and other anti-corruption laws, and material weaknesses in the Company’s internal control over financial reporting previously reported in its public filings. The Company is cooperating with the SEC. The subpoena and related investigation or other future requests for information could result in costs to the Company, including the expenditure of financial and managerial resources. In addition, this request may lead to the assertion of claims or the commencement of legal proceedings against the Company, which in turn may lead to material fines, penalties or other liabilities. However, at this time, the Company is unable to reasonably estimate an amount or range of reasonably possible loss, if any, that may result from these matters.

Note 13. Restructuring and Asset Impairment Charges

Restructuring and asset impairment charges includes costs related to restructuring actions taken by the Company as well as long-lived asset impairments.

The Company continually monitors market factors and industry trends and takes restructuring actions to reduce overall costs and improve operational profitability as appropriate. Restructuring actions generally result in charges for employee termination benefits, plant closures, asset impairments and contract termination costs.

Components of restructuring and asset impairment charges were as follows:

	Three Months Ended				Nine Months Ended
	February 1, 2025		January 27, 2024		February 1, 2025		January 27, 2024
(in millions)	(13 Weeks)		(13 Weeks)		(40 Weeks)		(39 Weeks)
Employee termination benefits	$	—	$	—	$	0.3	$	0.7
Asset impairment charges		—		0.1		0.4		0.7
Total	$	—	$	0.1	$	0.7	$	1.4

25

The table below presents restructuring and asset impairment charges by reportable segment.

	Three Months Ended				Nine Months Ended
	February 1, 2025		January 27, 2024		February 1, 2025		January 27, 2024
(in millions)	(13 Weeks)		(13 Weeks)		(40 Weeks)		(39 Weeks)
Automotive	$	—	$	—	$	0.3	$	0.2
Industrial		—		0.1		0.1		0.1
Interface		—		—		—		—
Medical		—		—		—		1.1
Eliminations/Corporate		—		—		0.3		—
Total	$	—	$	0.1	$	0.7	$	1.4
Recognized in:
Cost of products sold	$	—	$	0.1	$	0.4	$	0.9
Selling and administrative expenses		—		—		0.3		0.5
	$	—	$	0.1	$	0.7	$	1.4

The Company’s restructuring liability was $0.0 million and $0.7 million as of February 1, 2025 and April 27, 2024, respectively. Estimates of restructuring costs are based on information available at the time such charges are recorded. Due to the inherent uncertainty involved in estimating restructuring costs, actual amounts paid for such activities may differ from amounts initially recorded. Accordingly, the Company may record revisions of previous estimates by adjusting previously established accruals. The Company may take additional restructuring actions in future periods based upon market conditions and industry trends.

Note 14. Related Party Transactions

The Company’s former Interim Chief Financial Officer, David Rawden, is a director of AlixPartners, LLP (“AlixPartners”), a business advisory firm that provided a number of consulting services to the Company. The Company’s former Interim Chief Executive Officer, Kevin Nystrom, is a partner and managing director of AlixPartners. In the three and nine months ended February 1, 2025, the Company recognized $0.9 million and $9.8 million, respectively, of expense for consulting services provided by AlixPartners. As of February 1, 2025, $0.4 million was payable to AlixPartners which was reflected in accounts payable on the condensed consolidated balance sheets. As of April 27, 2024, $1.4 million was payable to AlixPartners which was reflected in other accrued liabilities on the condensed consolidated balance sheets.

26

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

As used herein, “we,” “us,” “our,” the “Company” or “Methode” means Methode Electronics, Inc. and its subsidiaries.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (“Quarterly Report”) includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect, when made, our current views with respect to current events and financial performance. Such forward-looking statements are subject to many risks, uncertainties and factors relating to our operations and business environment, which may cause our actual results to be materially different from any future results, express or implied, by such forward-looking statements. All statements that address future operating, financial or business performance or our strategies or expectations are forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook,” “upcoming,” or “continue,” and other comparable terminology. Factors that could cause actual results to differ materially from these forward-looking statements include, but are not limited to, the following:

•International trade disputes resulting in tariffs and our ability to mitigate tariffs;

•Dependence on the automotive, commercial vehicle, and construction industries;

•Timing, quality and cost of new program launches;

•Changes in electric vehicle (“EV”) demand;

•Investment in programs prior to the recognition of revenue;

•Failure to attract and retain qualified personnel;

•Impact from production delays or cancelled orders;

•Impact from inflation;

•Dependence on the availability and price of materials;

•Dependence on a small number of large customers, including one large automotive customer;

•Dependence on our supply chain;

•Risks related to conducting global operations;

•Effects of potential catastrophic events or other business interruptions;

•Ability to withstand pricing pressures, including price reductions;

•Potential impact of securities class action, other litigation, and government investigations and inquiries;

•Ability to compete effectively;

•Our lengthy sales cycle;

•Risks relating to our use of requirements contracts;

•Potential work stoppages;

•Ability to successfully benefit from acquisitions and divestitures;

•Ability to manage our debt levels and comply with restrictions and covenants under our credit agreement;

•Interest rate changes and variable rate instruments;

•Timing and magnitude of costs associated with restructuring activities;

•Recognition of goodwill and other intangible asset impairment charges;

•Ability to remediate material weaknesses in our internal control over financial reporting;

•Currency fluctuations;

•Income tax rate fluctuations;

•Judgments related to accounting for tax positions;

•Ability to withstand business interruptions;

•Potential IT security threats or breaches;

•Ability to protect our intellectual property;

•Costs associated with environmental, health and safety regulations;

•Impact from climate change and related regulations; and

•Ability to avoid design or manufacturing defects.

Additional details and factors are discussed under the caption “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended April 27, 2024 and in Part II, Item 1A of this Quarterly Report. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. Any forward-looking statements made by us speak only as of the date on which they are made. We are under no obligation to, and expressly disclaim any obligation to, update or alter our forward-looking statements, whether as a result of new information, subsequent events or otherwise.

27

Overview

We are a leading global supplier of custom engineered solutions with sales, engineering and manufacturing locations in North America, Europe, Middle East and Asia. We design, engineer and produce mechatronic products for Original Equipment Manufacturers (“OEMs”) utilizing our broad range of technologies for user interface, light-emitting diode (“LED”) lighting system, power distribution and sensor applications.

Our solutions are found in the end markets of transportation (including automotive, commercial vehicle, e-bike, aerospace, bus and rail), cloud computing infrastructure, construction equipment and consumer appliance.

Trade Policy/Tariffs

We are exposed to market risk with respect to duties currently assessed on raw materials, component parts and finished goods we import into the U.S. Since February 1, 2025 and up to March 4, 2025, the United States has announced and implemented various tariffs, including 25% tariffs on all products from Canada and Mexico, modifying the steel and aluminum tariffs that were imposed in 2018, and charging reciprocal tariffs against countries that tax or limit markets for U.S. goods.

The current situation is dynamic and we are continuing to assess the full implications of the newly announced tariffs. Given our sizable manufacturing operations in Mexico, China, Europe and Canada, should these enacted tariffs continue, raw materials and finished goods that we import will face higher prices, which could lead to reduced margins or increased prices that could cause decreased customer demand. We continue to monitor similar actions by other countries with which we do business. It is possible other countries may impose retaliatory tariffs on goods imported into their countries from the U.S. We will seek price increases from our customers to offset these incremental costs. If we are unable to obtain price increases, the impact of new or higher tariffs could have a material impact on our results of operations.

Macroeconomic Conditions

The global economy continues to experience volatile disruptions including to the commodity, labor and transportation markets, arising from a combination of geopolitical events and various economic and financial factors. These disruptions have affected our operations and may continue to affect our business, financial condition and results of operations. As a result of continued inflation, we have implemented measures to mitigate certain adverse effects of higher costs. However, we have been unable to fully mitigate or pass through the increases in our costs to our customers, which will likely continue in the future.

Our business in the future will be impacted by the broad trend of electrification. The adoption of EVs has been slower than anticipated, which may impact our financial condition and results of operations. In addition, there are various government policies, subsidies, and economic incentives designed to increase EV adoption. There is no guarantee these incentive programs will be available in the future.

Geopolitical Conditions

Russia’s invasion of Ukraine and the resulting economic sanctions imposed by the international community impacted the global economy and gave rise to potential global security issues that may adversely affect international business and economic conditions. Given our manufacturing operations in the Middle East and Asia, the continuation of the military conflict between Russia and Ukraine, the escalation or expansion of the Israel-Hamas war, or renewed terrorist attacks on Red Sea shipping, such as those by the Houthi, could lead to other supply chain disruptions, increased inflationary pressures, higher freight costs and volatility in global markets and industries that could negatively impact our operations. The full impact of the conflicts on our business operations and financial performance remains uncertain and will depend on future developments, including the severity and duration of the conflicts and their impact on regional and global economic conditions. We will continue to monitor the conflicts and assess the related restrictions and other effects on our employees, customers, suppliers and business.

Global Supply Chain Disruptions

Although we saw improvements in our supply chain in fiscal 2024, including easing of the worldwide semiconductor supply shortage, new supply chain disruptions may occur in the future. In addition, we have experienced, and may continue to experience, business interruptions, including customer shutdowns and increased material and logistics costs and labor shortages. Changes in government regulations in areas including, but not limited to, trade and tariff regulations as noted above, could also increase our costs. We continue to work closely with suppliers and customers to minimize the potential adverse impact from global supply chain disruptions. However, if we are not able to mitigate any direct or indirect supply chain disruptions, this may have a material adverse impact on our financial condition, results of operations and cash flows.

28

Consolidated Results of Operations

We maintain our financial records on the basis of a 52 or 53-week fiscal year ending on the Saturday closest to April 30. Fiscal 2025 is a 53-week year and fiscal 2024 was a 52-week year. The three months ended February 1, 2025 and January 27, 2024 were 13-week periods, while the nine months ended February 1, 2025 and January 27, 2024, were 40 and 39-week periods, respectively. The following discussions of comparative results among periods should be reviewed in this context.

The table below compares our results of operations between the three and nine months ended February 1, 2025 and the three and nine months ended January 27, 2024:

	Three Months Ended						Nine Months Ended
	February 1, 2025			January 27, 2024			February 1, 2025			January 27, 2024
(in millions)	(13 Weeks)			(13 Weeks)			(40 Weeks)			(39 Weeks)
Net sales	$	239.9		$	259.5		$	791.0		$	837.2
Cost of products sold		198.6			222.5			647.2			693.9
Gross profit		41.3			37.0			143.8			143.3
Selling and administrative expenses		37.7			33.9			126.5			119.3
Goodwill impairment		—			—			—			56.5
Amortization of intangibles		5.8			6.1			17.6			18.0
Interest expense, net		5.5			5.0			16.5			12.2
Other expense, net		0.5			2.5			2.9			2.3
Income tax expense		6.2			1.1			14.6			1.0
Net loss	$	(14.4	)	$	(11.6	)	$	(34.3	)	$	(66.0	)

Net sales

Net sales decreased $19.6 million, or 7.6%, to $239.9 million in the three months ended February 1, 2025, compared to $259.5 million in the three months ended January 27, 2024. Foreign currency translation decreased net sales by $3.3 million. Excluding foreign currency translation, net sales decreased $16.3 million. The decrease was primarily due to lower sales volumes in the Automotive segment, partially offset by higher sales volumes in the Industrial segment.

Net sales decreased $46.2 million, or 5.5%, to $791.0 million in the nine months ended February 1, 2025, compared to $837.2 million in the nine months ended January 27, 2024. Foreign currency translation decreased net sales by $0.7 million. Excluding foreign currency translation, net sales decreased $45.5 million. The decrease was primarily due to lower sales volumes in the Automotive segment, partially offset by higher sales volumes in the Industrial segment.

Cost of products sold

Cost of products sold decreased $23.9 million, or 10.7%, to $198.6 million (82.8% of net sales) in the three months ended February 1, 2025, compared to $222.5 million (85.7% of net sales) in the three months ended January 27, 2024. Foreign currency translation decreased cost of products sold by $2.3 million. Excluding foreign currency translation, cost of products sold decreased $21.6 million. The decrease was primarily due to lower material and freight costs as a result of lower sales volumes.

Cost of products sold decreased $46.7 million, or 6.7%, to $647.2 million (81.8% of net sales) in the nine months ended February 1, 2025, compared to $693.9 million (82.9% of net sales) in the nine months ended January 27, 2024. Foreign currency translation decreased cost of products sold by $0.3 million. Excluding foreign currency translation, cost of products sold decreased $46.4 million. The decrease was primarily due to lower material and freight costs as a result of a decrease in sales volumes, partially offset by higher salary and warranty expense. Restructuring and asset impairment charges included within cost of products sold were $0.4 million in the nine months ended February 1, 2025, compared to $0.9 million in the nine months ended January 27, 2024.

Gross profit margin

Gross profit margin was 17.2% of net sales in the three months ended February 1, 2025, compared to 14.3% of net sales in the three months ended January 27, 2024. Gross profit margin was 18.2% of net sales in the nine months ended February 1, 2025, compared to 17.1% of net sales in the nine months ended January 27, 2024.

The increase in gross profit margin in both periods was primarily a result of product mix from higher sales in the Industrial segment.

29

Selling and administrative expenses

Selling and administrative expenses increased $3.8 million, or 11.2%, to $37.7 million (15.7% of net sales) in the three months ended February 1, 2025, compared to $33.9 million (13.1% of net sales) in the three months ended January 27, 2024. Excluding foreign currency translation, selling and administrative expenses increased $4.1 million. The increase was due to higher stock-based compensation expense and professional fees. Stock-based compensation expense was higher as the three months ended January 27, 2024 included a $3.6 million expense reversal due to forfeitures in that period. Professional fees in the three months ended February 1, 2025 include $0.9 million for consulting services provided by AlixPartners.

Selling and administrative expenses increased $7.2 million, or 6.0%, to $126.5 million (16.0% of net sales) in the nine months ended February 1, 2025, compared to $119.3 million (14.2% of net sales) in the nine months ended January 27, 2024. Excluding foreign currency translation, selling and administrative expenses increased $7.3 million. The increase was primarily due to higher professional fees and incentive compensation expense, partially offset by lower salary expense. Professional fees in the nine months ended February 1, 2025 include $9.8 million for consulting and interim executive services provided by AlixPartners.

Goodwill impairment

In the nine months ended January 27, 2024, we recognized a goodwill impairment of $56.5 million in the Automotive segment. For further information, see Note 6, “Goodwill and Other Intangible Assets” to the condensed consolidated financial statements included in this Quarterly Report.

Amortization of intangibles

Amortization of intangibles was $5.8 million in the three months ended February 1, 2025, compared to $6.1 million in the three months ended January 27, 2024. Amortization of intangibles was $17.6 million in the nine months ended February 1, 2025, compared to $18.0 million in the nine months ended January 27, 2024.

Interest expense, net

Interest expense, net was $5.5 million in the three months ended February 1, 2025, compared to $5.0 million in the three months ended January 27, 2024. Interest expense, net was $16.5 million in the nine months ended February 1, 2025, compared to $12.2 million in the nine months ended January 27, 2024. The increase in both periods was due to a higher level of borrowings and increased interest rates.

Other expense, net

Other expense, net was $0.5 million in the three months ended February 1, 2025, compared to $2.5 million in the three months ended January 27, 2024. Net foreign exchange loss was $1.3 million in the three months ended February 1, 2025, compared to $2.8 million in the three months ended January 27, 2024. In the three months ended February 1, 2025, we received $0.8 million of international government assistance, compared to $0.2 million in the three months ended January 27, 2024.

Other expense, net was $2.9 million in the nine months ended February 1, 2025, compared to $2.3 million in the nine months ended January 27, 2024. Other expense, net in the nine months ended February 1, 2025 includes a non-cash write-off of $1.2 million of unamortized debt issuance costs. Net foreign exchange loss was $3.6 million in the nine months ended February 1, 2025, compared to $2.2 million in the nine months ended January 27, 2024. In the nine months ended February 1, 2025, we received $1.8 million of international government assistance, compared to $0.3 million in the nine months ended January 27, 2024.

Income tax expense

Income tax expense was $6.2 million (-75.6% effective tax rate) in the three months ended February 1, 2025, compared to $1.1 million (-10.5% effective tax rate) in the three months ended January 27, 2024. Income tax expense was $14.6 million (-74.1% effective tax rate) in the nine months ended February 1, 2025, compared to $1.0 million (-1.5% effective tax rate) in the nine months ended January 27, 2024.

The effective tax rate for the three and nine months ended February 1, 2025 differs from the U.S. federal statutory tax rate of 21% primarily due to an increase in a valuation allowance for U.S. deferred tax assets and an unfavorable impact from global intangible low-tax income, partially offset by the impact of income derived from foreign operations with lower statutory tax rates. The effective tax rate for the three and nine months ended January 27, 2024 differs from the U.S. federal statutory tax rate of 21% primarily due to income derived from foreign operations with lower statutory tax rates and research deductions claimed in foreign jurisdictions, partially offset by global intangible low-tax income and non-deductible expenses.

Net loss

Net loss was $14.4 million in the three months ended February 1, 2025, compared to $11.6 million in the three months ended January 27, 2024. Net loss was $34.3 million in the nine months ended February 1, 2025, compared to $66.0 million in the nine months ended January 27, 2024. The net loss was a result of the reasons described above.

30

Reportable Operating Segments

Automotive

	Three Months Ended						Nine Months Ended
	February 1, 2025			January 27, 2024			February 1, 2025			January 27, 2024
($ in millions)	(13 Weeks)			(13 Weeks)			(40 Weeks)			(39 Weeks)
Net sales
North America	$	51.8		$	56.7		$	187.8		$	194.4
Europe, the Middle East & Africa ("EMEA")		55.9			52.0			181.7			153.9
Asia		8.0			31.0			26.5			104.0
Net sales		115.7			139.7			396.0			452.3
Gross profit	$	3.0		$	4.5		$	25.8		$	31.4
As a percent of net sales		2.6	%		3.2	%		6.5	%		6.9	%
Loss from operations	$	(9.0	)	$	(11.0	)	$	(14.0	)	$	(75.3	)
As a percent of net sales		(7.8	)%		(7.9	)%		(3.5	)%		(16.6	)%

Net sales

Automotive segment net sales decreased $24.0 million, or 17.2%, to $115.7 million in the three months ended February 1, 2025, compared to $139.7 million in the three months ended January 27, 2024. Excluding foreign currency translation, net sales decreased $22.3 million.

Net sales in North America decreased $4.9 million to $51.8 million in the three months ended February 1, 2025, compared to $56.7 million in the three months ended January 27, 2024. The decrease was due to the roll-off of legacy programs, partially offset by new program launches. Net sales in EMEA increased $3.9 million to $55.9 million in the three months ended February 1, 2025, compared to $52.0 million in the three months ended January 27, 2024. Excluding foreign currency translation, net sales in EMEA increased $5.4 million due to new program launches, partially offset by lower sales volumes of sensor products. Net sales in Asia decreased $23.0 million to $8.0 million in the three months ended February 1, 2025, compared to $31.0 million in the three months ended January 27, 2024. Excluding foreign currency translation, net sales in Asia decreased $22.8 million primarily due to a program roll-off.

Automotive segment net sales decreased $56.3 million, or 12.4%, to $396.0 million in the nine months ended February 1, 2025, compared to $452.3 million in the nine months ended January 27, 2024. Excluding foreign currency translation, net sales decreased $55.8 million.

Net sales in North America decreased $6.6 million to $187.8 million in the nine months ended February 1, 2025, compared to $194.4 million in the nine months ended January 27, 2024. The decrease was due to the roll-off of legacy programs, partially offset by new program launches. Net sales in EMEA increased $27.8 million to $181.7 million in the nine months ended February 1, 2025, compared to $153.9 million in the nine months ended January 27, 2024. Excluding foreign currency translation, net sales in EMEA increased $28.2 million due to new program launches, partially offset by lower sales volumes of sensor products. Net sales in Asia decreased $77.5 million to $26.5 million in the nine months ended February 1, 2025, compared to $104.0 million in the nine months ended January 27, 2024. Excluding foreign currency translation, net sales in Asia decreased $77.4 million primarily due to a program roll-off.

Gross profit

Automotive segment gross profit decreased $1.5 million, or 33.3%, to $3.0 million in the three months ended February 1, 2025, compared to $4.5 million in the three months ended January 27, 2024. Excluding foreign currency translation, gross profit decreased $1.1 million. Gross profit margins decreased to 2.6% in the three months ended February 1, 2025, compared to 3.2% in the three months ended January 27, 2024. The decrease in gross profit was primarily due to lower sales volumes in Asia, partially offset by lower freight costs.

Automotive segment gross profit decreased $5.6 million, or 17.8%, to $25.8 million in the nine months ended February 1, 2025, compared to $31.4 million in the nine months ended January 27, 2024. Gross profit margins decreased to 6.5% in the nine months ended February 1, 2025, compared to 6.9% in the nine months ended January 27, 2024. The decrease in gross profit was due to lower sales volumes in Asia and higher salary and warranty expense, partially offset by lower freight costs.

31

Loss from operations

Automotive segment loss from operations was $9.0 million in the three months ended February 1, 2025, compared to $11.0 million in the three months ended January 27, 2024. The improvement was due to lower selling and administrative expenses, partially offset by lower gross profit. Selling and administrative expenses decreased due to lower compensation expense.

Automotive segment loss from operations was $14.0 million in the nine months ended February 1, 2025, compared to $75.3 million in the nine months ended January 27, 2024. Loss from operations in the nine months ended January 27, 2024, included goodwill impairment of $56.5 million. Excluding goodwill impairment, loss from operations decreased $4.8 million. The improvement was due to lower selling and administrative expenses, partially offset by lower gross profit. Selling and administrative expenses decreased due to lower outbound freight, travel and entertainment expense, compensation expense and professional fees.

Industrial

	Three Months Ended						Nine Months Ended
	February 1, 2025			January 27, 2024			February 1, 2025			January 27, 2024
($ in millions)	(13 Weeks)			(13 Weeks)			(40 Weeks)			(39 Weeks)
Net sales	$	111.9		$	107.1		$	354.8		$	342.9
Gross profit	$	35.2		$	30.3		$	106.0		$	103.8
As a percent of net sales		31.5	%		28.3	%		29.9	%		30.3	%
Income from operations	$	22.6		$	18.9		$	63.8		$	68.8
As a percent of net sales		20.2	%		17.6	%		18.0	%		20.1	%

Net sales

Industrial segment net sales increased $4.8 million, or 4.5%, to $111.9 million in the three months ended February 1, 2025, compared to $107.1 million in the three months ended January 27, 2024. Excluding foreign currency translation, net sales increased $6.4 million.

Industrial segment net sales increased $11.9 million, or 3.5%, to $354.8 million in the nine months ended February 1, 2025, compared to $342.9 million in the nine months ended January 27, 2024. Excluding foreign currency translation, net sales increased $12.1 million.

The increase in both periods was due to higher sales volumes of power distribution products for data centers, partially offset by lower sales volumes for lighting products in the commercial vehicle and off-road equipment markets.

Gross profit

Industrial segment gross profit increased $4.9 million, or 16.2%, to $35.2 million in the three months ended February 1, 2025, compared to $30.3 million in the three months ended January 27, 2024. Excluding foreign currency translation, gross profit increased $5.5 million. Gross profit margins increased to 31.5% in the three months ended February 1, 2025, compared to 28.3% in the three months ended January 27, 2024. Gross profit improved due to higher sales volumes and lower operating expenses.

Industrial segment gross profit increased $2.2 million, or 2.1%, to $106.0 million in the nine months ended February 1, 2025, compared to $103.8 million in the nine months ended January 27, 2024. Excluding foreign currency translation, gross profit increased $2.5 million. Gross profit improved due to higher sales volumes and lower operating expenses. Gross profit margins decreased to 29.9% in the nine months ended February 1, 2025, compared to 30.3% in the nine months ended January 27, 2024 due to product mix.

Income from operations

Industrial segment income from operations increased $3.7 million, or 19.6%, to $22.6 million in the three months ended February 1, 2025, compared to $18.9 million in the three months ended January 27, 2024. Excluding foreign currency translation, income from operations increased $4.1 million. The increase was primarily due to higher gross profit, partially offset by higher selling and administrative expenses. The increase in selling and administrative expenses was primarily due to higher compensation expense, partially offset by lower legal fees.

Industrial segment income from operations decreased $5.0 million, or 7.3%, to $63.8 million in the nine months ended February 1, 2025, compared to $68.8 million in the nine months ended January 27, 2024. Excluding foreign currency translation, income from operations decreased $4.9 million. The decrease was primarily due to higher selling and administrative expenses, partially offset by higher gross profit. The increase in selling and administrative expenses was primarily due to higher legal fees and compensation expense.

32

Interface

	Three Months Ended						Nine Months Ended
	February 1, 2025			January 27, 2024			February 1, 2025			January 27, 2024
($ in millions)	(13 Weeks)			(13 Weeks)			(40 Weeks)			(39 Weeks)
Net sales	$	12.3		$	12.7		$	40.2		$	39.6
Gross profit	$	2.9		$	2.2		$	10.7		$	7.7
As a percent of net sales		23.6	%		17.3	%		26.6	%		19.4	%
Income from operations	$	2.2		$	1.5		$	8.8		$	5.4
As a percent of net sales		17.9	%		11.8	%		21.9	%		13.6	%

Net sales

Interface segment net sales decreased $0.4 million, or 3.1% to $12.3 million in the three months ended February 1, 2025, compared to $12.7 million in the three months ended January 27, 2024. The decrease was primarily due to lower sales volumes of transceivers for servers, partially offset by higher sales volumes for touch panels for appliances.

Interface segment net sales increased $0.6 million, or 1.5%, to $40.2 million in the nine months ended February 1, 2025, compared to $39.6 million in the nine months ended January 27, 2024. The increase was due to higher sales volumes of touch panels for appliances.

Gross profit

Interface segment gross profit increased $0.7 million, or 31.8%, to $2.9 million in the three months ended February 1, 2025, compared to $2.2 million in the three months ended January 27, 2024. Gross profit margins increased to 23.6% in the three months ended February 1, 2025, compared to 17.3% in the three months ended January 27, 2024. The improvement was due to product mix.

Interface segment gross profit increased $3.0 million, or 39.0%, to $10.7 million in the nine months ended February 1, 2025, compared to $7.7 million in the nine months ended January 27, 2024. Gross profit margins increased to 26.6% in the nine months ended February 1, 2025, compared to 19.4% in the nine months ended January 27, 2024. The improvement was primarily due to higher sales volumes and product mix.

Income from operations

Interface segment income from operations increased $0.7 million, or 46.7%, to $2.2 million in the three months ended February 1, 2025, compared to $1.5 million in the three months ended January 27, 2024.

Interface segment income from operations increased $3.4 million, or 63.0%, to $8.8 million in the nine months ended February 1, 2025, compared to $5.4 million in the nine months ended January 27, 2024.

The increase in both periods was primarily due to higher gross profit and slightly lower selling and administrative expenses.

Medical

	Three Months Ended					Nine Months Ended
	February 1, 2025		January 27, 2024			February 1, 2025		January 27, 2024
(in millions)	(13 Weeks)		(13 Weeks)			(40 Weeks)		(39 Weeks)
Net sales	$	—	$	—		$	—	$	2.4
Gross profit	$	—	$	(0.1	)	$	—	$	(0.2	)
Loss from operations	$	—	$	(0.1	)	$	—	$	(3.0	)

In the first quarter of fiscal 2024, we made the decision to initiate the discontinuation of the Dabir business (which accounts for all of the Medical segment's financial results). Towards the end of the second quarter of fiscal 2024, we sold certain assets of the Dabir business and have now exited this business, which accounts for the variances in the table above.

33

Financial Condition, Liquidity and Capital Resources

Our liquidity requirements are primarily to fund our business operations, including capital expenditures and working capital requirements, as well as to fund debt service requirements, dividends and stock repurchases. Our primary sources of liquidity are cash flows from operations, existing cash balances and borrowings under our senior secured credit agreement. We believe our liquidity position will be sufficient to fund our existing operations and current commitments for at least the next twelve months. However, if economic conditions remain impacted for longer than we expect due to supply chain disruptions, inflationary pressure or other geopolitical risks, or if we are unable to maintain compliance with our debt covenants, our liquidity position could be severely impacted.

As of February 1, 2025, we had $103.8 million of cash and cash equivalents, of which $71.4 million was held in subsidiaries outside the U.S. Cash held by these subsidiaries is used to fund operational activities and can be repatriated, primarily through the payment of dividends and the repayment of intercompany loans, without creating material additional income tax expense.

Repurchases of Common Stock

On March 31, 2021, as subsequently amended on June 16, 2022, the Board of Directors authorized the purchase of up to $200.0 million of our outstanding common stock through June 14, 2024 (the “2021 Buyback Authorization”). On June 13, 2024, the Board of Directors approved a new share buyback authorization, commencing on June 17, 2024, for the purchase of up to $200.0 million of our outstanding common stock through June 17, 2026 (the “2024 Buyback Authorization”). Purchases may be made on the open market, including pursuant to purchase plans designed to comply with Rule 10b5-1 of the Securities Exchange Act of 1934, or in private transactions. Prior to its expiration, a total of 3,553,961 shares were purchased under the 2021 Buyback Authorization at a total cost of $134.6 million. No further shares can be purchased under the 2021 Buyback Authorization. In the three and nine months ended February 1, 2025, zero and 136,000 shares were purchased under the 2021 Buyback Authorization and no shares were purchased under the 2024 Buyback Authorization. As of February 1, 2025, the dollar value of shares that remained available to be purchased under 2024 Buyback Authorization was $200.0 million.

Amended Credit Agreement

On October 31, 2022, we entered into a Second Amended and Restated Credit Agreement (the “Credit Agreement”) with Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, and the Lenders and other parties named therein. On March 6, 2024, we entered into a First Amendment to Second Amended and Restated Credit Agreement (the “First Amendment”) and on July 9, 2024, we entered into a Second Amendment to Second Amended and Restated Credit Agreement and First Amendment to Second Amended and Restated Guaranty (the “Second Amendment”) with Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, the other Lenders party thereto and other parties thereto.

Among other things, the Second Amendment (i) reduced the revolving credit commitments under the Credit Agreement from $750 million to $500 million, (ii) granted a security interest in substantially all of the personal property of the Company and our U.S. subsidiaries that are guarantors, including 100% of the equity interests of their respective U.S. subsidiaries and 65% of the equity interests of their respective foreign subsidiaries (or such greater amount to the extent such pledge could not reasonably cause adverse tax consequences), (iii) amended the consolidated interest coverage ratio covenant for each quarter in fiscal year 2025, (iv) amended the consolidated leverage ratio covenant for the quarter ending July 27, 2024 and each subsequent fiscal quarter, (v) amended certain interest rate provisions, (vi) added a requirement to provide monthly financial statements to the lenders through the period ending July 25, 2025, (vii) decreased the general basket exceptions to certain covenants restricting certain Company investments, liens and indebtedness for specified periods of time, (viii) increased, for fiscal year 2025, the general basket exception to a covenant restricting certain Company dispositions of property, (ix) added an “anti-cash hoarding” requirement, applicable during the period from the effective date of the Second Amendment until the earlier to occur of (a) the delivery of financial statements and a compliance certificate for the fiscal quarter ending July 25, 2025 and (b) the delivery of compliance certificates for two consecutive fiscal quarters demonstrating that our consolidated leverage ratio as of the last day of such fiscal quarters was less than 3.00:1.00, that if we have cash on hand (subject to certain exceptions) of more than $65 million for 10 consecutive business days, we shall prepay the indebtedness under the credit facility by the amount of such excess and (x) made certain other changes to the investment, restricted payment and indebtedness baskets. The Credit Agreement, as amended by the First Amendment and the Second Amendment, is referred to herein as the “Amended Credit Agreement.”

The Amended Credit Agreement provides for a secured multicurrency revolving credit facility of $500 million. In addition, the Amended Credit Agreement permits us to increase the revolving commitments and/or add one or more tranches of term loans under the Amended Credit Agreement from time to time by up to an amount equal to (i) $250 million plus (ii) an additional amount so long as the consolidated leverage ratio would not exceed 3.00:1.00 on a pro forma basis, subject to, among other things, the receipt of additional commitments from existing and/or new lenders. The Amended Credit Agreement matures on October 31, 2027.

34

As of February 1, 2025, the outstanding balance under the revolving credit facility consisted of $285.0 million (€275.0 million) of euro-denominated borrowings and $45.0 million of US denominated borrowings. The Amended Credit Agreement contains various representations and warranties, financial covenants (including covenants requiring us to maintain compliance with a minimum consolidated interest coverage ratio and a maximum consolidated leverage ratio, in each case as of the end of each fiscal quarter), restrictive and other covenants, and events of default. The covenants in the Amended Credit Agreement include an “anti-cash hoarding” requirement, as discussed above. As of February 1, 2025, we were in compliance with all the covenants in the Amended Credit Agreement. For further information, see Note 8, “Debt” to the condensed consolidated financial statements included in this Quarterly Report.

Although we currently anticipate, based on our current projections and analyses, that we will be in compliance with the financial covenants contained in the Amended Credit Agreement, no assurance can be given that we will be and remain in compliance with such covenants in the future. Factors that could increase our risk of future non-compliance include those identified in Part I – Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended April 27, 2024, as supplemented by subsequent filings with the Securities and Exchange Commission, including under Part II – Item 1A, “Risk Factors” of this Quarterly Report.

Cash Flows

	Nine Months Ended
(in millions)	February 1, 2025			January 27, 2024
Operating activities:
Net loss	$	(34.3	)	$	(66.0	)
Non-cash items		51.0			99.2
Changes in operating assets and liabilities		(25.7	)		(10.6	)
Net cash (used in) provided by operating activities		(9.0	)		22.6
Net cash used in investing activities		(26.7	)		(39.0	)
Net cash used in financing activities		(16.6	)		(15.0	)
Effect of foreign currency exchange rate changes on cash and cash equivalents		(5.4	)		(2.7	)
Decrease in cash and cash equivalents		(57.7	)		(34.1	)
Cash and cash equivalents at beginning of the period		161.5			157.0
Cash and cash equivalents at end of the period	$	103.8		$	122.9

Operating activities

Net cash used in operating activities was $9.0 million in the nine months ended February 1, 2025, compared to net cash provided by operating activities of $22.6 million in the nine months ended January 27, 2024. The decrease was due to lower net loss adjusted for non-cash items and higher cash outflows from operating assets and liabilities. The $25.7 million of cash outflows for operating assets and liabilities in the nine months ended February 1, 2025 was primarily due to higher inventory and lower accounts payable, partially offset by lower accounts receivable.

Investing activities

Net cash used in investing activities was $26.7 million in the nine months ended February 1, 2025, compared to $39.0 million in the nine months ended January 27, 2024. Capital expenditures were $32.5 million in the nine months ended February 1, 2025, compared to $41.1 million in the nine months ended January 27, 2024. In the nine months ended February 1, 2025, we received proceeds of $2.7 million from the sale of assets, compared to $1.5 million in the nine months ended January 27, 2024. In the nine months ended February 1, 2025, we received proceeds of $3.1 million from the settlement of a net investment hedge as compared to $0.6 million in the nine months ended January 27, 2024.

Financing activities

Net cash used in financing activities was $16.6 million in the nine months ended February 1, 2025, compared to $15.0 million in the nine months ended January 27, 2024. We paid cash dividends of $15.3 million in the nine months ended February 1, 2025, compared to $15.0 million in the nine months ended January 27, 2024. In the nine months ended February 1, 2025, we had net proceeds from borrowings of $5.8 million, compared to net proceeds from borrowings of $25.7 million in the nine months ended January 27, 2024. In the nine months ended February 1, 2025, we paid $1.8 million of debt issuance costs associated with the Second Amendment. In the nine months ended February 1, 2025, we used $1.6 million of cash for the purchase of shares under the 2021 Buyback Authorization, compared to $10.8 million in the nine months ended January 27, 2024. In the nine months ended January 27, 2024, we paid $10.9 million for the purchase of redeemable noncontrolling interests related to Nordic Lights.

35

Recent Accounting Pronouncements

See Note 1, “Description of Business and Summary of Significant Accounting Policies” to the condensed consolidated financial statements included in Item 1.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements as defined under SEC rules.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risks from foreign currency exchange, interest rates, and commodity prices, which could affect our operating results, financial position and cash flows. We manage a portion of these risks through use of derivative financial instruments in accordance with our policies. We do not enter into derivative financial instruments for speculative or trading purposes.

There has been no significant change in our exposure to market risk during the nine months ended February 1, 2025. For a discussion of our exposure to market risk, refer to Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” contained in our Annual Report on Form 10-K for the year ended April 27, 2024.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report, we performed an evaluation under the supervision and with the participation of the Company’s management, including our Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”), of our “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934). Our disclosure controls and procedures are designed to ensure that the information required to be disclosed by the Company in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s applicable rules and forms. As a result of this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were not effective as of February 1, 2025 due to the material weaknesses that were previously reported in our Annual Report on Form 10-K for the year ended April 27, 2024.

Notwithstanding the ineffectiveness of our disclosure controls and procedures due to the material weaknesses in our internal control over financial reporting, we believe there are no material inaccuracies or omissions of material fact in this Quarterly Report, and, to the best of our knowledge, we believe that the condensed consolidated financial statements in this Quarterly Report fairly present in all material aspects our financial condition, results of operations and cash flows in conformity with GAAP.

Previously Disclosed Material Weaknesses

As previously disclosed in our Annual Report on Form 10-K for the year ended April 27, 2024, our management concluded that our internal controls over financial reporting were not effective due to a material weakness associated with ineffective information technology general controls (ITGCs) over one of its information technology (IT) systems that is relevant to the preparation of the financial information at a substantial portion of the Company’s subsidiaries throughout the year ended April 27, 2024, which resulted in ineffective business process controls (automated and IT-dependent manual controls) that could result in misstatements potentially impacting significant financial statement accounts and disclosures. Specifically, management did not design and execute program change management controls to provide reasonable assurance that IT program changes affecting financial applications are authorized, tested, and implemented appropriately. As a result, business process controls (automated and IT-dependent manual controls) that are reliant on the affected ITGCs, or that use data produced from the affected systems, were deemed ineffective at April 27, 2024.

Management also identified a material weakness associated with ineffective controls over its impairment analyses for goodwill. Specifically, management did not retain sufficient contemporaneous documentation to demonstrate the operation of sufficiently precise review controls over certain significant assumptions used in the determination of fair value of its reporting units.

Management also identified a material weakness associated with ineffective controls related to the application of GAAP to non-routine events and conditions. Specifically, we did not design and maintain controls to properly evaluate all of the events and conditions relevant to the Company’s going concern evaluation, including the assessment and disclosure of management’s plans in accordance with GAAP.

We are committed to maintaining a strong internal control environment. We and our Board of Directors treat the controls surrounding, and the integrity of, our financial statements with the utmost priority. Management is committed to the planning and implementation of remediation efforts to address control deficiencies and any other identified areas of risk. These remediation efforts are intended to both address the identified material weaknesses and to enhance our overall financial control environment.

36

Our remediation efforts include, among other items, (1) enhancing the design and operating effectiveness of internal controls over IT change management, review of significant assumptions used in goodwill impairment analyses, and the application of GAAP to non-routine events and conditions; and (2) developing and deploying additional training programs around the operation and importance of these controls.

As we continue to evaluate and work to improve our internal control over financial reporting, management may determine to take additional measures to strengthen controls or to modify the remediation plan described above. When fully implemented and operational, we believe the controls we have designed or plan to design will remediate the control deficiencies that led to the material weaknesses we have identified and strengthen our internal controls over financial reporting. The material weaknesses will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

Changes in Internal Control over Financial Reporting

Except as described above, there have been no changes in our internal control over financial reporting during the three months ended February 1, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

37

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

See Note 12, “Contingencies” to the condensed consolidated financial statements included in this Quarterly Report for a description of certain of our pending legal proceedings.

Item 1A. Risk Factors

Our business, financial condition, results of operations and cash flows are subject to various ‎risks which could cause actual results to vary from recent results or from anticipated future results. ‎Please refer to Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended April 27, 2024, for a description of certain material risks and uncertainties to which our business, financial condition and results of operations are subject. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially ‎and adversely affect our business, financial condition and/or operating results.‎

Except as updated below, there have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended April 27, 2024:

We are, and in the future may be, subject to securities class action and other litigation, as well as government investigations and inquiries, which may harm our business and results of operations.

We are involved in legal proceedings related to various matters, including securities litigation, and may become involved in other legal proceedings, as well as government investigations and inquiries, that arise from time to time in the future. For example, as discussed further in Note 12, “Contingencies” to the unaudited interim condensed consolidated financial statements contained in this Quarterly Report, on August 26, 2024, a purported shareholder of the Company filed a putative class action lawsuit alleging that the Company, its former Chief Executive Officer, and its former Chief Financial Officer violated the federal securities laws by making false and/or misleading statements relating to our business, operations and prospects, including in respect of our transition to production of more specialized components for manufacturers of electric vehicles and our operations at our facility in Monterrey, Mexico. The complaint seeks unspecified money damages along with equitable relief and costs and expenses, including counsel fees and expert fees. Another purported shareholder filed a substantially similar action against the same defendants and a former Chief Operating Officer of the Company on October 7, 2024. In addition, on November 26, 2024 and February 4, 2025, respectively, two purported shareholders filed derivative lawsuits on behalf of the Company against the current members of the Company’s Board of Directors, as well as certain former directors and executives, alleging that the defendants breached their fiduciary duties by allowing the Company to issue various statements that are alleged to have been false or misleading for the same reasons alleged in the securities class action complaints. The Company intends to vigorously defend itself against the allegations but there can be no assurance as to outcome. An unfavorable outcome in this litigation and other legal proceedings may have a material adverse effect on the consolidated financial position, results of operations, cash flows or liquidity of the Company. This type of litigation can also result in substantial costs, and a diversion of management’s attention and resources, which could adversely affect our business, operating results, or financial condition. In addition, the Company received a subpoena from the Securities and Exchange Commission dated November 1, 2024 seeking documents and information relating to, among other things, the Company’s operations in certain foreign countries, and certain financial reporting and accounting relating thereto, compliance with the Foreign Corrupt Practices Act and other anti-corruption laws, and material weaknesses in the Company’s internal control over financial reporting previously reported in its public filings. This request may lead to the assertion of claims or the commencement of legal proceedings against the Company, which in turn may lead to material fines, penalties or other liabilities. The subpoena and similar requests could result in costs to the Company, including the expenditure of financial and managerial resources in connection with responding to the subpoena and related investigation or any other future requests for information or investigations. Additionally, the dramatic increase in the cost of directors’ and officers’ liability insurance may cause us to opt for lower overall policy limits or to forgo insurance that we may otherwise rely on to cover any significant defense costs, settlements, and damages awarded to plaintiffs, or incur substantially higher costs to maintain the same or similar coverage. These factors may make it more difficult to attract and retain qualified executive officers and members of our board of directors.

38

We operate our business on a global basis and changes to trade policy, including tariffs and customs regulations, could have a material and adverse effect on our business.

We manufacture and sell our products globally and rely on a global supply chain to deliver the required raw materials, components, and parts, as well as the final products to our customers. Existing free trade laws and regulations, such as the United States-Mexico-Canada Agreement, provide certain duties and tariffs for qualifying imports and exports, subject to compliance with the applicable classification and other requirements. Changes in laws or policies governing the terms of foreign trade, and in particular increased trade restrictions, tariffs or taxes on imports from countries or geographic regions where we manufacture products, such as Canada, China, Egypt, Europe and Mexico, could have a material adverse effect on our business, financial condition and operating results. The U.S. and Chinese governments have imposed a series of significant incremental retaliatory tariffs to certain imported products. Most notably with respect to the automotive and commercial vehicle industries, the U.S. imposed tariffs on imports of electric vehicles and certain steel, aluminum and automotive components, and China imposed retaliatory tariffs on imports of U.S. vehicles and certain automotive components. The U.S. has also ordered an investigation into the imports of copper, particularly from China. Depending upon their continued duration and potential expansion, these tariffs and other regulatory actions could materially affect our business, including in the form of an increase in cost of goods sold, decreased margins, increased pricing for customers, and reduced sales.

As of March 4, 2025, the U.S. has enacted a 25% tariff on all goods imported from Mexico and Canada, and an additional 20% tariff on goods imported from China. Canada has announced a plan to imminently introduce 25% tariffs on a rolling schedule on a variety of U.S. goods, and Mexico has also indicated that it intends to impose retaliatory tariffs on U.S. goods. We do not know when such tariffs will take effect, how long any of these tariffs will last, or if some products may initially or eventually be subject to a different rate or be exempted. We continue to monitor statements made and actions taken by the U.S. government regarding tariffs on goods imported into the U.S. from Mexico, Canada, and other countries. We continue to also monitor similar actions by other countries with which we do business. It is possible other countries may impose retaliatory tariffs on goods imported into their countries from the U.S.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On June 13, 2024, the Board of Directors approved a share buyback authorization, commencing on June 17, 2024, for the purchase of up to $200.0 million of our outstanding common stock through June 17, 2026 (the “2024 Buyback Authorization”). Purchases under the 2024 Buyback Authorization may be made on the open market, including pursuant to purchase plans designed to comply with Rule 10b5-1 of the Securities Exchange Act of 1934, or in private transactions. We have not made any purchases under the 2024 Buyback Authorization.

The following table provides information about our purchases of equity securities during the three months ended February 1, 2025.

Period	Total number of shares purchased1		Average price paid per share		Total number of shares purchased as part of publicly announced plan		Approximate dollar value of shares that may yet be purchased under the program (in millions)
November 3, 2024 through November 30, 2024		325,816	$	9.03		—	$	200.0
December 1, 2024 through January 4, 2025		296	$	12.73		—	$	200.0
January 5, 2025 through February 1, 2025		—	$	—		—	$	200.0
(1) Represents 326,112 shares of common stock that were surrendered by employees to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Item 5. Other Information

During our last fiscal quarter, no director or officer of the Company, as defined in Rule 16a-1(f), adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” each as defined in Item 408 of Regulation S-K.

39

Item 6. Exhibits

Exhibit Number	Description
10.1**	Amendment to Offer Letter dated June 24, 2024 between Methode Electronics, Inc. and John DeGaynor.
10.2**	Amendment to Offer Letter dated August 27, 2024 between Methode Electronics, Inc. and Laura Kowalchik.
10.3**	Settlement Agreement and Release between Methode Electronics, Inc. and Avinash Avula.
10.4**	Separation Agreement between Methode Electronics, Inc. and Andrea J. Barry (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 30, 2025).
31.1	Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer.
31.2	Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer.
32*	Certification of Periodic Financial Report Pursuant to 18 U.S.C. Section 1350.
101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Schema With Embedded Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
*	Indicates that the exhibit is being furnished with this report and not filed as part of it.
**	Management compensatory plan.

40

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		METHODE ELECTRONICS, INC.
		By:	/s/ Laura Kowalchik
			Laura Kowalchik
			Chief Financial Officer
			(Principal Financial Officer)
Dated:	March 5, 2025

41

EX-10.1

Exhibit 10.1

Methode Electronics, Inc.

8750 West Bryn Mawr Avenue, Suite 1000

Chicago, Illinois 60131

January 21, 2025

Dear Jon:

By this letter (this “Offer Letter Amendment”), we agree to amend certain terms of your Offer Letter dated as of June 24, 2024 (the “Offer Letter”) as follows.

The first sentence in the Offer Letter next to the heading “Relocation and Personal Travel” (which now reads “Temporary housing will be covered for a period of up to twelve (12) months.”) is deleted and replaced with the following sentence:

Temporary housing will be covered for a period of up to twelve (12) months, and any amounts paid to you for such temporary housing shall be grossed up for applicable income and employment taxes.

Except as modified by this Offer Letter Amendment, the Offer Letter shall remain in full force and effect.

Please sign, date and return a copy of this Offer Letter Amendment to Ms. Andrea Barry at the Company, and retain a copy for your records.

Sincerely,

METHODE ELECTRONICS, INC.

By: /s/ Bruce Crowther

Bruce Crowther
Chair of the Compensation Committee

ACKNOWLEDGMENT AND AGREEMENT

I have read and agree to the above terms and conditions.

/s/ Jonathan DeGaynorJanuary 21, 2025

Jonathan DeGaynor Date

EX-10.2

Exhibit 10.2

Methode Electronics, Inc.

8750 West Bryn Mawr Avenue, Suite 1000

Chicago, Illinois 60131

January 21, 2025

Dear Laura:

By this letter (this “Offer Letter Amendment”), we agree to amend certain terms of your Offer Letter dated as of August 27, 2024 (the “Offer Letter”) as follows.

The first sentence in the Offer Letter next to the heading “Relocation and Personal Travel” (which now reads “Temporary housing will be covered for a period of up to six (6) months.”) is deleted and replaced with the following sentence:

Temporary housing will be covered for a period of up to six (6) months, and any amounts paid to you for such temporary housing shall be grossed up for applicable income and employment taxes.

Except as modified by this Offer Letter Amendment, the Offer Letter shall remain in full force and effect.

Please sign, date and return a copy of this Offer Letter Amendment to Ms. Andrea Barry at the Company, and retain a copy for your records.

Sincerely,

METHODE ELECTRONICS, INC.

By: /s/ Bruce Crowther

Bruce Crowther
Chair of the Compensation Committee

ACKNOWLEDGMENT AND AGREEMENT

I have read and agree to the above terms and conditions.

/s/ Laura KowalchikJanuary 21, 2025

Laura Kowalchik Date

EX-10.3

Exhibit 10.3

SETTLEMENT AGREEMENT AND RELEASE

This SETTLEMENT AGREEMENT AND RELEASE (this “Agreement”) is made and entered into between Avinash Avula (“Executive”) and Methode Electronics, Inc. (the “Company”) (Executive and the Company hereinafter being sometimes collectively referred to as the “Parties” and, individually, as a “Party”).

RECITALS

WHEREAS, disputes have arisen between Executive and the Company which are the subject of multiple claims asserted in: (1) a Complaint filed by Executive in The Superior Court of California San Mateo County, captioned Avinash Avula v. Methode Electronics, Inc., Case No. 24-CIV-05348 (“Lawsuit”); (2) a Demand for Arbitration filed by the Company with the American Arbitration Association (AAA) (“Demand”) and styled as Methode Electronics, Inc. v. Avinash Avula, AAA Case No. 01-24-0006-4787; and (3) a Motion to Compel Arbitration filed by the Company in the Circuit Court of Cook County, Illinois, captioned Methode Electronics, Inc. v. Avinash Avula, Case No. 2024CH09426 (“Motion”) (the Lawsuit, Demand, and Motion being sometimes collectively referred to herein as the “Proceedings”);

WHEREAS, the Company and Executive dispute the claims and allegations made in these Proceedings and deny any and all wrongdoing or liability whatsoever;

WHEREAS, in exchange for good and valuable consideration the receipt of which is hereby acknowledged, the Parties, by this Agreement, intend to settle, compromise and release, fully and completely, all existing and potential disputes, claims and controversies of any type or nature that may effectively be released under the law and which could be asserted relating to Executive’s relationship with the Company or otherwise, including without limitation the claims made in the Proceedings, with each of the Parties to bear his/its own costs and attorneys’ fees; and

NOW THEREFORE, for and in consideration of the representations, promises, covenants, agreements and acknowledgments made herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:

COVENANTS

1.Dismissal of Proceedings. As a condition of this Agreement, it is expressly understood and agreed by the Parties that all Proceedings between them shall be dismissed with prejudice and finality as to all claims, demands and causes of action between them. Such dismissals shall also reflect that each Party shall bear his/its own attorneys’ fees and costs. Counsel for Executive and the Company shall work cooperatively to execute and file all documents necessary as required by the Courts presiding over the Lawsuit and Motion and by AAA to achieve final dismissals, with prejudice, of the Proceedings. The execution and filing of such documents shall occur within five days of the Effective Date of this Agreement. The Parties agree that, except as expressly provided for in this Agreement, each Party shall bear his/its own respective costs and attorneys’ fees relating to the Proceedings and securing the final dismissals with prejudice described in this section.

- 1 -

2.Settlement Payment. As the monetary consideration for the settlement and full release of all claims by Executive, the Company agrees that not later than fourteen (14) days following the Effective Date of this Agreement (as defined below), the Company shall effectuate a wire transfer to Executive in accordance with instructions to be provided by Executive’s counsel in the total amount of six-hundred-fifty-thousand-dollars-and-zero-cents ($650,000.00), for which a Form 1099 to Executive will issue. Executive will complete and submit to the Company an IRS Form W-9 as a condition of payment.

3.Release of Claims by Executive.

(a)General Release. In consideration of the benefits provided under this Agreement, Executive, for and on behalf of himself and each of his heirs, administrators, executors, personal representatives, beneficiaries, successors and assigns, fully and completely releases the Company and its respective current and former parents, subsidiaries, and affiliates, and each of their respective current and former shareholders, owners, directors, officers, employees, benefit plans, plan fiduciaries, professional employer organizations, managers, members, partners, agents, trustees, insurers, representatives, heirs, administrators, executors, personal representatives, beneficiaries, attorneys, transferees, predecessors, successors and assigns (collectively, the “Releasees”), collectively, separately, and severally, of and from any and all claims, demands, damages, causes of action, actions, debts, indebtedness, liabilities, controversies, judgments, and suits of every kind and nature whatsoever, foreseen and unforeseen, known and unknown, accrued and unaccrued which Executive has had, now has, or may have against the Releasees (or any of them) from the beginning of time up until the time Executive signs this Agreement, with the exception of (i) any claims which cannot legally be waived by private agreement; (ii) any claims which may arise after the date Executive signs this Agreement; and(iii) any claims for breach of this Agreement. Subject to the limitations in the immediately preceding sentence, this general release of claims includes without limitation all claims arising under any federal, state or local law, statute, rule, regulation, order or ordinance, constitutional provision, public policy, common law or at equity, including without limitation all claims under Title VII of the Civil Rights Act of 1964, the Equal Pay Act, the Civil Rights Act of 1866, the Civil Rights Act of 1871, Executive Order 11246, the Employee Retirement Income Security Act (with respect to unvested benefits), the Consolidated Omnibus Budget Reconciliation Act, the Americans with Disabilities Act, the Rehabilitation Act, the Family and Medical Leave Act of 1993, the Age Discrimination in Employment Act, the Fair Labor Standards Act, the Equal Pay Act of 1963, the Worker Adjustment and Retraining Notification Act, 31 U.S.C. § 3730(h), the National Labor Relations Act, the Illinois Human Rights Act, the California Fair Employment and Housing Act, the California Family Rights Act, the California Pregnancy Disability Leave Law, the California Labor Code, the Private Attorneys General Act, and the California Business & Professions Code, all as amended; all claims for breach of any express or implied contract; all claims for breach of any covenant of good faith and fair dealing; all claims for promissory estoppel or detrimental reliance; all claims for wages, bonuses, compensation, benefits, expenses, severance, penalties, liquidated damages, and interest; all tort claims (including without limitation claims for fraud, slander, libel, defamation, disparagement, assault, battery, false imprisonment, and emotional distress); all employment-related claims, including without limitation wrongful termination, constructive discharge, discrimination, harassment, retaliation; all claims threatened or that could have been threatened in the Lawsuit; all claims asserted in the Lawsuit; all claims for compensatory, general, specific, exemplary, or injunctive relief, specific performance, or punitive

- 2 -

damages, or any other claim for damages, restitution, relief or injury of any kind whatsoever; and all claims for monetary recovery, including, without limitation, attorneys’ fees, expert fees, medical fees or expenses, costs and disbursements.

(b)Notwithstanding anything herein to the contrary or the generality of the foregoing, the release of claims recited in this Section 3 does not extend to, but expressly excludes, claims to workers’ compensation benefits, to unemployment compensation benefits, or to any other rights or benefits that, as a matter of law, may not be waived or released, including but not limited to non-waivable rights that Executive may have under federal and/or any state’s law. Executive’s releases through this Agreement shall also not limit or restrict Executive’s right to file a charge, complaint or report with, to participate or to cooperate in any investigation or inquiry conducted by or to share in any recovery secured by any Government Agency (see Sections 7 and 10, below), except as provided in the next sentence with respect to any potential claim filed by the U.S. Equal Employment Opportunity Commission (“EEOC”). This Agreement does not prevent Executive from filing a charge, testifying, assisting, or ‎cooperating with the EEOC, but Executive waives any right to any relief of any kind should the ‎EEOC pursue any claim on his behalf. Notwithstanding ‎any other provision of this Agreement, nothing ‎in this ‎Agreement limits Executive’s right to ‎receive an award for information ‎provided to the U.S. Securities and Exchange Commission (“‎SEC”).‎ ‎ ‎

(c)Section 1542 Acknowledgement. Executive acknowledges that he has been advised of California Civil Code Section 1542, which reads as follows:

A general release does not extend to claims which the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

Executive agrees that he is waiving any and all rights he may have under California Civil Code Section 1542 with respect to the general release of claims in this Section 3. In connection with this waiver, Executive acknowledges that he may hereafter discover claims presently unknown or unsuspected, or facts in addition to or different from those which he may now know or believe to be true, with respect to the claims released pursuant to this Section 3. Nevertheless, Executive intends to and does by this Agreement release, fully, finally and forever, in the manner described in this Section 3, all such claims as provided therein. This Agreement shall constitute the full and absolute release of all claims and rights released in this Agreement, notwithstanding the discovery or existence of any additional or different claims or facts relating thereto.

(d)Covenant Not to Sue. Except for an action brought to enforce this Agreement or as otherwise provided in Sections 3(a), 7, and 10, to the fullest extent permitted by law, Executive agrees to refrain from initiating or participating in any proceeding of any kind against any of the Releasees relating to matters released in this Agreement. As a condition of this settlement, it is expressly understood and agreed by the Parties that the Proceedings shall be dismissed, with prejudice, as to all named defendants, respondents, and all causes of action. The Parties agree that except as expressly provided for in this Agreement, each Party shall bear its own respective costs and attorneys’ fees relating to the Proceedings.

- 3 -

4.Executive’s Release of ADEA Claims.

(a) ADEA Claims Released. Executive understands that the general release set forth in Section 3 above includes a release of any claims he may have, if any, against the Releasees under the Age Discrimination in Employment Act of 1967, as amended (the “ADEA”). Executive understands that his waiver of rights and claims under the ADEA does not extend to any ADEA rights or claims arising after the date he signs this Agreement and he is not prohibited from challenging the validity of this release and waiver of claims under the ADEA.

(b) Consideration Period. Executive acknowledges that he has been given a period of at least twenty-one (21) days from the date this Agreement was initially delivered to him to decide whether to sign this Agreement. If he decides to sign this Agreement before the expiration of the consideration period, which is solely his choice, he represents that his decision is knowing and voluntary. Executive agrees that any revisions made to this Agreement after it was initially delivered to him were either not material or were requested by Executive, and do not re-start the consideration period. Executive is hereby advised to consult with his counsel prior to signing this Agreement.

(c) Revocation Period; Effective Date. Executive understands that he may revoke this Agreement within seven (7) days after he has signed it (the “Revocation Period”). In the event he chooses to revoke this Agreement, Executive must notify the Company in writing in accordance with Section 4(d) below, in which case this Agreement shall have no force or effect. This Agreement will become effective on the date immediately following the expiration of the Revocation Period (the “Effective Date”).

(d) Revocation Notice to Company. Any revocation of this Agreement pursuant to the foregoing Section 4(c) must be received by the Company’s Counsel, Bilal Zaheer, at bilal.zaheer@lockelord.com, in accordance hereof on or before 5:00 p.m. Central Time before expiration of the Revocation Period stated in Section (4)(c).

5.Company’s General Release of All Claims. The Company unqualifiedly waives, releases and discharges any and all claims against the Executive that it has, had, or may have through the date the Company executes this Agreement, whether known or unknown. Without limiting the generality of the foregoing, the Company specifically waives, releases and discharges all claims for or seeking from Executive the claw back, disgorgement, reimbursement or recovery of any benefits or compensation paid to Executive at any time, including without limitation the sums sought through the Demand. The Company’s waiver and release herein is intended to bar any form of legal claim, charge, complaint, arbitration, demand or any other form of action or proceeding against Executive seeking any form of relief including, without limitation, monetary damages, equitable relief (whether declaratory, injunctive or otherwise), the recovery of any

- 4 -

damages or any other form of monetary recovery whatsoever (including, without limitation, compensatory damages, punitive damages, attorneys’ fees and any other costs) against Executive, for any alleged action, inaction or circumstance which may arise or has arisen through the date the Company executes this Agreement. Notwithstanding anything herein to the contrary or the generality of the foregoing, the release of claims recited in this Section 5 does not extend to, but expressly excludes: (i) any rights or claims that, as a matter of law, may not be waived or released, including but not limited to non-waivable rights that the Company may have under federal and/or any state’s law; (ii) any claims which may arise after the date the Company signs this Agreement; and (iii) any claims for breach of this Agreement.

6.Representations and Warranties.

The Parties represent and warrant that:

(a)No litigation, charge or other proceeding other than the Proceedings have been filed or are pending by or between Executive and the Company or any of the other Releasees, nor have the Parties or any of the Releasees sold, assigned, transferred, conveyed or otherwise disposed of any of the claims, demands, obligations, or causes of action released herein; and

(b)Executive has been properly paid for all hours worked, and, subject to the Company making the Settlement Payment required by Section 2 hereof, the Executive shall have received all compensation due, including accrued and unused vacation / PTO, through and including his separation date.

7.Non-disparagement. Executive shall not make any statement or take any action (or cause anyone else to make a statement or take any action) that impugns the reputation or disparages the Company, except for such statements as may be specifically allowed by this Agreement. The Company will ensure that the following individuals shall not make any statement or take any action (or cause anyone else to make a statement or take any action) that impugns the reputation or disparages Executive: its president and chief executive officer, its chief administrative officer, chief financial officer, chief human resources officer/SVP human resources, its general counsel, its vice president North America; and the members of its board of directors. The ‎Company’s obligations with respect to any individual named ‎in the ‎‎preceding sentence cease ‎upon the named individual ending his or ‎her ‎‎employment with the Company (or, in the case of board members, the ending of such board member’s appointment).‎ Notwithstanding the foregoing, nothing in this Agreement shall apply to or restrict in any way the communication of any information by any Party or the individuals identified in this Section 7, in whatever form, to: (i) any person acting on behalf of a Government Agency conducting an investigation about which the Party or individual has relevant information; or (ii) any other person if required to do so by subpoena, court order or other legal process. Furthermore, nothing in this Agreement prevents Executive from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination, or any other conduct that Executive has reason to believe is unlawful. Furthermore, notwithstanding any other provision of this Agreement, ‎Executive is not ‎prohibited in any way ‎from: (i) reporting possible ‎violations of federal, state, or local law or ‎regulations, including any ‎‎possible securities law violations, to any Government Agencies, ‎including but not limited ‎to the U.S. Department of Justice, the SEC, the ‎U.S. Congress, or any ‎agency Inspector General; (ii) ‎participating in any investigation or ‎‎proceeding conducted by any

- 5 -

federal, state, or local ‎governmental agency ‎or entity; (iii) making ‎any other disclosures that are protected under the ‎‎whistleblower provisions of federal, state, or ‎local law or regulations; (iv) ‎providing truthful ‎testimony in response to a valid subpoena, court ‎order, ‎or regulatory request; (v) making disclosures ‎permitted by California Civil ‎Code § 1670.11, California ‎‎Code of Civil ‎Procedure § 1001, and ‎‎California Government Code § 12964.5; or (vi) otherwise fully ‎‎participating in any federal whistleblower ‎programs, including but not ‎limited to any such ‎programs managed by the SEC and/or the ‎‎Occupational Safety and Health Administration. ‎Executive further ‎acknowledges that he ‎is not required to obtain any prior authorization ‎of ‎the Company or any other person to make any ‎reports or disclosures ‎described in the preceding ‎sentence, and he is not required to notify ‎the ‎Company or any other person that such reports ‎or disclosures have been ‎made.‎

8.Confidentiality. Executive shall not disclose or cause to be disclosed the existence, terms of or negotiations leading to this Agreement to any person or entity, other than Executive’s spouse, attorneys, or tax advisors and representatives of Government Agencies as defined herein or pursuant to subpoena or court order. The Company shall not disclose or cause to be disclosed the existence, terms of or negotiations leading to this Agreement to any person or entity other than the Company’s attorneys, tax advisors, auditors, board members and as otherwise appropriate to conduct its business and carry out the terms of this Agreement or as otherwise may be required by federal or state securities laws or other applicable law (including the public disclosure of this Agreement to comply with securities laws). Nothing in this Agreement prohibits the Company from sharing truthful information with any governmental, regulatory and/or administrative entity or agency; with any court or legislative body; or in response to any compulsory legal process. Without acknowledging that Executive retains knowledge of any such information, Executive nevertheless agrees that, to the extent he has knowledge of any information meeting the definition of “Confidential Information” as set forth in Section 8(a) of this Agreement, Executive shall not use or disclose such Confidential Information, except as expressly permitted by this Agreement or applicable law. Furthermore, except as otherwise provided in this Agreement, Executive also affirms that so long as he is aware of any material non-public ‎information concerning the Company, he shall not, directly or indirectly (i) engage in any ‎transactions in the Company’s securities, (ii) recommend the purchase or sale of Company securities, ‎‎(iii) disclose material nonpublic information to any persons or entities, or (iv) assist anyone ‎engaged in any of the foregoing activities. Executive affirms that he has returned all of the Company’s property, ‎documents, and/or Confidential Information of the Company (as defined herein) in his possession or control, except as ‎permitted by Section 10. Executive also affirms that he is in possession of all of ‎his property that he had at the Company’s premises and that the Company is not in ‎possession of any of Executive’s property. ‎

(a) For purposes of this Agreement, the term “Confidential Information” means the Company’s trade secrets as defined under applicable law, as well as any other Company information or material that is not generally known to the public and which:

(i) is generated, collected by, or utilized in the operations of the Company’s business or relates to the actual or anticipated business products, research, or development of the Company or its customers or suppliers; or

(ii) is suggested by or results from any task assigned to Executive by the Company or work performed by Executive for or on behalf of the Company.

- 6 -

Confidential Information shall not be considered generally known to the public if Executive or others improperly reveal such information to the public without the Company’s express written consent and/or in violation of an obligation of confidentiality owed to the Company. Examples of Confidential Information include, but are not limited to, all customer, client, supplier and vendor lists, budget information, contents of any database, contracts, product designs, technical know-how, engineering data and/or drawings, specifications, pricing and cost information, performance standards, productivity standards, research and development work, software, business plans, proprietary data, projections, market research, strategic plans, marketing information, financial information (including financial statements), sales information, training manuals, employee lists and compensation of employees, and all other competitively sensitive information with respect to the Company, whether or not it is in tangible form, and including without limitation any of the foregoing contained or described on paper or in computer software or other storage devices, as the same may exist from time to time. Confidential Information does not include: (a) information about Executive’s own wages, hours, and other terms and conditions of employment; and (b) information regarding the wages, hours, and other terms and conditions of employment for other employees of the Company, except where Executive has access to such information only because of the nature of Executive’s job functions or where Executive’s job functions include safeguarding employee personnel information.

9.Attorneys’ Fees and Costs. Each Party shall bear its or his own attorneys’ fees and costs in connection with the Proceedings, the negotiation, review and execution of this Agreement and the matters and documents referred to herein.

10.Protected Rights.Subject to the provisions of Section 3, nothing contained in this Agreement limits Executive’s rights to file a charge, report or complaint with the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local government agency, authority or commission (collectively, “Government Agencies”), or prohibits Executive from providing truthful testimony in response to a lawfully-issued subpoena or court order. Further, this Agreement does not limit Executive’s rights to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company.

11.Notices. Any notice required to be sent to any of the Parties shall be sent to their respective Counsel.

(a)Notice to Executive shall be sent to “Executive’s Counsel” as follows:

Nicholas Anaclerio

Vedder Price P.C.

222 N. La Salle Street

Chicago, Illinois 60601

Phone: (312) 609-7538

nanaclerio@vedderprice.com

- 7 -

(b)Notice to the Company shall be sent to the “Company’s Counsel” as follows:

Bilal Zaheer

Locke Lord LLP

111 S. Wacker Drive, Suite 4100

Chicago, Illinois 60606

Phone: (312) 201-2875

Bilal.zaheer@lockelord.com

12.Non-Admission of Liability. It is understood and agreed by the Parties that the execution of this Agreement and the performance of the conditions set forth herein do not constitute evidence of or any admission of liability, violation of an applicable law or wrongdoing of any kind or nature whatsoever on the part of any of the Parties or the Releasees, and that nothing in this Agreement may be construed as such by any person.

13.Governing Law. This Agreement shall be governed by the internal laws (and not the law of conflicts) of the State of Delaware. Any dispute, controversy, or claim arising out of, relating to, or in ‎connection with this ‎Agreement, including with respect to its formation, ‎applicability, breach, termination, invalidity ‎or enforceability, shall ‎be adjudicated solely and exclusively in the state or federal courts seated in the State of Delaware, the personal and subject matter jurisdiction of which for such purposes the Parties do hereby acknowledge and confirm.

14.Entire Agreement and Severability. This Agreement constitutes the entire agreement between the Parties and supersedes all other agreements between them, including without limitation the offer letter, amendment to offer letter and the Proprietary Interests Protection Agreement (the “PIPA”) forming the alleged basis for, and/or which was referenced in, the Demand and/or Lawsuit. This Agreement may not be modified, altered or changed except by a written instrument signed by all Parties hereto. If any provision of this Agreement is held to be invalid, the remaining provisions will remain in full force and effect.

15.Arm’s Length Negotiation. This Agreement has been mutually negotiated at arm’s length by the Parties’ counsel. If any dispute should arise regarding any of its terms, no Party shall be deemed to be the drafter of any provision of this Agreement for purposes of its construction against that Party or otherwise. In any action to enforce the terms of this Agreement, the prevailing Party shall be entitled to recover against the non-prevailing Party his/its costs and reasonable expenses of suit including court and filing fees and experts’ fees and costs and reasonable attorneys’ fees.

16.Advice of Counsel. The Parties represent that they have been represented by independent legal counsel of their own choice throughout all of the negotiations which preceded the execution of this Agreement and that they have voluntarily executed this Agreement with the consent and upon the advice of such independent legal counsel, or that they have had the full opportunity to seek such consent and advice. Each Party acknowledges that they have read this Agreement and voluntarily assent to all the terms and conditions contained herein without any reservation whatsoever and that they have had, or have had the opportunity to have had, the same explained to them by their own counsel, who have answered any and all questions which have been asked of them, with regard to the meaning of any provision hereof.

- 8 -

17.No Tax Advice. Executive has been advised by his Counsel that neither Executive’s Counsel, the Company nor the Company’s Counsel are providing any tax advice regarding the Settlement Payment. Executive understands and agrees that he is solely responsible for any tax liabilities, penalties, and/or consequences arising out of the Settlement Payment and that the Releasees shall bear no responsibility for any such liabilities, penalties, and/or consequences in connection with the Settlement Payment. Furthermore, Executive will defend, ‎indemnify, and hold the Company free and harmless ‎from and against any and all costs or ‎liabilities ‎arising out of any claim that ‎the Company was obligated to withhold or pay taxes with respect to ‎any ‎portion of the Settlement Payment‎.‎

18.Waiver. No term or condition of this Agreement shall be deemed to have been waived, nor shall there be an estoppel against the enforcement of any provision of this Agreement, except by written instrument of the Party charged with such waiver or estoppel. The failure of either Party to seek enforcement of any provision of this Agreement in any instance or for any period of time shall not be construed as a waiver of such provision or of the Party’s right to seek enforcement of such provision in the future.

19.Assignment. Neither Party may assign this Agreement without the express, written consent of all Parties hereto.

20.Headings and Captions. The headings and captions used in this Agreement are for convenience of reference only, and shall in no way define, limit, expand or otherwise affect the meaning or construction of any provision of this Agreement.

21.Section 409A. Payments pursuant to this Agreement are intended to comply with or be exempt from Section 409A of the Internal Revenue Code and accompanying regulations and other binding guidance promulgated thereunder (“Section 409A”), and the provisions of this Agreement will be administered, interpreted and construed accordingly. Notwithstanding any other provision of this Agreement, payments provided under this Agreement may only be made upon an event and in a manner that complies with Section 409A or an applicable exemption. Any payments under this Agreement that may be excluded from Section 409A either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent possible. For purposes of Section 409A, each installment payment provided under this Agreement shall be treated as a separate payment. Any payments to be made under this Agreement upon a termination of employment shall only be made upon a “separation from service” under Section 409A. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with or are subject to Section 409A and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by Executive on account of non-compliance with Section 409A.

22.Good Faith Settlement. The Parties hereby stipulate and agree that the settlement memorialized in this Agreement is a good faith settlement between and among the Parties within the meaning of California Code of Civil Procedure Section 877.6.

23.Counterparts. Separate copies of this document shall constitute original documents which may be signed separately but which together will constitute a single agreement.

- 9 -

The exchange of a fully-executed Agreement (in counterparts or otherwise) by electronic transmission shall be sufficient to bind the Parties to the terms and conditions of this Agreement. A copied, electronic (including without limitation PDF or DocuSign), facsimile or scanned signature shall be deemed to be an original.

24.Integration. This Agreement constitutes a single, integrated, written contract expressing the entire agreement between the Parties regarding its subject matter, and the Parties further represent and warrant that they are not relying on any promises or representations which do not appear written herein. The Parties further understand and agree that this Agreement may be amended or modified only by a written agreement, signed by all of the Parties hereto.

25.Undertaking. Should Executive be served with a subpoena to testify in any matter in which the Company is a party, Executive agrees, upon request, to confer with the Company and/or its attorneys, in advance of providing any such testimony, in the virtual presence of Executive’s personal counsel and through videoconferencing only, during reasonable hours and for reasonable periods of time not to exceed eight (8) hours per calendar year (exclusive of any time Executive spends testifying in a deposition or in any other legal proceeding) to provide truthful nonprivileged ‎information regarding documents he authored in performing his job duties for the Company and facts personally known to him related to his employment with the Company (“Conferral Time”). The Company will reimburse ‎Executive for reasonable and customary out-of-pocket expenses, if any, that he ‎incurs related to this Undertaking consistent with the Company’s travel and expense reimbursement policies. Executive may retain personal counsel of his exclusive choice to represent him in preparation for and during Conferral Time, and, if the Company requests Conferral Time, the Company will reimburse Executive for all legal fees incurred by him during Conferral Time and in Executive’s preparation for Conferral Time, up to a total reimbursement of $20,000 for each eight (8) hours of Conferral Time (the $20,000 includes any legal fees incurred in preparation for the eight (8) hours of Conferral Time). The Company and its attorneys will schedule Conferral Time to minimize disruption to Executive’s other personal ‎or professional commitments. Pursuant to Section 11 hereof, Executive shall provide the Company with written notice in the event he is served with a subpoena or court order by or on behalf of a private litigant in a civil suit calling for oral testimony or the production of documents relating to the Company as soon as is reasonably practicable following such service.‎ This Undertaking and any obligation of Executive pursuant to it shall expire on the fifth (5th) anniversary of the Effective Date. For the avoidance of doubt, by agreeing to this Undertaking, Executive does not waive but expressly preserves any and all privileges or protections available to him under the law, including, but not limited to, the attorney-client privilege, the work product doctrine, right of privacy, and the protected rights set forth in Section 10 (collectively referred to as “Privileged Matter”). The Company and its counsel shall not ask Executive about nor seek to discover Privileged Matter from Executive and Executive shall not be obligated to disclose Privileged Matter as part of this Undertaking. Neither the Company or its counsel shall seek to discover from Executive or inquire of him regarding any communications by or between Executive and/or Executive’s counsel on the one hand and any Government Agency or the staff or personnel of any Government Agency on the other hand. Executive shall have no obligation to provide the Company with notice, whether pursuant to this Undertaking or otherwise, should Executive be served with a subpoena or court order calling for oral testimony or the production of documents relating to the Company by or on behalf of a Government Agency.

- 10 -

26.Executive Acknowledgment. By signing below, Executive confirms he has been notified that he has a right to consult an attorney regarding this Agreement, and has had more than twenty-one (21) days to do so. He confirms that his decision to sign this Agreement is knowing and voluntary and is not induced by the Company through fraud, misrepresentation, or a threat to withdraw or alter the offer prior to the expiration of the time period given him to review it, or by providing different terms to persons who agree to sign prior to the expiration of the time period given to review it. Executive agrees with and accepts the terms contained in this Agreement, and agrees to be bound by them.

[Signatures on following page.]

- 11 -

IN WITNESS WHEREOF, the undersigned have executed this Agreement.

Executive Methode Electronics, Inc.

/s/ Avinash Avula/s/ Kerry Vyverberg

Avinash Avula By_Kerry Vyverberg

[spell name]

Its __General Counsel

[title]

and fully-authorized agent

Dated: November 8, 2024 Dated: November 11, 2024

- 12 -

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Jonathan DeGaynor, certify that:

1.I have reviewed this report on Form 10-Q of Methode Electronics, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 5, 2025	By:	/s/ Jonathan DeGaynor
		Jonathan DeGaynor
		Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Laura Kowalchik, certify that:

1.I have reviewed this report on Form 10-Q of Methode Electronics, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 5, 2025	By:	/s/ Laura Kowalchik
		Laura Kowalchik
		Chief Financial Officer

EX-32

Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Methode Electronics, Inc. (the “Company”) certifies that the Quarterly Report on Form 10-Q of the Company for the quarter ended February 1, 2025 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in that Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

.

Date: March 5, 2025	By:	/s/ Jonathan DeGaynor
		Jonathan DeGaynor Chief Executive Officer
Date: March 5, 2025	By:	/s/ Laura Kowalchik
		Laura Kowalchik
		Chief Financial Officer

XML

Cover Page - shares	9 Months Ended
	Feb. 01, 2025	Mar. 03, 2025
Cover [Abstract]
Entity Registrant Name	METHODE ELECTRONICS, INC.
Entity Central Index Key	0000065270
Document Type	10-Q
Document Period End Date	Feb. 01, 2025
Amendment Flag	false
Current Fiscal Year End Date	--04-27
Entity Current Reporting Status	Yes
Trading Symbol	MEI
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		35,690,749
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q3
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity File Number	001-33731
Entity Tax Identification Number	36-2090085
Entity Address, Address Line One	8750 West Bryn Mawr Avenue
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60631-3518
City Area Code	708
Local Phone Number	867-6777
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, $0.50 Par Value
Security Exchange Name	NYSE

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024
Income Statement [Abstract]
Net sales	$ 239.9	$ 259.5	$ 791.0	$ 837.2
Cost of products sold	198.6	222.5	647.2	693.9
Gross profit	41.3	37.0	143.8	143.3
Selling and administrative expenses	37.7	33.9	126.5	119.3
Goodwill impairment				56.5
Amortization of intangibles	5.8	6.1	17.6	18.0
Loss from operations	(2.2)	(3.0)	(0.3)	(50.5)
Interest expense, net	5.5	5.0	16.5	12.2
Other expense, net	0.5	2.5	2.9	2.3
Pre-tax loss	(8.2)	(10.5)	(19.7)	(65.0)
Income tax expense	6.2	1.1	14.6	1.0
Net loss	$ (14.4)	$ (11.6)	$ (34.3)	$ (66.0)
Loss per share:
Basic	$ (0.41)	$ (0.33)	$ (0.97)	$ (1.86)
Diluted	(0.41)	(0.33)	(0.97)	(1.86)
Cash dividends per share	$ 0.14	$ 0.14	$ 0.42	$ 0.42

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024
Statement of Comprehensive Income [Abstract]
Net loss	$ (14.4)	$ (11.6)	$ (34.3)	$ (66.0)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	(15.5)	13.7	(13.9)	(9.0)
Derivative financial instruments	2.0	(2.0)	(0.6)	(3.2)
Other comprehensive (loss) income	(13.5)	11.7	(14.5)	(12.2)
Comprehensive (loss) income	$ (27.9)	$ 0.1	$ (48.8)	$ (78.2)

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Feb. 01, 2025	Apr. 27, 2024
Current assets:
Cash and cash equivalents	$ 103.8	$ 161.5
Accounts receivable, net	220.0	262.6
Inventories	218.8	186.2
Income tax receivable	4.2	4.0
Prepaid expenses and other current assets	22.7	18.7
Assets held for sale	2.7	4.7
Total current assets	572.2	637.7
Long-term assets:
Property, plant and equipment, net	208.6	212.1
Goodwill	167.4	169.9
Other intangible assets, net	235.7	256.7
Operating lease right-of-use assets, net	24.9	26.7
Deferred tax assets	34.3	34.7
Pre-production costs	40.0	44.1
Other long-term assets	21.5	21.6
Total long-term assets	732.4	765.8
Total assets	1,304.6	1,403.5
Current liabilities:
Accounts payable	107.7	132.4
Accrued employee liabilities	29.4	38.0
Other accrued liabilities	42.3	46.0
Short-term operating lease liabilities	7.5	6.7
Short-term debt	0.2	0.2
Income tax payable	14.3	8.1
Total current liabilities	201.4	231.4
Long-term liabilities:
Long-term debt	327.7	330.7
Long-term operating lease liabilities	19.8	20.6
Long-term income tax payable		9.3
Other long-term liabilities	21.7	16.8
Deferred tax liabilities	29.7	28.7
Total long-term liabilities	398.9	406.1
Total liabilities	600.3	637.5
Shareholders' equity:
Common stock, $0.50 par value, 100,000,000 shares authorized, 37,004,282 shares and 36,650,909 shares issued as of February 1, 2025 and April 27, 2024, respectively	18.5	18.3
Additional paid-in capital	190.2	183.6
Accumulated other comprehensive loss	(51.2)	(36.7)
Treasury stock, 1,346,624 shares as of February 1, 2025 and April 27, 2024	(11.5)	(11.5)
Retained earnings	558.3	612.3
Total shareholders' equity	704.3	766.0
Total liabilities and shareholders' equity	$ 1,304.6	$ 1,403.5

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Feb. 01, 2025	Apr. 27, 2024
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.50	$ 0.50
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	37,004,282	36,650,909
Treasury stock (in shares)	1,346,624	1,346,624

XML

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Redeemable Noncontrolling Interest	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Treasury stock	Retained Earnings
Beginning balance at Apr. 29, 2023	$ 941.8		$ 18.6	$ 181.0	$ (19.0)	$ (11.5)	$ 772.7
Beginning balance (in shares) at Apr. 29, 2023			37,167,375
Beginning balance at Apr. 29, 2023		$ 11.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock, net of tax withholding	(3.8)		$ 0.1	(0.1)			(3.8)
Issuance of restricted stock, net of tax withholding (in shares)			255,120
Cancellation of restricted stock	0.0		$ (0.1)	0.1
Cancellation of restricted stock (in shares)			(144,000)
Purchase of redeemable noncontrolling interest		$ (11.1)
Purchases of common stock	$ (10.8)		$ (0.2)				(10.6)
Purchases of common stock (in shares)	(453,371)		(453,371)
Stock-based compensation expense	$ 0.7			0.7
Other comprehensive income (loss)	(12.2)				(12.2)
Net loss	(66.0)						(66.0)
Dividends on common stock	(14.7)						(14.7)
Ending balance at Jan. 27, 2024	835.0		$ 18.4	181.7	(31.2)	(11.5)	677.6
Ending balance (in shares) at Jan. 27, 2024			36,825,124
Beginning balance at Oct. 28, 2023	844.9		$ 18.5	183.8	(42.9)	(11.5)	697.0
Beginning balance (in shares) at Oct. 28, 2023			37,034,050
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock, net of tax withholding (in shares)			65,666
Cancellation of restricted stock			$ (0.1)	0.1
Cancellation of restricted stock (in shares)			(144,000)
Purchases of common stock	$ (3.0)						(3.0)
Purchases of common stock (in shares)	(130,592)		(130,592)
Stock-based compensation expense	$ (2.2)			(2.2)
Other comprehensive income (loss)	11.7				11.7
Net loss	(11.6)						(11.6)
Dividends on common stock	(4.8)						(4.8)
Ending balance at Jan. 27, 2024	835.0		$ 18.4	181.7	(31.2)	(11.5)	677.6
Ending balance (in shares) at Jan. 27, 2024			36,825,124
Beginning balance at Apr. 27, 2024	766.0		$ 18.3	183.6	(36.7)	(11.5)	612.3
Beginning balance (in shares) at Apr. 27, 2024			36,650,909
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock, net of tax withholding	(3.3)		$ 0.3	(0.1)			(3.5)
Issuance of restricted stock, net of tax withholding (in shares)			568,698
Cancellation of restricted stock (in shares)			(79,325)
Conversion of cash bonus to RSUs	2.1			2.1
Purchases of common stock	$ (1.6)		$ (0.1)				(1.5)
Purchases of common stock (in shares)	(136,000)		(136,000)
Stock-based compensation expense	$ 4.6			4.6
Other comprehensive income (loss)	(14.5)				(14.5)
Net loss	(34.3)						(34.3)
Dividends on common stock	(14.7)						(14.7)
Ending balance at Feb. 01, 2025	704.3		$ 18.5	190.2	(51.2)	(11.5)	558.3
Ending balance (in shares) at Feb. 01, 2025			37,004,282
Beginning balance at Nov. 02, 2024	738.3		$ 18.3	188.6	(37.7)	(11.5)	580.6
Beginning balance (in shares) at Nov. 02, 2024			36,621,507
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock, net of tax withholding	(3.0)		$ 0.2	(0.2)			(3.0)
Issuance of restricted stock, net of tax withholding (in shares)			382,775
Purchases of common stock	$ 0.0
Purchases of common stock (in shares)	0
Stock-based compensation expense	$ 1.8			1.8
Other comprehensive income (loss)	(13.5)				(13.5)
Net loss	(14.4)						(14.4)
Dividends on common stock	(4.9)						(4.9)
Ending balance at Feb. 01, 2025	$ 704.3		$ 18.5	$ 190.2	$ (51.2)	$ (11.5)	$ 558.3
Ending balance (in shares) at Feb. 01, 2025			37,004,282

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024
Operating activities:
Net loss	$ (34.3)	$ (66.0)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	42.5	43.3
Stock-based compensation expense	5.5	1.8
Amortization of debt issuance costs	0.8	0.5
Partial write-off of unamortized debt issuance costs	1.2
(Gain) loss on sale of assets	(0.3)	0.6
Impairment of long-lived assets	0.4	0.7
Goodwill impairment		56.5
Change in deferred income taxes	(0.2)	(4.0)
Other	1.1	(0.2)
Changes in operating assets and liabilities:
Accounts receivable	35.5	47.7
Inventories	(34.5)	(47.1)
Prepaid expenses and other assets	(0.4)	(8.8)
Accounts payable	(19.0)	11.0
Other liabilities	(7.3)	(13.4)
Net cash (used in) provided by operating activities	(9.0)	22.6
Investing activities:
Purchases of property, plant and equipment	(32.5)	(41.1)
Proceeds from settlement of net investment hedge	3.1	0.6
Proceeds from disposition of assets	2.7	1.5
Net cash used in investing activities	(26.7)	(39.0)
Financing activities:
Taxes paid related to net share settlement of equity awards	(3.5)	(3.8)
Repayments of finance leases	(0.2)	(0.2)
Debt issuance costs	(1.8)
Purchases of common stock	(1.6)	(10.8)
Cash dividends	(15.3)	(15.0)
Purchase of redeemable noncontrolling interest		(10.9)
Proceeds from borrowings	60.0	232.9
Repayments of borrowings	(54.2)	(207.2)
Net cash used in financing activities	(16.6)	(15.0)
Effect of foreign currency exchange rate changes on cash and cash equivalents	(5.4)	(2.7)
Decrease in cash and cash equivalents	(57.7)	(34.1)
Cash and cash equivalents at beginning of the period	161.5	157.0
Cash and cash equivalents at end of the period	103.8	122.9
Cash paid during the period for:
Interest	17.5	12.7
Income taxes, net of refunds	17.6	17.0
Operating lease obligations	$ 6.9	$ 6.9

XML

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024
Pay vs Performance Disclosure
Net Income (Loss)	$ (14.4)	$ (11.6)	$ (34.3)	$ (66.0)

XML

Insider Trading Arrangements	3 Months Ended
	Feb. 01, 2025
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML

Description of Business and Summary of Significant Accounting Policies

9 Months Ended

Feb. 01, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Business and Summary of Significant Accounting Policies

Note 1. Description of Business and Summary of Significant Accounting Policies

Description of business

Methode Electronics, Inc. (the “Company” or “Methode”) is a leading global supplier of custom engineered solutions with sales, engineering and manufacturing locations in North America, Europe, Middle East and Asia. The Company designs, engineers and produces mechatronic products for Original Equipment Manufacturers (“OEMs”) utilizing its broad range of technologies for user interface, light-emitting diode (“LED”) lighting system, power distribution and sensor applications.

The Company’s solutions are found in the end markets of transportation (including automotive, commercial vehicle, e-bike, aerospace, bus and rail), cloud computing infrastructure, construction equipment and consumer appliance.

Basis of presentation

The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). All intercompany balances and transactions have been eliminated in consolidation. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. These interim condensed consolidated financial statements include all adjustments (consisting of normal recurring adjustments, except as otherwise disclosed) that management believes are necessary for a fair presentation of the results of operations, financial position and cash flows of the Company for the interim periods presented. These financial statements should be read in conjunction with the consolidated financial statements included in the Company’s Form 10-K for the year ended April 27, 2024, filed with the SEC on July 11, 2024. Results may vary from quarter to quarter for reasons other than seasonality.

Financial reporting periods

The Company’s fiscal year ends on the Saturday closest to April 30 of the following year, typically resulting in a 52-week year, but occasionally giving rise to an additional week, resulting in a 53-week year. The current fiscal year ending May 3, 2025 is a 53-week fiscal year, with the additional week being included in the second fiscal quarter. The three months ended February 1, 2025 and January 27, 2024 were 13-week periods, while the nine months ended February 1, 2025 and January 27, 2024 were 40 and 39-week periods, respectively.

Use of estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. These estimates and assumptions are subject to an inherent degree of uncertainty and may change, as new events occur, and additional information is obtained. As a result, actual results may differ from previously estimated amounts, and such differences may be material to the condensed consolidated financial statements. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the period they occur.

Accounting pronouncements not yet adopted

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which requires entities to provide disclosures about their reportable segments’ significant expenses on an interim and annual basis. The updated standard is effective for the Company’s annual periods beginning in fiscal 2025 and interim periods beginning in the first quarter of fiscal 2026. Early adoption is permitted. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures.

In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU No. 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU No. 2023-09 will become effective for the Company in the first quarter of fiscal 2026 and will be applied on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on its financial statement disclosures.

In November 2024, the FASB issued ASU 2024-03, “Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures.” ASU 2024-03 requires public entities to disclose more detailed information about certain costs and expenses presented in the income statement, including inventory purchases, employee compensation, selling expenses and depreciation. ASU 2024-03 will become effective for the Company’s annual periods beginning in fiscal 2028. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on its financial statement disclosures.

There have been no other newly issued or newly applicable accounting pronouncements that have had, or are expected to have, a material impact on the Company’s condensed consolidated financial statements. Further, at February 1, 2025, there are no other pronouncements pending adoption that are expected to have a material impact on the Company’s condensed consolidated financial statements.

Summary of significant accounting policies

The Company’s significant accounting policies are described in Note 1, “Description of Business and Summary of Significant Accounting Policies,” to the consolidated financial statements included in the Company’s Form 10-K for the year ended April 27, 2024. There have been no material changes to the significant accounting policies in the nine months ended February 1, 2025.

Foreign currency translation.

The functional currencies of the majority of the Company’s foreign subsidiaries are their local currencies. The results of operations of these foreign subsidiaries are translated into U.S. dollars using average monthly rates, while the assets and liabilities are translated using period-end exchange rates. The resulting translation adjustments are recorded as a component of accumulated other comprehensive income (loss) (“AOCI”). Gains and losses arising from transactions denominated in a currency other than the functional currency, except certain long-term intercompany transactions, are included in the condensed consolidated statements of operations in other expense, net. Net foreign exchange loss was $1.3 million in the three months ended February 1, 2025, compared to $2.8 million in the three months ended January 27, 2024. Net foreign exchange loss was $3.6 million in the nine months ended February 1, 2025, compared to $2.2 million in the nine months ended January 27, 2024.

XML

Revenue

9 Months Ended

Feb. 01, 2025

Revenue from Contract with Customer [Abstract]

Revenue

Note 2. Revenue

The Company generates revenue from manufacturing products for customers in diversified global markets under multi-year programs. Typically, these programs do not reach the level of a performance obligation until the Company receives either a purchase order and/or a materials release from the customer for a specific quantity at a specified price, at which point an enforceable contract exists. Contracts may also provide for annual price reductions over the production life of a program, and prices may be adjusted on an ongoing basis to reflect changes in product content/cost and other commercial factors. Sales and other taxes collected concurrent with revenue-producing activities are excluded from revenue.

The majority of the Company’s revenue is recognized at a point in time. The Company has determined that the most definitive demonstration that control has transferred to a customer is physical shipment or delivery, depending on the contractual shipping terms, except for consignment transactions. Consignment transactions are arrangements where the Company transfers product to a customer location but retains ownership and control of such product until it is used by the customer. Revenue for consignment arrangements is recognized upon the customer’s usage. The Company’s revenue also includes customer cost recoveries, which represent reimbursements the Company receives from customers for incremental costs associated with spot purchases of raw materials and premium freight incurred in fulfilling its performance obligation to the customer. Given these cost recoveries are generally negotiated after contract inception, the Company accounts for these cost recoveries as a modification to the existing contract. The Company recognizes cost recoveries as revenue when (or as) the remaining performance obligations per the contract are satisfied, or on the modification date if all performance obligations under the contract have been previously satisfied.

Revenue associated with products which the Company believes have no alternative use (such as highly customized parts), and where the Company has an enforceable right to payment, are recognized on an over time basis. Revenue is recognized based on progress to date, which is typically even over the production process through transfer of control to the customer.

The Company’s payment terms with its customers are typically 30-45 days from the time control transfers. As the Company’s standard payment terms are less than one year, the Company has elected the practical expedient under Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers” to not assess whether a contract has a significant financing component.

Contract balances

The Company receives payment from customers based on the contractual billing schedule and specific performance requirements established in the contract. Billings are recorded as accounts receivable when an unconditional right to the contractual consideration exists. A contract asset is an entity’s right to consideration in exchange for goods or services that the entity has transferred to a customer. A contract liability exists when an entity has received consideration, or the amount is due from the customer in advance of revenue recognition. Contract assets and contract liabilities are recognized in other current assets and other accrued liabilities, respectively in the condensed consolidated balance sheets and were immaterial as of February 1, 2025 and April 27, 2024.

Disaggregated revenue information

The following table represents a disaggregation of revenue from contracts with customers by segment and geographical location. Net sales are attributed to regions based on the location of production. Though revenue recognition patterns and contracts are generally consistent, the amount, timing and uncertainty of revenue and cash flows may vary in each reportable segment due to geographic and economic factors.

	Three Months Ended February 1, 2025 (13 Weeks)
(in millions)	Automotive		Industrial		Interface		Medical		Total
Geographic net sales:
North America	$	51.8	$	38.6	$	12.3	$	—	$	102.7
Europe, the Middle East & Africa ("EMEA")		55.9		41.4		—		—		97.3
Asia		8.0		31.9		—		—		39.9
Total net sales	$	115.7	$	111.9	$	12.3	$	—	$	239.9
Timing of revenue recognition:
Goods transferred at a point in time	$	111.8	$	111.9	$	12.3	$	—	$	236.0
Goods transferred over time		3.9		—		—		—		3.9
Total net sales	$	115.7	$	111.9	$	12.3	$	—	$	239.9

	Three Months Ended January 27, 2024 (13 Weeks)
(in millions)	Automotive		Industrial		Interface		Medical		Total
Geographic net sales:
North America	$	56.7	$	45.6	$	12.7	$	—	$	115.0
EMEA		52.0		37.5		—		—		89.5
Asia		31.0		24.0		—		—		55.0
Total net sales	$	139.7	$	107.1	$	12.7	$	—	$	259.5
Timing of revenue recognition:
Goods transferred at a point in time	$	136.6	$	107.1	$	12.7	$	—	$	256.4
Goods transferred over time		3.1		—		—		—		3.1
Total net sales	$	139.7	$	107.1	$	12.7	$	—	$	259.5

	Nine Months Ended February 1, 2025 (40 Weeks)
(in millions)	Automotive		Industrial		Interface		Medical		Total
Geographic net sales:
North America	$	187.8	$	133.8	$	40.2	$	—	$	361.8
EMEA		181.7		129.5		—		—		311.2
Asia		26.5		91.5		—		—		118.0
Total net sales	$	396.0	$	354.8	$	40.2	$	—	$	791.0
Timing of revenue recognition:
Goods transferred at a point in time	$	387.2	$	354.8	$	40.2	$	—	$	782.2
Goods transferred over time		8.8		—		—		—		8.8
Total net sales	$	396.0	$	354.8	$	40.2	$	—	$	791.0

	Nine Months Ended January 27, 2024 (39 Weeks)
(in millions)	Automotive		Industrial		Interface		Medical		Total
Geographic net sales:
North America	$	194.4	$	137.6	$	39.6	$	2.3	$	373.9
EMEA		153.9		131.4		—		—		285.3
Asia		104.0		73.9		—		0.1		178.0
Total net sales	$	452.3	$	342.9	$	39.6	$	2.4	$	837.2
Timing of revenue recognition:
Goods transferred at a point in time	$	440.7	$	342.9	$	39.6	$	2.4	$	825.6
Goods transferred over time		11.6		—		—		—		11.6
Total net sales	$	452.3	$	342.9	$	39.6	$	2.4	$	837.2

XML

Disposition

9 Months Ended

Feb. 01, 2025

Discontinued Operations and Disposal Groups [Abstract]

Disposition

Note 3. Disposition

In the first quarter of fiscal 2024, the Company made the decision to initiate the discontinuation of the Dabir business in the Medical segment. In fiscal 2024, the Company sold certain assets and contracts of its Dabir business to a third party for consideration of $1.5 million and recorded a loss on the sale, including transaction costs, of $0.6 million. The discontinuation of the Dabir business does not qualify as a discontinued operation as it does not represent a strategic shift that will have a major effect on the Company’s operations or financial results.

XML

Income Taxes

9 Months Ended

Feb. 01, 2025

Income Tax Disclosure [Abstract]

Income Taxes

Note 4. Income Taxes

For the three and nine months ended February 1, 2025, the Company utilized the discrete effective tax rate method, treating the year-to-date period as if it was the annual period to calculate its interim income tax provision, as allowed by ASC 740-270-30-18, “Income Taxes-Interim Reporting.” The Company concluded it could not use the estimated annual effective tax rate method as it could not calculate a reliable estimate of the annual effective tax rate due to it being highly sensitive to minor changes in the forecasted amounts, thus generating significant variability in the estimated annual effective tax rate and distorting the customary relationship between income tax expense and pre-tax income in interim periods.

The Company’s income tax expense and effective tax rate for the three and nine months ended February 1, 2025 and January 27, 2024 were as follows:

	Three Months Ended						Nine Months Ended
	February 1, 2025			January 27, 2024			February 1, 2025			January 27, 2024
($ in millions)	(13 Weeks)			(13 Weeks)			(40 Weeks)			(39 Weeks)
Pre-tax loss	$	(8.2	)	$	(10.5	)	$	(19.7	)	$	(65.0	)
Income tax expense		6.2			1.1			14.6			1.0
Effective tax rate		(75.6	)%		(10.5	)%		(74.1	)%		(1.5	)%

The effective tax rate for the three and nine months ended February 1, 2025 differs from the U.S. federal statutory tax rate of 21% primarily due to an increase in a valuation allowance for U.S. deferred tax assets and an unfavorable impact from global intangible low-tax income (“GILTI”), partially offset by the impact of income derived from foreign operations with lower statutory tax rates. The effective tax rate for the three months ended January 27, 2024 differs from the U.S. federal statutory tax rate of 21% primarily due to the impact of income derived from foreign operations with lower statutory tax rates and research deductions claimed in foreign jurisdictions, offset by GILTI. The effective tax rate for the nine months ended January 27, 2024 differs from the U.S. federal statutory tax rate of 21% primarily due to an impairment of goodwill which is non-deductible for tax purposes, income derived from foreign operations with lower statutory tax rates and research deductions claimed in foreign jurisdictions, offset by GILTI.

As of February 1, 2025, the Company determined that recovery of some of its U.S. deferred tax assets was not more likely than not, and recorded a valuation allowance to income tax expense of $6.5 million for the three months ended February 1, 2025 and $14.0 million for the nine months ended February 1, 2025. The valuation allowance was recorded based on the evaluation of all available evidence.

The Organization for Economic Cooperation and Development’s (“OECD”) Pillar II Initiative introduced a 15% global minimum tax for certain multinational groups exceeding minimum annual global revenue thresholds. Some countries in which the Company operates have enacted legislation adopting the minimum tax effective January 1, 2024. To date, the Company has determined that there is an immaterial global minimum tax liability as a result of Pillar II, as certain tax jurisdictions either will not have Pillar II enacted until after December 31, 2024, or have satisfied the safe harbor test to prevent any minimum tax under Pillar II. The Company continues to monitor its jurisdictions for any changes and include any appropriate minimum tax throughout the fiscal year.

The Company’s gross unrecognized income tax benefits were $4.5 million and $4.4 million as of February 1, 2025 and April 27, 2024, respectively. If any portion of the Company’s unrecognized tax benefits is recognized, it would impact the Company’s effective tax rate. The unrecognized tax benefits are reviewed periodically and adjusted for changing facts and circumstances, such as tax audits, the lapsing of applicable statutes of limitations and changes in tax law. The Company recognizes interest and penalties related to income tax uncertainties in income tax expense. Accrued interest and penalties were $0.6 million and $0.4 million as of February 1, 2025 and April 27, 2024, respectively.

XML

Balance Sheet Components

9 Months Ended

Feb. 01, 2025

Balance Sheet Components [Abstract]

Balance Sheet Components

Note 5. Balance Sheet Components

Cash and cash equivalents

Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less. Highly liquid investments include money market funds which are classified within Level 1 of the fair value hierarchy. As of February 1, 2025 and April 27, 2024, the Company had a balance of $0.2 million and $73.2 million, respectively, in money market accounts.

Accounts receivable and allowance for doubtful accounts

Accounts receivable are customer obligations due under normal trade terms and are presented net of an allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts based on the current expected credit loss impairment model. The Company applies a historical loss rate based on historic write-offs to aging categories. The historical loss rate is adjusted for current conditions and reasonable and supportable forecasts of future losses as necessary. The Company may also record a specific reserve for individual accounts when it becomes aware of specific customer circumstances, such as in the case of a bankruptcy filing or deterioration in the customer’s operating results or financial position. The allowance for doubtful accounts balance was $2.7 million and $1.4 million as of February 1, 2025 and April 27, 2024, respectively.

Inventories

Inventories are stated at the lower-of-cost or net realizable value. Cost is determined using the first-in, first-out method. Finished products and work-in-process inventories include direct material costs and direct and indirect manufacturing costs. The Company records reserves for inventory that may be obsolete or in excess of current and future market demand. A summary of inventories is shown below:

(in millions)	February 1, 2025		April 27, 2024
Finished products	$	47.1	$	45.6
Work in process		24.1		16.1
Raw materials		147.6		124.5
Total inventories	$	218.8	$	186.2

Assets held for sale

The Company classifies long-lived assets to be sold as held for sale in the period in which all of the required criteria under ASC 360 “Property, Plant, and Equipment” are met. The Company initially measures a long-lived asset that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Upon determining that a long-lived asset meets the criteria to be classified as held for sale, the Company ceases depreciation and reports long-lived assets as “Assets held for sale” on the condensed consolidated balance sheets. Assets held for sale at April 27, 2024 consisted of three non-core real estate assets, two of which were sold in the nine months ended February 1, 2025. The two non-core real estate assets had an aggregate carrying value of $2.0 million and the Company recognized a gain of $0.3 million from these sales. The Company has accepted an offer for the asset held for sale at February 1, 2025, and currently expects the sale to be completed prior to the end of its fourth quarter ending May 3, 2025. The Company expects to recognize an immaterial gain from the sale of this non-core real estate asset.

Property, plant and equipment

Property, plant and equipment is stated at cost. Maintenance and repair costs are expensed as incurred. Depreciation is calculated using the straight-line method using estimated useful lives of 5 to 40 years for buildings and building improvements and 3 to 15 years for machinery and equipment. A summary of property, plant and equipment is shown below:

(in millions)	February 1, 2025			April 27, 2024
Land	$	3.3		$	3.3
Buildings and building improvements		98.4			98.5
Machinery and equipment		395.4			394.6
Construction in progress		48.1			50.4
Total property, plant and equipment, gross		545.2			546.8
Less: accumulated depreciation		(336.6	)		(334.7	)
Property, plant and equipment, net	$	208.6		$	212.1

Depreciation expense was $8.3 million and $8.8 million in the three months ended February 1, 2025 and January 27, 2024, respectively. Depreciation expense was $24.9 million and $25.3 million in the nine months ended February 1, 2025 and January 27, 2024, respectively. As of February 1, 2025 and April 27, 2024, capital expenditures recorded in accounts payable totaled $2.3 million and $6.1 million, respectively.

Pre-production tooling costs related to long-term supply arrangements

The Company incurs pre-production tooling costs related to products produced for its customers under long-term supply arrangements. Engineering, testing and other costs incurred in the design and development of production parts are expensed as incurred, unless the costs are reimbursable by the customer. As of February 1, 2025 and April 27, 2024, the Company had $40.0 million and $44.1 million, respectively, of pre-production tooling costs related to customer-owned tools for which reimbursement is contractually guaranteed by the customer or for which the customer has provided a non-cancelable right to use the tooling.

Costs for molds, dies and other tools used in products produced for its customers under long-term supply arrangements for which the Company has title are capitalized in property, plant and equipment and amortized over the shorter of the life of the arrangement or the estimated useful life of the assets. As of February 1, 2025 and April 27, 2024, Company-owned tooling was $12.5 million and $14.0 million, respectively.

XML

Goodwill and Other Intangible Assets

9 Months Ended

Feb. 01, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

Note 6. Goodwill and Other Intangible Assets

Goodwill

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. All of the Company’s goodwill is in the Industrial segment. A summary of the changes in the carrying amount of goodwill is shown below:

(in millions)	Total
Balance as of April 27, 2024	$	169.9
Foreign currency translation		(2.5	)
Balance as of February 1, 2025	$	167.4

A summary of goodwill by reporting unit is as follows:

(in millions)	February 1, 2025		April 27, 2024
Grakon Industrial	$	123.2	$	124.4
Nordic Lights		42.6		43.9
Other		1.6		1.6
Total	$	167.4	$	169.9

The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis as of the beginning of the fourth quarter each fiscal year. In addition, the Company continuously monitors for events and circumstances that could negatively impact the key assumptions used in determining fair value and therefore require interim goodwill impairment testing, including long-term revenue growth projections, profitability, discount rates, volatility in the Company's market capitalization, and general industry, market and macroeconomic conditions. No impairment indicators were identified in the third quarter of fiscal 2025.

October 28, 2023 goodwill impairment

During the three months ended October 28, 2023, the Company identified an impairment triggering event associated with a sustained decrease in the Company’s publicly quoted share price, market capitalization and lower than expected operating results. These factors suggested that the fair value of one or more of the Company’s reporting units may have fallen below their carrying amounts. As a result, the Company performed an interim quantitative impairment test and recognized a non-cash goodwill impairment charge of $56.5 million for two reporting units in its Automotive segment.

Other intangible assets, net

Details of identifiable intangible assets are shown below:

	As of February 1, 2025
(in millions)	Gross		Accumulated amortization			Net		Weighted average remaining useful life (years)
Amortized intangible assets:
Customer relationships and agreements	$	303.0	$	(96.5	)	$	206.5		14.2
Trade names, patents and technology licenses		74.4		(47.0	)		27.4		6.5
Total amortized intangible assets		377.4		(143.5	)		233.9
Unamortized trade name		1.8		—			1.8
Total other intangible assets	$	379.2	$	(143.5	)	$	235.7

	As of April 27, 2024
(in millions)	Gross		Accumulated amortization			Net		Weighted average remaining useful life (years)
Amortized intangible assets:
Customer relationships and agreements	$	306.6	$	(84.7	)	$	221.9		14.8
Trade names, patents and technology licenses		75.3		(42.3	)		33.0		6.9
Total amortized intangible assets		381.9		(127.0	)		254.9
Unamortized trade name		1.8		—			1.8
Total other intangible assets	$	383.7	$	(127.0	)	$	256.7

Based on the current amount of intangible assets subject to amortization, the estimated aggregate amortization expense for each of the five succeeding fiscal years and thereafter is as follows:

(in millions)
Fiscal Year:
Remainder of 2025	$	5.7
2026		22.3
2027		21.6
2028		19.3
2029		18.1
Thereafter		146.9
Total	$	233.9

XML

Derivative Instruments and Hedging Activities

9 Months Ended

Feb. 01, 2025

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities

Note 7. Derivative Instruments and Hedging Activities

The Company is exposed to various market risks including, but not limited to, foreign currency exchange rates and market interest rates. The Company strives to control its exposure to these risks through our normal operating activities and, where appropriate, through the use of derivative financial instruments. Derivative financial instruments are measured at fair value on a recurring basis using various pricing models that incorporate observable market parameters, such as interest rate yield curves and foreign currency rates and are classified as Level 2 within the fair value hierarchy.

For a designated cash flow hedge, the effective portion of the change in the fair value of the derivative financial instrument is recorded in AOCI in the condensed consolidated balance sheets. When the underlying hedged transaction is realized, the gain or loss previously included in AOCI is recorded in earnings and reflected in the condensed consolidated statements of operations on the same line as the gain or loss on the hedged item attributable to the hedged risk. The gain or loss associated with changes in the fair value of derivatives not designated as hedges are recorded immediately in the condensed consolidated statements of operations on the same line as the associated risk. For a designated net investment hedge, the effective portion of the change in the fair value of the derivative financial instrument is recorded as a cumulative translation adjustment in AOCI in the condensed consolidated balance sheets.

Net investment hedges

The Company is exposed to the risk that adverse changes in foreign currency exchange rates could impact its net investment in non-U.S. subsidiaries. To manage this risk, the Company designates certain qualifying derivative and non-derivative instruments, including cross-currency swaps and foreign currency-denominated debt, as net investment hedges of certain non-U.S. subsidiaries.

The Company had a fixed-rate, cross-currency swap, with a notional value of $60.0 million (€54.8 million), that settled in December 2024 with a gross gain of approximately $3.1 million. The cross-currency swap was designated as a hedge of the Company’s net investment in a euro-based subsidiary. The gain will remain in AOCI until the hedged net investment is sold or substantially liquidated.

Hedge effectiveness is assessed at the inception of the hedging relationship and quarterly thereafter, under the spot-to-spot method. The Company recognizes the impact of all other changes in fair value of the derivative, which represents the interest rate differential of the cross-currency swap, through interest expense. For the three months ended February 1, 2025 and January 27, 2024, the Company recorded a loss of $0.1 million and zero, respectively, in interest expense, net in the condensed consolidated statements of operations. For the nine months ended February 1, 2025 and January 27, 2024, the Company recorded gains of $0.4 million and $1.1 million, respectively, in interest expense, net in the condensed consolidated statements of operations.

The Company has €275.0 million of long-term borrowings under its Amended Credit Agreement (see Note 8 “Debt”) which was designated as a net investment hedge of the foreign currency exposure of its investment in its euro-denominated subsidiaries. On December 18, 2024, the Company de-designated these long-term borrowings as a net investment hedge. As of December 18, 2024, the cumulative gain, net of tax, was $9.0 million which will remain in AOCI until there is a substantial liquidation of the Company’s net investment of its euro-denominated subsidiaries. Due to changes in the value of the euro-denominated long-term borrowings designated as a net investment hedge, in the three months ended February 1, 2025 (through the date of de-designation) and January 27, 2024, a gain, net of tax, of $7.7 million and loss, net of tax, of $5.9 million, respectively, were recognized within the currency translation section of other comprehensive income (loss). In the nine months ended February 1, 2025 (through the date of de-designation) and January 27, 2024, a gain, net of tax, of $4.8 million and $1.4 million, respectively, were recognized within the currency translation section of other comprehensive income (loss). Included in AOCI related to this net investment hedge were cumulative gains of $9.0 million and $4.2 million, respectively, as of February 1, 2025 and April 27, 2024. The Company is now managing the related foreign exchange risk of its €275.0 million of long-term borrowings not designated as a net investment hedge through certain Euro denominated financial assets.

Interest rate swaps

The Company utilizes interest rate swaps to limit its exposure to market fluctuations on its variable-rate borrowings. The interest rate swaps effectively convert a portion of the Company's variable rate borrowings to a fixed rate based upon a determined notional amount. The Company has an interest rate swap, maturing on October 31, 2027, with a notional value of $137.0 million (€132.0 million). The interest rate swaps are designated as cash flow hedges.

Hedge effectiveness is assessed at the inception of the hedging relationship and quarterly thereafter. The effective portion of the periodic changes in fair value is recognized in AOCI in the condensed consolidated balance sheets. Subsequently, the accumulated gains and losses recorded in AOCI are reclassified to income in the period during which the hedged cash flow impacts earnings, which are expected to be immaterial over the next 12 months. No ineffectiveness was recognized in the three or nine months ended February 1, 2025 and January 27, 2024.

Derivatives not designated as hedges

The Company uses short-term foreign currency forward contracts to reduce the earnings impact that exchange rate fluctuations have on non-functional currency balance sheet exposures. These forward contracts are not designated as hedging instruments. Gains and losses on these forward contracts are recognized in other expense, net, along with the foreign currency gains and losses on monetary assets and liabilities, in the condensed consolidated statements of operations.

As of February 1, 2025 and April 27, 2024, the Company held foreign currency forward contracts with a notional value of $152.8 million and $110.9 million, respectively. During the three and nine months ended February 1, 2025, the Company recognized a loss of $4.7 million and $4.2 million, respectively, related to foreign currency forward contracts in the condensed consolidated statements of operations. During the three and nine months ended January 27, 2024, the Company recognized a gain of $0.6 million and a loss of $2.1 million, respectively, related to foreign currency forward contracts in the condensed consolidated statements of operations.

Effect of derivative instruments on comprehensive income (loss)

The pre-tax effects of derivative financial instruments recorded in other comprehensive income (loss) were as follows:

	Three Months Ended					Nine Months Ended
	February 1, 2025		January 27, 2024			February 1, 2025			January 27, 2024
(in millions)	(13 Weeks)		(13 Weeks)			(40 Weeks)			(39 Weeks)
Net investment hedges	$	2.6	$	0.3		$	1.8		$	1.5
Interest rate swaps		0.1		(3.1	)		(2.6	)		(5.8	)
Total	$	2.7	$	(2.8	)	$	(0.8	)	$	(4.3	)

Fair value of derivative instruments on the balance sheet

The fair value of derivative instruments are classified as Level 2 within the fair value hierarchy and are recorded in the condensed consolidated balance sheets as follows:

		Asset/(Liability)
(in millions)	Financial Statement Caption	February 1, 2025			April 27, 2024
Derivatives designated as hedging instruments:
Net investment hedges	Prepaid expenses and other current assets	$	—		$	1.3
Interest rate swaps	Other long-term liabilities	$	(4.7	)	$	(2.1	)
Derivatives not designated as hedging instruments:
Foreign currency forward contracts	Other accrued liabilities	$	(0.8	)	$	(0.2	)

XML

Debt

9 Months Ended

Feb. 01, 2025

Debt Disclosure [Abstract]

Debt

Note 8. Debt

A summary of debt is shown below:

(in millions)	February 1, 2025			April 27, 2024
Revolving credit facility	$	330.0		$	333.0
Other debt		1.3			1.5
Unamortized debt issuance costs		(3.4	)		(3.6	)
Total debt		327.9			330.9
Less: current maturities		(0.2	)		(0.2	)
Total long-term debt	$	327.7		$	330.7

Revolving credit facility

On October 31, 2022, the Company entered into a Second Amended and Restated Credit Agreement (the “Credit Agreement”) among the Company, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, and the Lenders and other parties named therein. On March 6, 2024, the Company entered into a First Amendment to Second Amended and Restated Credit Agreement (the “First Amendment”) and on July 9, 2024, the Company entered into a Second Amendment to Second Amended and Restated Credit Agreement and First Amendment to Second Amended and Restated Guaranty (the “Second Amendment”) among the Company, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, the other Lenders party thereto and other parties thereto.

Among other things, the Second Amendment (i) reduced the revolving credit commitments under the Credit Agreement from $750 million to $500 million, (ii) granted a security interest in substantially all of the personal property of the Company and its U.S. subsidiaries that are guarantors, including 100% of the equity interests of their respective U.S. subsidiaries and 65% of the equity interests of their respective foreign subsidiaries (or such greater amount to the extent such pledge could not reasonably cause adverse tax consequences), (iii) amended the consolidated interest coverage ratio covenant for each quarter in fiscal year 2025, (iv) amended the consolidated leverage ratio covenant for the quarter ending July 27, 2024 and each subsequent fiscal quarter, (v) amended certain interest rate provisions, (vi) added a requirement to provide monthly financial statements to the lenders through the period ending July 25, 2025, (vii) decreased the general basket exceptions to certain covenants restricting certain Company investments, liens and indebtedness for specified periods of time, (viii) increased, for fiscal year 2025, the general basket exception to a covenant restricting certain Company dispositions of property, (ix) added an “anti-cash hoarding” requirement, applicable during the period from the effective date of the Second Amendment until the earlier to occur of (a) the delivery of financial statements and a compliance certificate for the fiscal quarter ending July 25, 2025 and (b) the delivery of compliance certificates for two consecutive fiscal quarters demonstrating that the Company’s consolidated leverage ratio as of the last day of such fiscal quarters was less than 3.00:1.00, that if the Company has cash on hand (subject to certain exceptions) of more than $65 million for 10 consecutive business days, the Company shall prepay the indebtedness under the credit facility by the amount of such excess and (x) made certain other changes to the investment, restricted payment and indebtedness baskets. The Credit Agreement, as amended by the First Amendment and the Second Amendment, is referred to herein as the “Amended Credit Agreement.”

The Amended Credit Agreement provides for a secured multicurrency revolving credit facility of $500 million. In addition, the Amended Credit Agreement permits the Company to increase the revolving commitments and/or add one or more tranches of term loans under the Amended Credit Agreement from time to time by up to an amount equal to (i) $250 million plus (ii) an additional amount so long as the consolidated leverage ratio would not exceed 3.00:1.00 on a pro forma basis, subject to, among other things, the receipt of additional commitments from existing and/or new lenders. The Amended Credit Agreement matures on October 31, 2027.

The Second Amendment was accounted for as a debt modification, which resulted in a non-cash loss of $1.2 million in the nine months ended February 1, 2025 related to the partial write-off of unamortized debt issuance costs as a result of the reduction in the credit facility size. The non-cash loss was recognized in other expense, net in the Company’s condensed consolidated statement of operations. Additionally, the Company incurred debt issuance costs of approximately $1.8 million associated with the Second Amendment which were capitalized and, along with the current unamortized debt issuance costs, are being amortized to interest expense on a straight-line basis over remaining term of the Amended Credit Agreement.

Loans denominated in US dollars under the Amended Credit Agreement bear interest at either (a) an adjusted base rate or (b) an adjusted term Secured Overnight Financing Rate (“SOFR”) rate or term SOFR daily floating rate (in each case, as determined in accordance with the provisions of the Amended Credit Agreement in each case plus an applicable rate (the “Applicable Rate”) ranging between 0.375% and 1.75%, in the case of adjusted base rate loans, and between 1.375% and 2.75%, in the case of adjusted term SOFR rate loans and term SOFR daily floating rate loans. Loans denominated in euros will bear interest at the Euro Interbank Offered Rate plus an Applicable Rate ranging between 1.375% and 2.75%. The Applicable Rate is set based on the Company’s consolidated leverage ratio.

As of February 1, 2025, the outstanding balance under the revolving credit facility consisted of $285.0 million (€275.0 million) of euro-denominated borrowings and $45.0 million of US dollar denominated borrowings.

The weighted-average interest rate on outstanding US dollar and euro-denominated borrowings under the Amended Credit Agreement was approximately 7.4% and 5.7% as of February 1, 2025. The Amended Credit Agreement contains customary representations and warranties, financial covenants, restrictive covenants and events of default.

The Amended Credit Agreement contains various representations and warranties, financial covenants (including covenants requiring the Company to maintain compliance with a minimum consolidated interest coverage ratio and a maximum consolidated leverage ratio, in each case as of the end of each fiscal quarter), restrictive and other covenants, and events of default. The covenants in the Amended Credit Agreement include an “anti-cash hoarding” requirement, as discussed above. As of February 1, 2025, the Company was in compliance with all the covenants in the Amended Credit Agreement.

Other debt

One of the Company’s European subsidiaries has debt that consists of one note with a maturity in 2031. The weighted-average interest rate on this debt was approximately 1.8% as of February 1, 2025 and $0.2 million of the debt was classified as short-term.

XML

Shareholders' Equity

9 Months Ended

Feb. 01, 2025

Share-Based Payment Arrangement [Abstract]

Shareholders' Equity

Note 9. Shareholders’ Equity

Repurchases of Common Stock

On March 31, 2021, as subsequently amended on June 16, 2022, the Board of Directors authorized the purchase of up to $200.0 million of the Company’s outstanding common stock through June 14, 2024 (the “2021 Buyback Authorization”). On June 13, 2024, the Board of Directors approved a new share buyback authorization, commencing on June 17, 2024, for the purchase of up to $200.0 million of the Company’s outstanding common stock through June 17, 2026 (the “2024 Buyback Authorization”). Purchases may be made on the open market, including pursuant to purchase plans designed to comply with Rule 10b5-1 of the Securities Exchange Act of 1934, or in private transactions.

The following table summarizes activity under the 2021 Buyback Authorization:

	Three Months Ended				Nine Months Ended
	February 1, 2025		January 27, 2024		February 1, 2025		January 27, 2024
(in millions, except share and per share data)	(13 Weeks)		(13 Weeks)		(40 Weeks)		(39 Weeks)
Shares purchased		—		130,592		136,000		453,371
Average price per share	$	—	$	22.99	$	11.55	$	23.73
Total cost	$	—	$	3.0	$	1.6	$	10.8

Prior to its expiration, a total of 3,553,961 shares were purchased under the 2021 Buyback Authorization at a total cost of $134.6 million. All purchased shares were retired and are reflected as a reduction of common stock for the par value of shares, with the excess applied as a reduction to retained earnings. In the three and nine months ended February 1, 2025, there were zero and 136,000 shares purchased under the 2021 Buyback Authorization and no shares purchased under the 2024 Buyback Authorization. No further shares can be purchased under the 2021 Buyback Authorization. As of February 1, 2025, the dollar value of shares that remained available to be purchased by the Company under 2024 Buyback Authorization was $200.0 million.

Dividends

The Company paid dividends totaling $5.3 million and $4.9 million in the three months ended February 1, 2025 and January 27, 2024, respectively. The Company paid dividends totaling $15.3 million and $15.0 million in the nine months ended February 1, 2025 and January 27, 2024, respectively. Dividends paid in the three months ended February 1, 2025 include $0.6 million of dividend equivalent payments for restricted stock units that vested. Dividends paid in the nine months ended February 1, 2025 and January 27, 2024, include $0.8 million and $0.4 million of dividend equivalent payments for restricted stock units that vested.

Accumulated other comprehensive income (loss)

Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. A summary of changes in AOCI, net of tax is shown below:

	Three Months Ended February 1, 2025 (13 Weeks)									Nine Months Ended February 1, 2025 (40 Weeks)
(in millions)	Currency translation adjustments			Derivative instruments			Total			Currency translation adjustments			Derivative instruments			Total
Balance at beginning of period	$	(34.9	)	$	(2.8	)	$	(37.7	)	$	(36.5	)	$	(0.2	)	$	(36.7	)
Other comprehensive income (loss)		(13.3	)		2.7			(10.6	)		(12.5	)		(0.8	)		(13.3	)
Tax (expense) benefit		(2.2	)		(0.7	)		(2.9	)		(1.4	)		0.2			(1.2	)
Net other comprehensive income (loss)		(15.5	)		2.0			(13.5	)		(13.9	)		(0.6	)		(14.5	)
Balance at the end of period	$	(50.4	)	$	(0.8	)	$	(51.2	)	$	(50.4	)	$	(0.8	)	$	(51.2	)

	Three Months Ended January 27, 2024 (13 Weeks)									Nine Months Ended January 27, 2024 (39 Weeks)
(in millions)	Currency translation adjustments			Derivative instruments			Total			Currency translation adjustments			Derivative instruments			Total
Balance at beginning of period	$	(42.5	)	$	(0.4	)	$	(42.9	)	$	(19.8	)	$	0.8		$	(19.0	)
Other comprehensive income (loss)		11.7			(2.8	)		8.9			(8.6	)		(4.3	)		(12.9	)
Tax benefit (expense)		2.0			0.8			2.8			(0.4	)		1.1			0.7
Net other comprehensive income (loss)		13.7			(2.0	)		11.7			(9.0	)		(3.2	)		(12.2	)
Balance at the end of period	$	(28.8	)	$	(2.4	)	$	(31.2	)	$	(28.8	)	$	(2.4	)	$	(31.2	)

Stock-based compensation

The Company has granted stock options, restricted stock awards (“RSAs”), performance units (“PUs”), restricted stock units (“RSUs”), performance stock units (“PSUs”) and stock awards to employees and non-employee directors under the Methode Electronics, Inc. 2022 Omnibus Incentive Plan (“2022 Plan”), the Methode Electronics, Inc. 2014 Omnibus Incentive Plan (“2014 Plan”), the Methode Electronics, Inc. 2010 Stock Plan (“2010 Plan”), and the Methode Electronics, Inc. 2004 Stock Plan (“2004 Plan”). The Company can no longer make grants under the 2014 Plan, 2010 Plan and 2004 Plan.

Subject to adjustment as provided in the 2022 Plan and the 2022 Plan’s share counting provisions, the number of shares of the Company's common stock that will be available for all awards under the 2022 Plan is 5,550,000, less an amount to reflect shares, options or other awards granted under prior plans after April 30, 2022. As of February 1, 2025, there were approximately 3.6 million shares available for award under the 2022 Plan.

Restricted stock awards and performance units

As of February 1, 2025, the Company had 710,349 RSAs outstanding which may be earned based on the achievement of an earnings before net interest, taxes, fixed asset depreciation and intangible asset amortization (“EBITDA”) measure for fiscal 2025. The RSAs will vest ranging from 0% (for performance below threshold) to 100% (target performance) based on the achievement of the EBITDA performance measure and continued employment. In addition, if the target performance is exceeded, up to an additional 355,175 PUs can be earned that will be settled in cash.

The fair value of the RSAs was based on the closing stock price on the date of grant and the RSAs earn dividend equivalents during the vesting period, which are forfeitable if the RSAs do not vest. Compensation expense for the RSAs is recognized when it is probable the minimum threshold performance criteria will be achieved. Compensation expense for the PUs is recognized when it is probable that the target performance criteria will be exceeded. The Company assesses the probability of vesting at each balance sheet date and adjusts compensation costs based on the probability assessment. The cash-settled PUs represent a non-equity unit with a conversion value equal to the fair market value of a share of the Company’s common stock on the vesting date. The PUs are classified as liability awards due to the cash settlement feature and are re-measured at each balance sheet date. In accordance with ASC 718, “Compensation - Stock Compensation” based on projections of the Company’s current business portfolio, no compensation expense has been recognized for the RSAs or PUs to date, as the performance conditions are not probable of being met. Unrecognized stock-based compensation expense at target level of performance is $20.5 million as of February 1, 2025, which, subject to the performance conditions being met, will be recognized through fiscal 2025. The following table summarizes RSA activity:

	Restricted stock awards			Weighted average grant date fair value
Non-vested at April 27, 2024		789,674		$	28.81
Awarded		—		$	—
Vested		—		$	—
Forfeited		(79,325	)	$	28.28
Non-vested at February 1, 2025		710,349		$	28.87

Performance stock units

In the nine months ended February 1, 2025, the Company granted 208,661 PSUs which will vest upon the achievement of a total stockholder return (“TSR”) measure based on the growth in the Company’s stock price over a three-year performance period that ends April 30, 2027. The number of shares to be issued may range from 0% to a maximum of 200% of the PSUs granted. The Company estimated the grant date fair value of the PSUs using the Monte Carlo simulation model, as the TSR metric and changes in stock price are considered market conditions under ASC 718. The following table provides a summary of the weighted-average assumptions for the PSUs granted:

	Assumptions
Expected volatility		52.40	%
Risk free interest rate		4.07	%
Expected term (in years)		2.72
Grant date fair value	$	14.09

The PSUs earn dividend equivalents during the vesting periods, which are forfeitable if the PSUs do not vest. As of February 1, 2025, unrecognized share-based compensation expense for the PSUs was $2.5 million, which is expected to be recognized over a weighted average period of approximately three years. The following table summarizes PSU activity:

	Performance stock units		Weighted average grant date fair value
Non-vested at April 27, 2024		—	$	—
Awarded		208,661	$	14.09
Vested		—	$	—
Forfeited		—	$	—
Non-vested at February 1, 2025		208,661	$	14.09

Restricted stock units

RSUs granted vest over a pre-determined period of time, up to five years from the date of grant. The fair value of the RSUs granted are based on the closing stock price on the date of grant and earn dividend equivalents during the vesting periods, which are forfeitable if the RSUs do not vest. The following table summarizes RSU activity:

	Restricted stock units			Weighted average grant date fair value
Non-vested at April 27, 2024		941,640		$	26.43
Awarded		326,244		$	12.01
Conversion of cash bonus to RSUs		160,401		$	12.87
Vested		(396,744	)	$	28.29
Forfeited		(183,930	)	$	22.73
Non-vested at February 1, 2025		847,611		$	18.25

In the nine months ended February 1, 2025, 160,401 RSUs were awarded in exchange for cash bonuses earned by certain employees. These RSUs vest on March 7, 2025. As the expense associated with the cash bonuses was previously recognized in fiscal 2024, there is no incremental expense to be recognized for the RSUs. The Company reclassified $2.1 million from accrued employee liabilities to additional paid-in capital on its condensed consolidated balance sheets related to the conversion of the cash bonuses to RSUs.

Under the various stock plans, RSUs that have vested for certain executives, including Ronald L.G. Tsoumas, the Company’s former CFO, will not be delivered in common stock until the first day of the seventh month following the executive’s termination from the Company or upon a change of control. As of February 1, 2025, common stock to be delivered to these executives totaled 85,553 shares, of which 60,875 shares were delivered on February 4, 2025. The vested deferred RSUs are considered outstanding for earnings per share calculations. As of February 1, 2025, unrecognized share-based compensation expense for RSUs was $4.8 million which will be recognized over a weighted-average amortization period of 1.3 years.

Director awards

The Company grants stock awards to its non-employee directors as a component of their compensation. The stock awards vest immediately upon grant. Non-employee directors may elect to defer receipt of their shares under the Company’s non-qualified deferred compensation plan. The following table summarizes awards granted to non-employee directors:

	Non-employee director awards			Deferred non-employee director awards			Total			Weighted average grant date fair value
Outstanding at April 27, 2024		—			77,319			77,319		$	37.23
Awarded		56,680			90,725			147,405		$	9.92
Issued		(56,680	)		(23,756	)		(80,436	)	$	10.49
Outstanding at February 1, 2025		—			144,288			144,288		$	22.80

Stock options

The following table summarizes stock option activity:

	Stock options			Weighted average exercise price		Weighted- average life (years)		Aggregate intrinsic value (in millions)
Outstanding and exercisable at April 27, 2024		8,000		$	37.01		0.2	$	0.0
Exercised		—		$	—
Forfeited		(8,000	)	$	37.01
Outstanding and exercisable at February 1, 2025		—		$	—		0.0	$	0.0

Stock-based compensation expense

All stock-based awards to employees and non-employee directors are recognized in selling and administrative expenses on the condensed consolidated statements of operations. Awards subject to graded vesting are recognized using the accelerated recognition method over the requisite service period. The table below summarizes the stock-based compensation expense related to the equity awards:

	Three Months Ended					Nine Months Ended
	February 1, 2025		January 27, 2024			February 1, 2025		January 27, 2024
(in millions)	(13 Weeks)		(13 Weeks)			(40 Weeks)		(39 Weeks)
RSUs	$	1.5	$	(2.1	)	$	3.5	$	0.2
PSUs		0.3		—			0.5		—
Deferred non-employee director awards		—		—			0.9		1.0
Non-employee director awards		—		—			0.6		0.6
Total stock-based compensation expense	$	1.8	$	(2.1	)	$	5.5	$	1.8

XML

Loss per Share

9 Months Ended

Feb. 01, 2025

Earnings Per Share [Abstract]

Loss per Share

Note 10. Loss per Share

Basic loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the applicable period, but excludes any contingently issued shares where the contingency has not been resolved. The weighted average number of common shares used in the diluted loss per share calculation is determined using the treasury stock method which includes the effect of all potential dilutive common shares outstanding during the period.

The following table sets forth the computation of basic and diluted loss per share:

	Three Months Ended						Nine Months Ended
	February 1, 2025			January 27, 2024			February 1, 2025			January 27, 2024
	(13 Weeks)			(13 Weeks)			(40 Weeks)			(39 Weeks)
Numerator:
Net loss (in millions)	$	(14.4	)	$	(11.6	)	$	(34.3	)	$	(66.0	)
Denominator:
Denominator for basic loss per share - weighted average shares outstanding and vested/unissued restricted stock units		35,182,166			35,327,995			35,370,099			35,562,513
Dilutive potential common shares		—			—			—			—
Denominator for diluted loss per share		35,182,166			35,327,995			35,370,099			35,562,513
Loss per share:
Basic	$	(0.41	)	$	(0.33	)	$	(0.97	)	$	(1.86	)
Diluted	$	(0.41	)	$	(0.33	)	$	(0.97	)	$	(1.86	)
Number of anti-dilutive potentially issuable shares excluded from diluted common shares outstanding		1,303,187			1,319,577			1,176,069			1,463,996

In the three and nine months ended February 1, 2025 and January 27, 2024, all potential common shares issuable for PSUs and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for PSUs and RSUs on the weighted-average number of common shares outstanding would have been approximately 362,000 and 503,000 common shares for the three months ended February 1, 2025 and January 27, 2024, respectively. The dilutive effect of potential common shares issuable for PSUs and RSUs on the weighted-average number of common shares outstanding would have been approximately 221,000 and 560,000 common shares for the nine months ended February 1, 2025 and January 27, 2024, respectively.

XML

Segment Information

9 Months Ended

Feb. 01, 2025

Segment Reporting [Abstract]

Segment Information

Note 11. Segment Information

An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and incur expenses, and about which separate financial information is regularly evaluated by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources. The CODM is the Company’s Chief Executive Officer (“CEO”).

The Automotive segment supplies electronic and electro-mechanical devices and related products to automobile OEMs, either directly or through their tiered suppliers. Products include integrated overhead and center consoles, hidden and ergonomic switches, transmission lead-frames, insert molded components, LED-based lighting and sensors, which incorporate magneto-elastic sensing and other sensing technologies that monitor the operation or status of a component or system.

The Industrial segment manufactures exterior and interior lighting solutions, industrial safety radio remote controls, braided flexible cables, current-carrying laminated busbars and devices, custom power-product assemblies, such as our PowerRail® solution, high-current high-voltage flexible power cabling systems and powder-coated busbars that are used in various markets and applications, including aerospace, commercial vehicles, data centers, industrial equipment, power conversion, military, telecommunications and transportation.

The Interface segment provides a variety of high-speed digital communication over copper media solutions for the data center and broadband markets, and interface panel solutions for the appliance market. Solutions include copper transceivers, distribution point units, and solid-state field-effect consumer touch panels.

The Medical segment was made up of the Company’s medical device business, Dabir Surfaces, with its surface support technology aimed at pressure injury prevention. In the first quarter of fiscal 2024, the Company made the decision to initiate the discontinuation of Dabir Surfaces. In the second quarter of fiscal 2024, the Company sold certain assets of its Dabir Surfaces business. See Note 3, “Disposition” for more information.

The tables below present information about the Company’s reportable segments:

	Three Months Ended February 1, 2025 (13 Weeks)
(in millions)	Automotive			Industrial			Interface		Medical		Eliminations/ Corporate			Consolidated
Net sales	$	120.1		$	119.3		$	12.3	$	—	$	(11.8	)	$	239.9
Transfers between segments		(4.4	)		(7.4	)		—		—		11.8			—
Net sales to unaffiliated customers	$	115.7		$	111.9		$	12.3	$	—	$	—		$	239.9
Income (loss) from operations	$	(9.0	)	$	22.6		$	2.2	$	—	$	(18.0	)	$	(2.2	)
Interest expense, net															5.5
Other expense, net															0.5
Pre-tax loss														$	(8.2	)

	Three Months Ended January 27, 2024 (13 Weeks)
(in millions)	Automotive			Industrial			Interface		Medical			Eliminations /Corporate			Consolidated
Net sales	$	142.4		$	117.1		$	12.7	$	—		$	(12.7	)	$	259.5
Transfers between segments		(2.7	)		(10.0	)		—		—			12.7			—
Net sales to unaffiliated customers	$	139.7		$	107.1		$	12.7	$	—		$	—		$	259.5
Income (loss) from operations	$	(11.0	)	$	18.9		$	1.5	$	(0.1	)	$	(12.3	)	$	(3.0	)
Interest expense, net																5.0
Other expense, net																2.5
Pre-tax loss															$	(10.5	)

	Nine Months Ended February 1, 2025 (40 Weeks)
(in millions)	Automotive			Industrial			Interface		Medical		Eliminations/ Corporate			Consolidated
Net sales	$	404.9		$	375.8		$	40.2	$	—	$	(29.9	)	$	791.0
Transfers between segments		(8.9	)		(21.0	)		—		—		29.9			—
Net sales to unaffiliated customers	$	396.0		$	354.8		$	40.2	$	—	$	—		$	791.0
Income (loss) from operations	$	(14.0	)	$	63.8		$	8.8	$	—	$	(58.9	)	$	(0.3	)
Interest expense, net															16.5
Other expense, net															2.9
Pre-tax loss														$	(19.7	)

	Nine Months Ended January 27, 2024 (39 Weeks)
(in millions)	Automotive			Industrial			Interface			Medical			Eliminations /Corporate			Consolidated
Net sales	$	461.5		$	367.7		$	39.7		$	2.4		$	(34.1	)	$	837.2
Transfers between segments		(9.2	)		(24.8	)		(0.1	)		—			34.1			—
Net sales to unaffiliated customers	$	452.3		$	342.9		$	39.6		$	2.4		$	—		$	837.2
Income (loss) from operations	$	(75.3	)	$	68.8		$	5.4		$	(3.0	)	$	(46.4	)	$	(50.5	)
Interest expense, net																	12.2
Other income, net																	2.3
Pre-tax loss																$	(65.0	)
Goodwill impairment	$	56.5		$	—		$	—		$	—		$	—		$	56.5

(in millions)	February 1, 2025		April 27, 2024
Identifiable assets:
Automotive	$	592.9	$	592.7
Industrial		583.4		604.5
Interface		66.6		67.1
Medical		—		0.2
Eliminations/Corporate		61.7		139.0
Total identifiable assets	$	1,304.6	$	1,403.5

XML

Contingencies

9 Months Ended

Feb. 01, 2025

Commitments and Contingencies Disclosure [Abstract]

Contingencies

Note 12. Contingencies

Certain litigation arising in the normal course of business is pending against us. The Company is, from time-to-time, subject to various legal actions and claims incidental to our business, including those arising out of alleged defects, breach of contracts, employment-related matters, environmental matters and intellectual property matters. The Company has established loss provisions for matters in which losses are deemed probable and reasonably estimable. The Company considers insurance coverage and third-party indemnification, among other things, when determining required accruals for pending litigation and claims. Although the outcome of potential legal actions and claims cannot be predicted with certainty, it is the Company's opinion, based on the information available, that it has adequate reserves for these liabilities. However, the ultimate outcome of any matter could require payment in excess of any amount that the Company may have accrued.

Hetronic Germany-GmbH Matters

For several years, Hetronic Germany-GmbH and Hydronic-Steuersysteme-GmbH (the “Fuchs companies”) served as our distributors for Germany, Austria and other central and eastern European countries pursuant to their respective intellectual property licenses and distribution and assembly agreements. The Company became aware that the Fuchs companies and their managing director, Albert Fuchs, had materially violated those agreements. As a result, the Company terminated all of its agreements with the Fuchs companies. On June 20, 2014, the Company filed a lawsuit against the Fuchs companies in the Federal District Court for the Western District of Oklahoma alleging material breaches of the distribution and assembly agreements and seeking damages, as well as various forms of injunctive relief. The defendants filed counterclaims alleging breach of contract, interference with business relations and business slander. On April 2, 2015, the Company amended its complaint against the Fuchs companies to add additional unfair competition and Lanham Act claims and to add additional affiliated parties.

A trial with respect to the matter began in February 2020. During the trial, the defendants dismissed their one remaining counterclaim with prejudice. On March 2, 2020, the jury returned a verdict in favor of the Company. The verdict included approximately $102 million in compensatory damages and $11 million in punitive damages. On April 22, 2020, the District Court entered a permanent injunction barring defendants from selling infringing products and ordering them to return Hetronic’s confidential information. Defendants appealed entry of the permanent injunction. On May 29, 2020, the District Court held defendants in contempt for violating the permanent injunction and entered the final judgment. Defendants appealed entry of the final monetary judgment as well. The appeal of the permanent injunction and the appeal of the final judgment were consolidated into a single appeal before the U.S. Court of Appeals for the Tenth Circuit. On August 24, 2021, the Tenth Circuit issued a decision affirming the lower court’s ruling with the exception that it instructed the District Court to modify the injunction from the entire world to all of the countries in which Hetronic sells its products. On April 20 and 21, 2022, the District Court held a hearing related to modifying the injunction pursuant to the Tenth Circuit’s opinion, and the parties have filed post-hearing briefs. The defendants also filed a petition for certiorari with the United States Supreme Court seeking to further appeal the extraterritorial application of the Lanham Act in this case. The Company opposed that petition. The Supreme Court requested the views of the Solicitor General on the petition for certiorari, and the Solicitor General recommended granting the petition. On November 4, 2022, the Supreme Court granted the petition. The Supreme Court heard arguments in this matter on March 21, 2023. On June 29, 2023, the Supreme Court vacated the Tenth Circuit’s August 2021 decision and remanded the matter back to the Tenth Circuit for further proceedings. On September 1, 2023, the Tenth Circuit requested supplemental briefing from the parties regarding the effect of the Supreme Court’s decision on the appeal and the proper course of further proceedings. That briefing was thereafter submitted, and the Tenth Circuit heard argument in this matter on January 24, 2024. On April 23, 2024, the Tenth Circuit issued an opinion affirming the District Court’s final judgment on the state law breach of contract and tort claims (this affirmed final judgment amount represents only approximately $22.5 million of the vacated original $113 million final judgment that had been entered in 2020) and remanding for further non-trial proceedings with respect to the appropriate remedies for the Lanham Act claims in light of the Supreme’s Court ruling that the Lanham Act does not apply extraterritorially. On August 5, 2024, the District Court entered an amended permanent injunction and amended final judgment. The amended permanent injunction limited the geographic reach of the permanent injunction barring defendants from selling infringing products so that it only applies in the United States and reaffirmed the court’s prior order requiring defendants to return Hetronic’s confidential information. The amended final judgment reaffirmed the final judgment of approximately $22.5 million plus interest for the state law breach of contract and tort claims and entered judgment in an amended amount of approximately $0.3 million plus interest for the infringing U.S. sales under the Lanham Act. The deadline for any appeals of the District Court’s orders was September 4, 2024 and no appeal of those orders was filed before that deadline.

The Company has not received payment of any portion of the judgment from the defendants. Like any judgment, particularly a judgment involving defendants outside of the United States, there is no guarantee that the Company will be able to collect all or any portion of the judgment. Furthermore, defendants Abitron Germany and Hetronic Germany filed for insolvency in German court in September and October 2023 respectively, and the Germany insolvency court then appointed a receiver. These insolvency proceedings could potentially adversely impact our ability to enforce or collect upon the judgment or portions of the judgment or otherwise pursue or enforce claims or rights against those defendants.

Stockholder Litigation

On August 26, 2024, a putative class action lawsuit on behalf of purchasers of Company common stock between June 23, 2022 and March 6, 2024, inclusive, entitled Marie Salem v. Methode Electronics, Inc. et al. was filed in the U.S. District Court for the Northern District of Illinois against the Company, a former Chief Executive Officer, President and director of the Company and a former Chief Financial Officer of the Company. The complaint alleges, among other things, that the defendants made false and/or misleading statements relating to the Company’s business, operations and prospects, including in respect of the Company’s transition to production of more specialized components for manufacturers of electric vehicles and the Company’s operations at its facility in Monterrey, Mexico, in violation of Sections 10(b) and 20 of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The complaint seeks, among other things, unspecified money damages along with equitable relief and costs and expenses, including counsel fees and expert fees. Another purported shareholder filed a substantially similar action in the U.S. District Court for the Northern District of Illinois on October 7, 2024 against the same defendants and a former Chief Operating Officer of the Company, in a case entitled City of Cape Coral Municipal General Employees Retirement Plan v. Methode Electronics, Inc., et al. The second securities class action was filed on behalf of a broader putative class of purchasers of Company common stock between December 2, 2021 and March 6, 2024. In addition, two purported shareholders filed derivative lawsuits on November 26, 2024 and February 4, 2025, respectively. The derivative lawsuits were filed on behalf of the Company in the U.S. District Court for the Northern District of Illinois against the current members of the Company’s Board of Directors, as well as certain former directors and executives, alleging that the defendants breached their fiduciary duties by allowing the Company to issue various statements that are alleged to have been false or misleading for the same reasons alleged in the securities class action complaints. The derivative lawsuits are entitled Ray Homsi v. Donald Duda, et al. and Kevin D. Murphy v. Mark D. Schwabero, et al. (collectively with the Salem and City of Cape Coral matters, the “Stockholder Actions”).

The Company disagrees with and intends to vigorously defend against the Stockholder Actions. The Stockholder Actions could result in costs and losses to the Company, including potential costs associated with the indemnification of the other defendants. At this time, given the current status of the Stockholder Actions, the Company is unable to reasonably estimate an amount or range of reasonably possible loss, if any, that may result from the Stockholder Actions.

SEC Investigation

The Company received a subpoena from the SEC dated November 1, 2024 seeking documents and information relating to, among other things, the Company’s operations in certain foreign countries, certain financial and accounting matters relating thereto, compliance with the Foreign Corrupt Practices Act and other anti-corruption laws, and material weaknesses in the Company’s internal control over financial reporting previously reported in its public filings. The Company is cooperating with the SEC. The subpoena and related investigation or other future requests for information could result in costs to the Company, including the expenditure of financial and managerial resources. In addition, this request may lead to the assertion of claims or the commencement of legal proceedings against the Company, which in turn may lead to material fines, penalties or other liabilities. However, at this time, the Company is unable to reasonably estimate an amount or range of reasonably possible loss, if any, that may result from these matters.

XML

Restructuring and Asset Impairment Charges

9 Months Ended

Feb. 01, 2025

Restructuring and Related Activities [Abstract]

Restructuring and Asset Impairment Charges

Note 13. Restructuring and Asset Impairment Charges

Restructuring and asset impairment charges includes costs related to restructuring actions taken by the Company as well as long-lived asset impairments.

The Company continually monitors market factors and industry trends and takes restructuring actions to reduce overall costs and improve operational profitability as appropriate. Restructuring actions generally result in charges for employee termination benefits, plant closures, asset impairments and contract termination costs.

Components of restructuring and asset impairment charges were as follows:

	Three Months Ended				Nine Months Ended
	February 1, 2025		January 27, 2024		February 1, 2025		January 27, 2024
(in millions)	(13 Weeks)		(13 Weeks)		(40 Weeks)		(39 Weeks)
Employee termination benefits	$	—	$	—	$	0.3	$	0.7
Asset impairment charges		—		0.1		0.4		0.7
Total	$	—	$	0.1	$	0.7	$	1.4

The table below presents restructuring and asset impairment charges by reportable segment.

	Three Months Ended				Nine Months Ended
	February 1, 2025		January 27, 2024		February 1, 2025		January 27, 2024
(in millions)	(13 Weeks)		(13 Weeks)		(40 Weeks)		(39 Weeks)
Automotive	$	—	$	—	$	0.3	$	0.2
Industrial		—		0.1		0.1		0.1
Interface		—		—		—		—
Medical		—		—		—		1.1
Eliminations/Corporate		—		—		0.3		—
Total	$	—	$	0.1	$	0.7	$	1.4
Recognized in:
Cost of products sold	$	—	$	0.1	$	0.4	$	0.9
Selling and administrative expenses		—		—		0.3		0.5
	$	—	$	0.1	$	0.7	$	1.4

The Company’s restructuring liability was $0.0 million and $0.7 million as of February 1, 2025 and April 27, 2024, respectively. Estimates of restructuring costs are based on information available at the time such charges are recorded. Due to the inherent uncertainty involved in estimating restructuring costs, actual amounts paid for such activities may differ from amounts initially recorded. Accordingly, the Company may record revisions of previous estimates by adjusting previously established accruals. The Company may take additional restructuring actions in future periods based upon market conditions and industry trends.

XML

Related Party Transactions

9 Months Ended

Feb. 01, 2025

Related Party Transactions [Abstract]

Related Party Transactions

Note 14. Related Party Transactions

The Company’s former Interim Chief Financial Officer, David Rawden, is a director of AlixPartners, LLP (“AlixPartners”), a business advisory firm that provided a number of consulting services to the Company. The Company’s former Interim Chief Executive Officer, Kevin Nystrom, is a partner and managing director of AlixPartners. In the three and nine months ended February 1, 2025, the Company recognized $0.9 million and $9.8 million, respectively, of expense for consulting services provided by AlixPartners. As of February 1, 2025, $0.4 million was payable to AlixPartners which was reflected in accounts payable on the condensed consolidated balance sheets. As of April 27, 2024, $1.4 million was payable to AlixPartners which was reflected in other accrued liabilities on the condensed consolidated balance sheets.

XML

Description of Business and Summary of Significant Accounting Policies (Policies)

9 Months Ended

Feb. 01, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

Basis of presentation

The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). All intercompany balances and transactions have been eliminated in consolidation. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. These interim condensed consolidated financial statements include all adjustments (consisting of normal recurring adjustments, except as otherwise disclosed) that management believes are necessary for a fair presentation of the results of operations, financial position and cash flows of the Company for the interim periods presented. These financial statements should be read in conjunction with the consolidated financial statements included in the Company’s Form 10-K for the year ended April 27, 2024, filed with the SEC on July 11, 2024. Results may vary from quarter to quarter for reasons other than seasonality.

Financial Reporting Periods

Financial reporting periods

The Company’s fiscal year ends on the Saturday closest to April 30 of the following year, typically resulting in a 52-week year, but occasionally giving rise to an additional week, resulting in a 53-week year. The current fiscal year ending May 3, 2025 is a 53-week fiscal year, with the additional week being included in the second fiscal quarter. The three months ended February 1, 2025 and January 27, 2024 were 13-week periods, while the nine months ended February 1, 2025 and January 27, 2024 were 40 and 39-week periods, respectively.

Use of Estimates

Use of estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. These estimates and assumptions are subject to an inherent degree of uncertainty and may change, as new events occur, and additional information is obtained. As a result, actual results may differ from previously estimated amounts, and such differences may be material to the condensed consolidated financial statements. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the period they occur.

Accounting pronouncements not yet adopted

Accounting pronouncements not yet adopted

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which requires entities to provide disclosures about their reportable segments’ significant expenses on an interim and annual basis. The updated standard is effective for the Company’s annual periods beginning in fiscal 2025 and interim periods beginning in the first quarter of fiscal 2026. Early adoption is permitted. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures.

In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU No. 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU No. 2023-09 will become effective for the Company in the first quarter of fiscal 2026 and will be applied on a prospective basis, with a retrospective option. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on its financial statement disclosures.

In November 2024, the FASB issued ASU 2024-03, “Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures.” ASU 2024-03 requires public entities to disclose more detailed information about certain costs and expenses presented in the income statement, including inventory purchases, employee compensation, selling expenses and depreciation. ASU 2024-03 will become effective for the Company’s annual periods beginning in fiscal 2028. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on its financial statement disclosures.

There have been no other newly issued or newly applicable accounting pronouncements that have had, or are expected to have, a material impact on the Company’s condensed consolidated financial statements. Further, at February 1, 2025, there are no other pronouncements pending adoption that are expected to have a material impact on the Company’s condensed consolidated financial statements.

Summary of Significant Accounting Policies

Summary of significant accounting policies

The Company’s significant accounting policies are described in Note 1, “Description of Business and Summary of Significant Accounting Policies,” to the consolidated financial statements included in the Company’s Form 10-K for the year ended April 27, 2024. There have been no material changes to the significant accounting policies in the nine months ended February 1, 2025.

Foreign Currency Translation

Foreign currency translation.

The functional currencies of the majority of the Company’s foreign subsidiaries are their local currencies. The results of operations of these foreign subsidiaries are translated into U.S. dollars using average monthly rates, while the assets and liabilities are translated using period-end exchange rates. The resulting translation adjustments are recorded as a component of accumulated other comprehensive income (loss) (“AOCI”). Gains and losses arising from transactions denominated in a currency other than the functional currency, except certain long-term intercompany transactions, are included in the condensed consolidated statements of operations in other expense, net. Net foreign exchange loss was $1.3 million in the three months ended February 1, 2025, compared to $2.8 million in the three months ended January 27, 2024. Net foreign exchange loss was $3.6 million in the nine months ended February 1, 2025, compared to $2.2 million in the nine months ended January 27, 2024.

Inventory

Inventories are stated at the lower-of-cost or net realizable value. Cost is determined using the first-in, first-out method. Finished products and work-in-process inventories include direct material costs and direct and indirect manufacturing costs. The Company records reserves for inventory that may be obsolete or in excess of current and future market demand.

Property, Plant and Equipment

Property, plant and equipment is stated at cost. Maintenance and repair costs are expensed as incurred. Depreciation is calculated using the straight-line method using estimated useful lives of 5 to 40 years for buildings and building improvements and 3 to 15 years for machinery and equipment.

Loss per Share

Basic loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the applicable period, but excludes any contingently issued shares where the contingency has not been resolved. The weighted average number of common shares used in the diluted loss per share calculation is determined using the treasury stock method which includes the effect of all potential dilutive common shares outstanding during the period.

Contingencies

Certain litigation arising in the normal course of business is pending against us. The Company is, from time-to-time, subject to various legal actions and claims incidental to our business, including those arising out of alleged defects, breach of contracts, employment-related matters, environmental matters and intellectual property matters. The Company has established loss provisions for matters in which losses are deemed probable and reasonably estimable. The Company considers insurance coverage and third-party indemnification, among other things, when determining required accruals for pending litigation and claims. Although the outcome of potential legal actions and claims cannot be predicted with certainty, it is the Company's opinion, based on the information available, that it has adequate reserves for these liabilities. However, the ultimate outcome of any matter could require payment in excess of any amount that the Company may have accrued.

XML

Revenue (Tables)

9 Months Ended

Feb. 01, 2025

Revenue from Contract with Customer [Abstract]

Disaggregated Revenue Information

The following table represents a disaggregation of revenue from contracts with customers by segment and geographical location. Net sales are attributed to regions based on the location of production. Though revenue recognition patterns and contracts are generally consistent, the amount, timing and uncertainty of revenue and cash flows may vary in each reportable segment due to geographic and economic factors.

	Three Months Ended February 1, 2025 (13 Weeks)
(in millions)	Automotive		Industrial		Interface		Medical		Total
Geographic net sales:
North America	$	51.8	$	38.6	$	12.3	$	—	$	102.7
Europe, the Middle East & Africa ("EMEA")		55.9		41.4		—		—		97.3
Asia		8.0		31.9		—		—		39.9
Total net sales	$	115.7	$	111.9	$	12.3	$	—	$	239.9
Timing of revenue recognition:
Goods transferred at a point in time	$	111.8	$	111.9	$	12.3	$	—	$	236.0
Goods transferred over time		3.9		—		—		—		3.9
Total net sales	$	115.7	$	111.9	$	12.3	$	—	$	239.9

	Three Months Ended January 27, 2024 (13 Weeks)
(in millions)	Automotive		Industrial		Interface		Medical		Total
Geographic net sales:
North America	$	56.7	$	45.6	$	12.7	$	—	$	115.0
EMEA		52.0		37.5		—		—		89.5
Asia		31.0		24.0		—		—		55.0
Total net sales	$	139.7	$	107.1	$	12.7	$	—	$	259.5
Timing of revenue recognition:
Goods transferred at a point in time	$	136.6	$	107.1	$	12.7	$	—	$	256.4
Goods transferred over time		3.1		—		—		—		3.1
Total net sales	$	139.7	$	107.1	$	12.7	$	—	$	259.5

	Nine Months Ended February 1, 2025 (40 Weeks)
(in millions)	Automotive		Industrial		Interface		Medical		Total
Geographic net sales:
North America	$	187.8	$	133.8	$	40.2	$	—	$	361.8
EMEA		181.7		129.5		—		—		311.2
Asia		26.5		91.5		—		—		118.0
Total net sales	$	396.0	$	354.8	$	40.2	$	—	$	791.0
Timing of revenue recognition:
Goods transferred at a point in time	$	387.2	$	354.8	$	40.2	$	—	$	782.2
Goods transferred over time		8.8		—		—		—		8.8
Total net sales	$	396.0	$	354.8	$	40.2	$	—	$	791.0

	Nine Months Ended January 27, 2024 (39 Weeks)
(in millions)	Automotive		Industrial		Interface		Medical		Total
Geographic net sales:
North America	$	194.4	$	137.6	$	39.6	$	2.3	$	373.9
EMEA		153.9		131.4		—		—		285.3
Asia		104.0		73.9		—		0.1		178.0
Total net sales	$	452.3	$	342.9	$	39.6	$	2.4	$	837.2
Timing of revenue recognition:
Goods transferred at a point in time	$	440.7	$	342.9	$	39.6	$	2.4	$	825.6
Goods transferred over time		11.6		—		—		—		11.6
Total net sales	$	452.3	$	342.9	$	39.6	$	2.4	$	837.2

XML

Income Taxes (Tables)

9 Months Ended

Feb. 01, 2025

Income Tax Disclosure [Abstract]

Schedule of Income Tax Expense And Effective Tax Rate

The Company’s income tax expense and effective tax rate for the three and nine months ended February 1, 2025 and January 27, 2024 were as follows:

	Three Months Ended						Nine Months Ended
	February 1, 2025			January 27, 2024			February 1, 2025			January 27, 2024
($ in millions)	(13 Weeks)			(13 Weeks)			(40 Weeks)			(39 Weeks)
Pre-tax loss	$	(8.2	)	$	(10.5	)	$	(19.7	)	$	(65.0	)
Income tax expense		6.2			1.1			14.6			1.0
Effective tax rate		(75.6	)%		(10.5	)%		(74.1	)%		(1.5	)%

XML

Balance Sheet Components (Tables)

9 Months Ended

Feb. 01, 2025

Balance Sheet Components [Abstract]

Summary of Inventories

A summary of inventories is shown below:

(in millions)	February 1, 2025		April 27, 2024
Finished products	$	47.1	$	45.6
Work in process		24.1		16.1
Raw materials		147.6		124.5
Total inventories	$	218.8	$	186.2

Summary of Property, Plant and Equipment

A summary of property, plant and equipment is shown below:

(in millions)	February 1, 2025			April 27, 2024
Land	$	3.3		$	3.3
Buildings and building improvements		98.4			98.5
Machinery and equipment		395.4			394.6
Construction in progress		48.1			50.4
Total property, plant and equipment, gross		545.2			546.8
Less: accumulated depreciation		(336.6	)		(334.7	)
Property, plant and equipment, net	$	208.6		$	212.1

XML

Goodwill and Other Intangible Assets (Tables)

9 Months Ended

Feb. 01, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of the Changes in the Carrying Amount of Goodwill by Segment

A summary of the changes in the carrying amount of goodwill is shown below:

(in millions)	Total
Balance as of April 27, 2024	$	169.9
Foreign currency translation		(2.5	)
Balance as of February 1, 2025	$	167.4

Summary of Goodwill by Reporting Unit

A summary of goodwill by reporting unit is as follows:

(in millions)	February 1, 2025		April 27, 2024
Grakon Industrial	$	123.2	$	124.4
Nordic Lights		42.6		43.9
Other		1.6		1.6
Total	$	167.4	$	169.9

Schedule of Other Intangible Assets, Net

Details of identifiable intangible assets are shown below:

	As of February 1, 2025
(in millions)	Gross		Accumulated amortization			Net		Weighted average remaining useful life (years)
Amortized intangible assets:
Customer relationships and agreements	$	303.0	$	(96.5	)	$	206.5		14.2
Trade names, patents and technology licenses		74.4		(47.0	)		27.4		6.5
Total amortized intangible assets		377.4		(143.5	)		233.9
Unamortized trade name		1.8		—			1.8
Total other intangible assets	$	379.2	$	(143.5	)	$	235.7

	As of April 27, 2024
(in millions)	Gross		Accumulated amortization			Net		Weighted average remaining useful life (years)
Amortized intangible assets:
Customer relationships and agreements	$	306.6	$	(84.7	)	$	221.9		14.8
Trade names, patents and technology licenses		75.3		(42.3	)		33.0		6.9
Total amortized intangible assets		381.9		(127.0	)		254.9
Unamortized trade name		1.8		—			1.8
Total other intangible assets	$	383.7	$	(127.0	)	$	256.7

Schedule of Estimated Aggregate Amortization Expense of Intangible Assets

Based on the current amount of intangible assets subject to amortization, the estimated aggregate amortization expense for each of the five succeeding fiscal years and thereafter is as follows:

(in millions)
Fiscal Year:
Remainder of 2025	$	5.7
2026		22.3
2027		21.6
2028		19.3
2029		18.1
Thereafter		146.9
Total	$	233.9

XML

Derivative Instruments and Hedging Activities (Tables)

9 Months Ended

Feb. 01, 2025

Text Block [Abstract]

Schedule of Derivative Instruments Effect on Other Comprehensive Income (Loss)

Effect of derivative instruments on comprehensive income (loss)

The pre-tax effects of derivative financial instruments recorded in other comprehensive income (loss) were as follows:

	Three Months Ended					Nine Months Ended
	February 1, 2025		January 27, 2024			February 1, 2025			January 27, 2024
(in millions)	(13 Weeks)		(13 Weeks)			(40 Weeks)			(39 Weeks)
Net investment hedges	$	2.6	$	0.3		$	1.8		$	1.5
Interest rate swaps		0.1		(3.1	)		(2.6	)		(5.8	)
Total	$	2.7	$	(2.8	)	$	(0.8	)	$	(4.3	)

Schedule of Fair Value of Derivative Instruments Classified as Level 2 Within Fair Value Recorded in the Condensed Consolidated Balance Sheet

The fair value of derivative instruments are classified as Level 2 within the fair value hierarchy and are recorded in the condensed consolidated balance sheets as follows:

		Asset/(Liability)
(in millions)	Financial Statement Caption	February 1, 2025			April 27, 2024
Derivatives designated as hedging instruments:
Net investment hedges	Prepaid expenses and other current assets	$	—		$	1.3
Interest rate swaps	Other long-term liabilities	$	(4.7	)	$	(2.1	)
Derivatives not designated as hedging instruments:
Foreign currency forward contracts	Other accrued liabilities	$	(0.8	)	$	(0.2	)

XML

Debt (Tables)

9 Months Ended

Feb. 01, 2025

Debt Disclosure [Abstract]

Summary of Debt

A summary of debt is shown below:

(in millions)	February 1, 2025			April 27, 2024
Revolving credit facility	$	330.0		$	333.0
Other debt		1.3			1.5
Unamortized debt issuance costs		(3.4	)		(3.6	)
Total debt		327.9			330.9
Less: current maturities		(0.2	)		(0.2	)
Total long-term debt	$	327.7		$	330.7

XML

Shareholders' Equity (Tables)

9 Months Ended

Feb. 01, 2025

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Summary of Activity under 2021 Buyback Program

The following table summarizes activity under the 2021 Buyback Authorization:

	Three Months Ended				Nine Months Ended
	February 1, 2025		January 27, 2024		February 1, 2025		January 27, 2024
(in millions, except share and per share data)	(13 Weeks)		(13 Weeks)		(40 Weeks)		(39 Weeks)
Shares purchased		—		130,592		136,000		453,371
Average price per share	$	—	$	22.99	$	11.55	$	23.73
Total cost	$	—	$	3.0	$	1.6	$	10.8

Summary of Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax

A summary of changes in AOCI, net of tax is shown below:

	Three Months Ended February 1, 2025 (13 Weeks)									Nine Months Ended February 1, 2025 (40 Weeks)
(in millions)	Currency translation adjustments			Derivative instruments			Total			Currency translation adjustments			Derivative instruments			Total
Balance at beginning of period	$	(34.9	)	$	(2.8	)	$	(37.7	)	$	(36.5	)	$	(0.2	)	$	(36.7	)
Other comprehensive income (loss)		(13.3	)		2.7			(10.6	)		(12.5	)		(0.8	)		(13.3	)
Tax (expense) benefit		(2.2	)		(0.7	)		(2.9	)		(1.4	)		0.2			(1.2	)
Net other comprehensive income (loss)		(15.5	)		2.0			(13.5	)		(13.9	)		(0.6	)		(14.5	)
Balance at the end of period	$	(50.4	)	$	(0.8	)	$	(51.2	)	$	(50.4	)	$	(0.8	)	$	(51.2	)

	Three Months Ended January 27, 2024 (13 Weeks)									Nine Months Ended January 27, 2024 (39 Weeks)
(in millions)	Currency translation adjustments			Derivative instruments			Total			Currency translation adjustments			Derivative instruments			Total
Balance at beginning of period	$	(42.5	)	$	(0.4	)	$	(42.9	)	$	(19.8	)	$	0.8		$	(19.0	)
Other comprehensive income (loss)		11.7			(2.8	)		8.9			(8.6	)		(4.3	)		(12.9	)
Tax benefit (expense)		2.0			0.8			2.8			(0.4	)		1.1			0.7
Net other comprehensive income (loss)		13.7			(2.0	)		11.7			(9.0	)		(3.2	)		(12.2	)
Balance at the end of period	$	(28.8	)	$	(2.4	)	$	(31.2	)	$	(28.8	)	$	(2.4	)	$	(31.2	)

Summary of RSA and RSU Activity

The following table summarizes RSA activity:

	Restricted stock awards			Weighted average grant date fair value
Non-vested at April 27, 2024		789,674		$	28.81
Awarded		—		$	—
Vested		—		$	—
Forfeited		(79,325	)	$	28.28
Non-vested at February 1, 2025		710,349		$	28.87

The following table summarizes RSU activity:

	Restricted stock units			Weighted average grant date fair value
Non-vested at April 27, 2024		941,640		$	26.43
Awarded		326,244		$	12.01
Conversion of cash bonus to RSUs		160,401		$	12.87
Vested		(396,744	)	$	28.29
Forfeited		(183,930	)	$	22.73
Non-vested at February 1, 2025		847,611		$	18.25

Summary of the Weighted-Average Assumptions for the PSUs Granted

The following table provides a summary of the weighted-average assumptions for the PSUs granted:

	Assumptions
Expected volatility		52.40	%
Risk free interest rate		4.07	%
Expected term (in years)		2.72
Grant date fair value	$	14.09

Summary of PSU Activity

The following table summarizes PSU activity:

	Performance stock units		Weighted average grant date fair value
Non-vested at April 27, 2024		—	$	—
Awarded		208,661	$	14.09
Vested		—	$	—
Forfeited		—	$	—
Non-vested at February 1, 2025		208,661	$	14.09

Summary of Awards Granted to Non-employee Directors

The following table summarizes awards granted to non-employee directors:

	Non-employee director awards			Deferred non-employee director awards			Total			Weighted average grant date fair value
Outstanding at April 27, 2024		—			77,319			77,319		$	37.23
Awarded		56,680			90,725			147,405		$	9.92
Issued		(56,680	)		(23,756	)		(80,436	)	$	10.49
Outstanding at February 1, 2025		—			144,288			144,288		$	22.80

Summary of combined stock option activity and related information for stock options granted

The following table summarizes stock option activity:

	Stock options			Weighted average exercise price		Weighted- average life (years)		Aggregate intrinsic value (in millions)
Outstanding and exercisable at April 27, 2024		8,000		$	37.01		0.2	$	0.0
Exercised		—		$	—
Forfeited		(8,000	)	$	37.01
Outstanding and exercisable at February 1, 2025		—		$	—		0.0	$	0.0

Summary of Stock-based Compensation Expense Related to Equity Awards

The table below summarizes the stock-based compensation expense related to the equity awards:

	Three Months Ended					Nine Months Ended
	February 1, 2025		January 27, 2024			February 1, 2025		January 27, 2024
(in millions)	(13 Weeks)		(13 Weeks)			(40 Weeks)		(39 Weeks)
RSUs	$	1.5	$	(2.1	)	$	3.5	$	0.2
PSUs		0.3		—			0.5		—
Deferred non-employee director awards		—		—			0.9		1.0
Non-employee director awards		—		—			0.6		0.6
Total stock-based compensation expense	$	1.8	$	(2.1	)	$	5.5	$	1.8

XML

Loss per Share (Tables)

9 Months Ended

Feb. 01, 2025

Earnings Per Share [Abstract]

Schedule of Computation of Basic and Diluted Loss Per Share

The following table sets forth the computation of basic and diluted loss per share:

	Three Months Ended						Nine Months Ended
	February 1, 2025			January 27, 2024			February 1, 2025			January 27, 2024
	(13 Weeks)			(13 Weeks)			(40 Weeks)			(39 Weeks)
Numerator:
Net loss (in millions)	$	(14.4	)	$	(11.6	)	$	(34.3	)	$	(66.0	)
Denominator:
Denominator for basic loss per share - weighted average shares outstanding and vested/unissued restricted stock units		35,182,166			35,327,995			35,370,099			35,562,513
Dilutive potential common shares		—			—			—			—
Denominator for diluted loss per share		35,182,166			35,327,995			35,370,099			35,562,513
Loss per share:
Basic	$	(0.41	)	$	(0.33	)	$	(0.97	)	$	(1.86	)
Diluted	$	(0.41	)	$	(0.33	)	$	(0.97	)	$	(1.86	)
Number of anti-dilutive potentially issuable shares excluded from diluted common shares outstanding		1,303,187			1,319,577			1,176,069			1,463,996

XML

Segment Information (Tables)

9 Months Ended

Feb. 01, 2025

Segment Reporting [Abstract]

Schedule of Reportable Segments

The tables below present information about the Company’s reportable segments:

	Three Months Ended February 1, 2025 (13 Weeks)
(in millions)	Automotive			Industrial			Interface		Medical		Eliminations/ Corporate			Consolidated
Net sales	$	120.1		$	119.3		$	12.3	$	—	$	(11.8	)	$	239.9
Transfers between segments		(4.4	)		(7.4	)		—		—		11.8			—
Net sales to unaffiliated customers	$	115.7		$	111.9		$	12.3	$	—	$	—		$	239.9
Income (loss) from operations	$	(9.0	)	$	22.6		$	2.2	$	—	$	(18.0	)	$	(2.2	)
Interest expense, net															5.5
Other expense, net															0.5
Pre-tax loss														$	(8.2	)

	Three Months Ended January 27, 2024 (13 Weeks)
(in millions)	Automotive			Industrial			Interface		Medical			Eliminations /Corporate			Consolidated
Net sales	$	142.4		$	117.1		$	12.7	$	—		$	(12.7	)	$	259.5
Transfers between segments		(2.7	)		(10.0	)		—		—			12.7			—
Net sales to unaffiliated customers	$	139.7		$	107.1		$	12.7	$	—		$	—		$	259.5
Income (loss) from operations	$	(11.0	)	$	18.9		$	1.5	$	(0.1	)	$	(12.3	)	$	(3.0	)
Interest expense, net																5.0
Other expense, net																2.5
Pre-tax loss															$	(10.5	)

	Nine Months Ended February 1, 2025 (40 Weeks)
(in millions)	Automotive			Industrial			Interface		Medical		Eliminations/ Corporate			Consolidated
Net sales	$	404.9		$	375.8		$	40.2	$	—	$	(29.9	)	$	791.0
Transfers between segments		(8.9	)		(21.0	)		—		—		29.9			—
Net sales to unaffiliated customers	$	396.0		$	354.8		$	40.2	$	—	$	—		$	791.0
Income (loss) from operations	$	(14.0	)	$	63.8		$	8.8	$	—	$	(58.9	)	$	(0.3	)
Interest expense, net															16.5
Other expense, net															2.9
Pre-tax loss														$	(19.7	)

	Nine Months Ended January 27, 2024 (39 Weeks)
(in millions)	Automotive			Industrial			Interface			Medical			Eliminations /Corporate			Consolidated
Net sales	$	461.5		$	367.7		$	39.7		$	2.4		$	(34.1	)	$	837.2
Transfers between segments		(9.2	)		(24.8	)		(0.1	)		—			34.1			—
Net sales to unaffiliated customers	$	452.3		$	342.9		$	39.6		$	2.4		$	—		$	837.2
Income (loss) from operations	$	(75.3	)	$	68.8		$	5.4		$	(3.0	)	$	(46.4	)	$	(50.5	)
Interest expense, net																	12.2
Other income, net																	2.3
Pre-tax loss																$	(65.0	)
Goodwill impairment	$	56.5		$	—		$	—		$	—		$	—		$	56.5

(in millions)	February 1, 2025		April 27, 2024
Identifiable assets:
Automotive	$	592.9	$	592.7
Industrial		583.4		604.5
Interface		66.6		67.1
Medical		—		0.2
Eliminations/Corporate		61.7		139.0
Total identifiable assets	$	1,304.6	$	1,403.5

XML

Restructuring and Asset Impairment Charges (Tables)

9 Months Ended

Feb. 01, 2025

Restructuring and Related Activities [Abstract]

Schedule of Components of Restructuring and Asset Impairment Charges

Components of restructuring and asset impairment charges were as follows:

	Three Months Ended				Nine Months Ended
	February 1, 2025		January 27, 2024		February 1, 2025		January 27, 2024
(in millions)	(13 Weeks)		(13 Weeks)		(40 Weeks)		(39 Weeks)
Employee termination benefits	$	—	$	—	$	0.3	$	0.7
Asset impairment charges		—		0.1		0.4		0.7
Total	$	—	$	0.1	$	0.7	$	1.4

Schedule of Restructuring and Asset Impairment Charges by Reportable Segment

The table below presents restructuring and asset impairment charges by reportable segment.

	Three Months Ended				Nine Months Ended
	February 1, 2025		January 27, 2024		February 1, 2025		January 27, 2024
(in millions)	(13 Weeks)		(13 Weeks)		(40 Weeks)		(39 Weeks)
Automotive	$	—	$	—	$	0.3	$	0.2
Industrial		—		0.1		0.1		0.1
Interface		—		—		—		—
Medical		—		—		—		1.1
Eliminations/Corporate		—		—		0.3		—
Total	$	—	$	0.1	$	0.7	$	1.4
Recognized in:
Cost of products sold	$	—	$	0.1	$	0.4	$	0.9
Selling and administrative expenses		—		—		0.3		0.5
	$	—	$	0.1	$	0.7	$	1.4

XML

Description of Business and Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Fiscal period duration	91 days	91 days	280 days	273 days
Net foreign exchange gains (losses)	$ (1.3)	$ (2.8)	$ (3.6)	$ (2.2)

XML

Revenue (Details)	9 Months Ended
	Feb. 01, 2025
Minimum
Accounts Receivable and Allowance for Doubtful Accounts [Line Items]
Accounts receivable collection terms	30 days
Maximum
Accounts Receivable and Allowance for Doubtful Accounts [Line Items]
Accounts receivable collection terms	45 days

XML

Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024
Disaggregation of Revenue [Line Items]
Net sales	$ 239.9	$ 259.5	$ 791.0	$ 837.2
Automotive
Disaggregation of Revenue [Line Items]
Net sales	115.7	139.7	396.0	452.3
Industrial
Disaggregation of Revenue [Line Items]
Net sales	111.9	107.1	354.8	342.9
Interface
Disaggregation of Revenue [Line Items]
Net sales	12.3	12.7	40.2	39.6
Medical
Disaggregation of Revenue [Line Items]
Net sales	0.0	0.0	0.0	2.4
Goods Transferred at a Point in Time
Disaggregation of Revenue [Line Items]
Net sales	236.0	256.4	782.2	825.6
Goods Transferred at a Point in Time | Automotive
Disaggregation of Revenue [Line Items]
Net sales	111.8	136.6	387.2	440.7
Goods Transferred at a Point in Time | Industrial
Disaggregation of Revenue [Line Items]
Net sales	111.9	107.1	354.8	342.9
Goods Transferred at a Point in Time | Interface
Disaggregation of Revenue [Line Items]
Net sales	12.3	12.7	40.2	39.6
Goods Transferred at a Point in Time | Medical
Disaggregation of Revenue [Line Items]
Net sales	0.0			2.4
Goods Transferred Over Time
Disaggregation of Revenue [Line Items]
Net sales	3.9	3.1	8.8	11.6
Goods Transferred Over Time | Automotive
Disaggregation of Revenue [Line Items]
Net sales	3.9	3.1	8.8	11.6
North America
Disaggregation of Revenue [Line Items]
Net sales	102.7	115.0	361.8	373.9
North America | Automotive
Disaggregation of Revenue [Line Items]
Net sales	51.8	56.7	187.8	194.4
North America | Industrial
Disaggregation of Revenue [Line Items]
Net sales	38.6	45.6	133.8	137.6
North America | Interface
Disaggregation of Revenue [Line Items]
Net sales	12.3	12.7	40.2	39.6
North America | Medical
Disaggregation of Revenue [Line Items]
Net sales		0.0		2.3
EMEA
Disaggregation of Revenue [Line Items]
Net sales	97.3	89.5	311.2	285.3
EMEA | Automotive
Disaggregation of Revenue [Line Items]
Net sales	55.9	52.0	181.7	153.9
EMEA | Industrial
Disaggregation of Revenue [Line Items]
Net sales	41.4	37.5	129.5	131.4
Asia
Disaggregation of Revenue [Line Items]
Net sales	39.9	55.0	118.0	178.0
Asia | Automotive
Disaggregation of Revenue [Line Items]
Net sales	8.0	31.0	26.5	104.0
Asia | Industrial
Disaggregation of Revenue [Line Items]
Net sales	$ 31.9	24.0	$ 91.5	73.9
Asia | Medical
Disaggregation of Revenue [Line Items]
Net sales		$ 0.0		$ 0.1

XML

Disposition - Narrative (Details) - Dabir Business $ in Millions	12 Months Ended
	Apr. 27, 2024 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration from sale of business	$ 1.5
Loss on the sale of business, including transaction costs	$ (0.6)

XML

Income Taxes - Schedule of Income before Income Taxes, Income Tax Expense and Effective Income Tax Rate (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024
Income Tax Disclosure [Abstract]
Pre-tax loss	$ (8.2)	$ (10.5)	$ (19.7)	$ (65.0)
Income tax expense	$ 6.2	$ 1.1	$ 14.6	$ 1.0
Effective tax rate	(75.60%)	(10.50%)	(74.10%)	(1.50%)

XML

Income Taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024	Apr. 27, 2024
Income Tax Disclosure [Abstract]
Income tax at statutory rate	21.00%	21.00%	21.00%	21.00%
Deferred tax assets, valuation allowance available to income tax expense	$ 6.5		$ 14.0
Global minimum tax, threshold percentage			15.00%
Gross unrecognized income tax benefits	4.5		$ 4.5		$ 4.4
Income tax penalties and interest accrued	$ 0.6		$ 0.6		$ 0.4

XML

Balance Sheet Components - Cash and Cash Equivalents - Narrative (Details) - USD ($) $ in Millions	Feb. 01, 2025	Apr. 27, 2024
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents	$ 103.8	$ 161.5
Money Market Accounts
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents	$ 0.2	$ 73.2

XML

Balance Sheet Components - Accounts Receivable and Allowance for Doubtful Accounts - Narrative (Details) - USD ($) $ in Millions	Feb. 01, 2025	Apr. 27, 2024
Inventory, Net, Items Net of Reserve Alternative [Abstract]
Allowance for doubtful accounts receivable	$ 2.7	$ 1.4

XML

Balance Sheet Components - Summary of Inventories (Details) - USD ($) $ in Millions	Feb. 01, 2025	Apr. 27, 2024
Inventory, Net, Items Net of Reserve Alternative [Abstract]
Finished products	$ 47.1	$ 45.6
Work in process	24.1	16.1
Raw materials	147.6	124.5
Total inventories	$ 218.8	$ 186.2

XML

Balance Sheet Components - Assets held for sale - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024
Balance Sheet Components [Abstract]
Non-core real estate assets, aggregate carrying value	$ 2.0
Gain on sale of assets	$ 0.3	$ (0.6)

XML

Balance Sheet Components - Property, Plant and Equipment - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024	Apr. 27, 2024
Property Plant And Equipment [Line Items]
Depreciation	$ 8.3	$ 8.8	$ 24.9	$ 25.3
Capital expenditures recorded in accounts payable			$ 2.3		$ 6.1
Minimum | Buildings and Building Improvements
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful life	5 years		5 years
Minimum | Machinery and Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful life	3 years		3 years
Maximum | Buildings and Building Improvements
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful life	40 years		40 years
Maximum | Machinery and Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful life	15 years		15 years

XML

Balance Sheet Components - Property, Plant and Equipment (Details) - USD ($) $ in Millions	Feb. 01, 2025	Apr. 27, 2024
Property Plant And Equipment [Line Items]
Total property, plant and equipment, gross	$ 545.2	$ 546.8
Less: accumulated depreciation	(336.6)	(334.7)
Property, plant and equipment, net	208.6	212.1
Land
Property Plant And Equipment [Line Items]
Total property, plant and equipment, gross	3.3	3.3
Buildings and Building Improvements
Property Plant And Equipment [Line Items]
Total property, plant and equipment, gross	98.4	98.5
Machinery and Equipment
Property Plant And Equipment [Line Items]
Total property, plant and equipment, gross	395.4	394.6
Construction In Progress
Property Plant And Equipment [Line Items]
Total property, plant and equipment, gross	$ 48.1	$ 50.4

XML

Balance Sheet Components - Pre-production Tooling Costs Related to Long-term Supply Arrangements - Narrative (Details) - USD ($) $ in Millions	Feb. 01, 2025	Apr. 27, 2024
Preproduction Tooling Costs Relatedto Longterm Supply Arrangements [Abstract]
Pre-production costs	$ 40.0	$ 44.1
Preproduction costs related to long-term supply arrangements, asset for molds dies and tools owned	$ 12.5	$ 14.0

XML

Goodwill and Other Intangible Assets - Schedule of Summary of the Changes in the Carrying Amount of Goodwill by Segment (Details) $ in Millions	9 Months Ended
	Feb. 01, 2025 USD ($)
Goodwill [Line Items]
Beginning balance	$ 169.9
Foreign currency translation	(2.5)
Ending balance	$ 167.4

XML

Goodwill and Other Intangible Assets - Summary of Goodwill by Reporting Unit (Details) - USD ($) $ in Millions	Feb. 01, 2025	Apr. 27, 2024
Goodwill [Line Items]
Goodwill	$ 167.4	$ 169.9
Grakon Industrial
Goodwill [Line Items]
Goodwill	123.2	124.4
Nordic Lights
Goodwill [Line Items]
Goodwill	42.6	43.9
Other
Goodwill [Line Items]
Goodwill	$ 1.6	$ 1.6

XML

Goodwill and Other Intangible Assets - Narrative (Details) $ in Millions	3 Months Ended	9 Months Ended
	Oct. 28, 2023 USD ($) ReportingUnit	Jan. 27, 2024 USD ($)
Goodwill [Line Items]
Goodwill impairment		$ 56.5
Automotive
Goodwill [Line Items]
Goodwill impairment	$ 56.5	$ 56.5
Number of reporting units | ReportingUnit	2

XML

Goodwill and Other Intangible Assets - Schedule of Other Intangible Assets, Net (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Feb. 01, 2025	Apr. 27, 2024
Finite-lived Intangible Assets [Roll Forward]
Gross	$ 377.4	$ 381.9
Accumulated Amortization	(143.5)	(127.0)
Net/Total	233.9	254.9
Other intangible assets, gross	379.2	383.7
Other intangible assets, accumulated amortization	(143.5)	(127.0)
Other intangible assets, net	235.7	256.7
Unamortized Trade Name
Finite-lived Intangible Assets [Roll Forward]
Gross	1.8	1.8
Net	1.8	1.8
Customer Relationships and Agreements
Finite-lived Intangible Assets [Roll Forward]
Gross	303.0	306.6
Accumulated Amortization	(96.5)	(84.7)
Net/Total	$ 206.5	$ 221.9
Weighted average remaining useful life (years)	14 years 2 months 12 days	14 years 9 months 18 days
Trade Names, Patents and Technology Licenses
Finite-lived Intangible Assets [Roll Forward]
Gross	$ 74.4	$ 75.3
Accumulated Amortization	(47.0)	(42.3)
Net/Total	$ 27.4	$ 33.0
Weighted average remaining useful life (years)	6 years 6 months	6 years 10 months 24 days

XML

Goodwill and Other Intangible Assets - Schedule of Estimated Aggregate Amortization Expense of Intangible Assets (Details) - USD ($) $ in Millions	Feb. 01, 2025	Apr. 27, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2025	$ 5.7
2026	22.3
2027	21.6
2028	19.3
2029	18.1
Thereafter	146.9
Net/Total	$ 233.9	$ 254.9

XML

Derivative Instruments and Hedging Activities - Narrative Information (Details) € in Millions, $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Dec. 31, 2024 USD ($)	Feb. 01, 2025 USD ($)	Jan. 27, 2024 USD ($)	Feb. 01, 2025 USD ($)	Jan. 27, 2024 USD ($)	Feb. 01, 2025 EUR (€)	Dec. 18, 2024 USD ($)	Apr. 27, 2024 USD ($)
Derivatives, Fair Value [Line Items]
Gains on derivative		$ (0.1)	$ (0.0)	$ 0.4	$ 1.1
Euro-denominated long-term borrowings under amended credit agreement as net investment hedge | €						€ 275.0
Euro-denominated long-term borrowings designated as a net investment hedge, gains (losses), net of tax		7.7	(5.9)	4.8	1.4
Cumulative gain associated with net investment hedge reported in AOCI		9.0		$ 9.0			$ 9.0	$ 4.2
Interest Rate Swap
Derivatives, Fair Value [Line Items]
Derivative, maturity date				Oct. 31, 2027
Derivative, notional amount		137.0		$ 137.0		132.0
Foreign Exchange Forward
Derivatives, Fair Value [Line Items]
Derivative, notional amount		152.8		152.8				$ 110.9
Gain (loss) on foreign currency derivatives recorded in earnings, net		(4.7)	$ 0.6	(4.2)	$ (2.1)
Cross-Currency Swap | Fixed Rate | Derivatives Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Derivative, notional amount		$ 60.0		$ 60.0		€ 54.8
Gains on derivative	$ 3.1

XML

Derivative Instruments and Hedging Activities - Schedule of Derivative Instruments Effect on Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024
Derivative Instruments, Gain (Loss) [Line Items]
Gross amounts recorded in other comprehensive income (loss) Net	$ 2.7	$ (2.8)	$ (0.8)	$ (4.3)
Net Investment Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Gross amounts recorded in other comprehensive income (loss) Net	2.6	0.3	1.8	1.5
Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Gross amounts recorded in other comprehensive income (loss) Net	$ 0.1	$ (3.1)	$ (2.6)	$ (5.8)

XML

Derivative Instruments and Hedging Activities - Schedule of Fair Value of Derivative Instruments Classified as Level 2 Within Fair Value Recorded in the Condensed Consolidated Balance Sheet (Details) - Level 2 - USD ($) $ in Millions	Feb. 01, 2025	Apr. 27, 2024
Derivatives Designated as Hedging Instruments | Net Investment Hedges | Prepaid Expenses and Other Current Assets
Derivative Instruments, Gain (Loss) [Line Items]
Fair value of derivative instruments assets (liabilities) net	$ 0.0	$ 1.3
Derivatives Designated as Hedging Instruments | Interest Rate Swap | Other Long-term Liabilities
Derivative Instruments, Gain (Loss) [Line Items]
Fair value of derivative instruments assets (liabilities) net	(4.7)	(2.1)
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Forward | Other Accrued Liabilities
Derivative Instruments, Gain (Loss) [Line Items]
Fair value of derivative instruments assets (liabilities) net	$ (0.8)	$ (0.2)

XML

Debt - Summary of Debt (Details) - USD ($) $ in Millions	Feb. 01, 2025	Apr. 27, 2024
Debt Instrument [Line Items]
Unamortized debt issuance costs	$ (3.4)	$ (3.6)
Total debt	327.9	330.9
Less: current maturities	(0.2)	(0.2)
Long-term debt	327.7	330.7
Revolving Credit Facility
Debt Instrument [Line Items]
Debt	330.0	333.0
Other Debt
Debt Instrument [Line Items]
Debt	1.3	$ 1.5
Less: current maturities	$ (0.2)

XML

Debt - Revolving Credit Facility/Term Loan (Details) € in Millions, $ in Millions			9 Months Ended
	Jul. 09, 2024 USD ($)	Oct. 31, 2022 USD ($)	Feb. 01, 2025 USD ($)	Feb. 01, 2025 EUR (€)	Jul. 08, 2024 USD ($)
Debt Instrument [Line Items]
Partial write-off of unamortized debt issuance costs			$ 1.2
Debt issuance costs			1.8
Revolving Credit Facility | Nordic Lights
Debt Instrument [Line Items]
Euro-denominated outstanding borrowings under revolving credit facility			$ 285.0
Revolving Credit Facility | Euro denominated borrowings
Debt Instrument [Line Items]
Interest rate (as a percent)			0.70%	0.70%
Revolving Credit Facility | Euro denominated borrowings | Nordic Lights
Debt Instrument [Line Items]
Euro-denominated outstanding borrowings under revolving credit facility | €				€ 275.0
Revolving Credit Facility | US dollar borrowings
Debt Instrument [Line Items]
Interest rate (as a percent)			7.40%	7.40%
Revolving Credit Facility | US dollar borrowings | Nordic Lights
Debt Instrument [Line Items]
Euro-denominated outstanding borrowings under revolving credit facility			$ 45.0
Line of credit | Bank of America, N.A., and Wells Fargo Bank, N.A. [Member] | Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 750.0				$ 500.0
Consolidated leverage ratio	3
Cash on hand	$ 65.0
Line of credit | Bank of America, N.A., and Wells Fargo Bank, N.A. [Member] | Revolving Credit Facility | U.S. Subsidiaries
Debt Instrument [Line Items]
Percentage of stock of subsidiaries to grant a security interest	100.00%
Line of credit | Bank of America, N.A., and Wells Fargo Bank, N.A. [Member] | Revolving Credit Facility | Foreign Subsidiaries
Debt Instrument [Line Items]
Percentage of stock of subsidiaries to grant a security interest	65.00%
Line of credit | Bank of America, N.A., and Wells Fargo Bank, N.A. [Member] | Secured Multicurrency Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 500.0
Line of credit | Bank of America, N.A. | Revolving Credit Facility
Debt Instrument [Line Items]
Leverage ratio on pro forma basis		3
Credit agreement termination date		Oct. 31, 2027
Partial write-off of unamortized debt issuance costs			1.2
Debt issuance costs			$ 1.8
Line of credit | Bank of America, N.A. | Revolving Credit Facility | Base Rate | Maximum
Debt Instrument [Line Items]
Adjusted interest rate	1.75%
Line of credit | Bank of America, N.A. | Revolving Credit Facility | Base Rate | Minimum
Debt Instrument [Line Items]
Adjusted interest rate	0.375%
Line of credit | Bank of America, N.A. | Revolving Credit Facility | SOFR Daily Floating Rate Loans | Maximum
Debt Instrument [Line Items]
Adjusted interest rate	2.75%
Line of credit | Bank of America, N.A. | Revolving Credit Facility | SOFR Daily Floating Rate Loans | Minimum
Debt Instrument [Line Items]
Adjusted interest rate	1.375%
Line of credit | Bank of America, N.A. | Revolving Credit Facility | Euro Interbank Offered Rate Plus | Maximum
Debt Instrument [Line Items]
Adjusted interest rate	2.75%
Line of credit | Bank of America, N.A. | Revolving Credit Facility | Euro Interbank Offered Rate Plus | Minimum
Debt Instrument [Line Items]
Adjusted interest rate	1.375%
Term loan | Bank of America, N.A. | Revolving Credit Facility
Debt Instrument [Line Items]
Increase in revolving commitments		$ 250.0

XML

Debt - Other Debt (Details) $ in Millions	6 Months Ended
	Nov. 02, 2024 Note	Feb. 01, 2025 USD ($)	Apr. 27, 2024 USD ($)
Debt Instrument [Line Items]
Number of notes | Note	1
Debt, short-term		$ 0.2	$ 0.2
Other Debt
Debt Instrument [Line Items]
Weighted-average interest rate (as a percent)	1.80%
Debt, short-term		$ 0.2

XML

Shareholders' Equity - Share Repurchase Program (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		46 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jun. 13, 2024	Jun. 16, 2022
Equity Class Of Treasury Stock [Line Items]
Shares purchased	0	130,592	136,000	453,371
2021 Buyback Program
Equity Class Of Treasury Stock [Line Items]
Shares purchased	0		136,000		3,553,961
Stock repurchase cost					$ 134.6
2024 Buyback Program
Equity Class Of Treasury Stock [Line Items]
Shares purchased			0
Remaining authorized repurchase amount	$ 200.0		$ 200.0		$ 200.0
Maximum | 2021 Buyback Program
Equity Class Of Treasury Stock [Line Items]
Stock repurchase program, Authorized amount							$ 200.0
Maximum | 2024 Buyback Program
Equity Class Of Treasury Stock [Line Items]
Stock repurchase program, Authorized amount						$ 200.0

XML

Shareholders' Equity - Summary of Activity under 2021 Buyback Program (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024
Share-Based Payment Arrangement [Abstract]
Shares purchased	0	130,592	136,000	453,371
Average price per share	$ 0	$ 22.99	$ 11.55	$ 23.73
Total cost	$ 0.0	$ 3.0	$ 1.6	$ 10.8

XML

Shareholders' Equity - Dividends (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cash dividends	$ 5.3	$ 4.9	$ 15.3	$ 15.0
RSAs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cash dividends	$ 0.6		$ 0.8	$ 0.4

XML

Shareholders' Equity - Summary of Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	$ 738.3	$ 844.9	$ 766.0	$ 941.8
Other comprehensive income (loss)	(10.6)	8.9	(13.3)	(12.9)
Tax expense (benefit)	(2.9)	2.8	(1.2)	0.7
Other comprehensive (loss) income	(13.5)	11.7	(14.5)	(12.2)
Ending balance	704.3	835.0	704.3	835.0
Currency Translation Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(34.9)	(42.5)	(36.5)	(19.8)
Other comprehensive income (loss)	(13.3)	11.7	(12.5)	(8.6)
Tax expense (benefit)	(2.2)	2.0	(1.4)	(0.4)
Other comprehensive (loss) income	(15.5)	13.7	(13.9)	(9.0)
Ending balance	(50.4)	(28.8)	(50.4)	(28.8)
Derivative Instruments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(2.8)	(0.4)	(0.2)	0.8
Other comprehensive income (loss)	2.7	(2.8)	(0.8)	(4.3)
Tax expense (benefit)	(0.7)	0.8	0.2	1.1
Other comprehensive (loss) income	2.0	(2.0)	(0.6)	(3.2)
Ending balance	(0.8)	(2.4)	(0.8)	(2.4)
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(37.7)	(42.9)	(36.7)	(19.0)
Other comprehensive (loss) income	(13.5)	11.7	(14.5)	(12.2)
Ending balance	$ (51.2)	$ (31.2)	$ (51.2)	$ (31.2)

XML

Shareholders' Equity - General (Details) - 2022 Incentive Plan - shares	9 Months Ended
	Feb. 01, 2025	Sep. 14, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for award (in shares)	3,600,000	5,550,000
Stock-based compensation, description	the number of shares of the Company's common stock that will be available for all awards under the 2022 Plan is 5,550,000, less an amount to reflect shares, options or other awards granted under prior plans after April 30, 2022. As of February 1, 2025, there were approximately 3.6 million shares available for award under the 2022 Plan.

XML

Shareholders' Equity - Narrative (Details) - USD ($)	9 Months Ended
	Feb. 01, 2025	Feb. 04, 2025
RSAs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares granted in period (in shares)	710,349
Additional stock issuable, shares	355,175
Unrecognized stock-based compensation cost	$ 20,500,000
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation cost	$ 4,800,000
Weighted average period expected for recognition	1 year 3 months 18 days
Deferred RSU's	85,553
Shares granted	326,244
Shares awarded in exchange for cash bonuses	160,401
Employee related liabilities current reclassified	$ 2,100,000
Additional incremental expense to be recognized	0
RSUs | Subsequent Event
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Deferred RSU's		60,875
PSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation cost	$ 2,500,000
Weighted average period expected for recognition	3 years
Vesting period	3 years
Shares granted	208,661
Minimum | RSAs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage	0.00%
Minimum | PSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares to be issued, percentage	0.00%
Maximum | RSAs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage	100.00%
Maximum | RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	5 years
Maximum | PSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares to be issued, percentage	200.00%

XML

Shareholders' Equity - Summary of Restricted Stock Awards and Restricted Stock Units Activity (Details)	9 Months Ended
	Feb. 01, 2025 $ / shares shares
RSAs | Management | 2020 EBITDA Maximum Performance
Shares
Non-vested Outstanding beginning balance (in shares) | shares	789,674
Awarded (in shares) | shares	0
Vested (in shares) | shares	0
Forfeited (in shares) | shares	(79,325)
Non-vested Outstanding ending balance (in shares) | shares	710,349
Weighted average grant date fair value
Weighted average grant date fair value - beginning balance (in dollars per share) | $ / shares	$ 28.81
Weighted average value, awarded (in dollars per share) | $ / shares	0
Weighted average value, vested (in dollars per share) | $ / shares	0
Weighted average value, forfeited (in dollars per share) | $ / shares	28.28
Weighted average grant date fair value - ending balance (in dollars per share) | $ / shares	$ 28.87
RSUs
Shares
Non-vested Outstanding beginning balance (in shares) | shares	941,640
Awarded (in shares) | shares	326,244
Conversion of cash bonus to RSUs | shares	160,401
Vested (in shares) | shares	(396,744)
Forfeited (in shares) | shares	(183,930)
Non-vested Outstanding ending balance (in shares) | shares	847,611
Weighted average grant date fair value
Weighted average grant date fair value - beginning balance (in dollars per share) | $ / shares	$ 26.43
Weighted average value, awarded (in dollars per share) | $ / shares	12.01
Weighted average grant date fair value, Conversion of cash bonus to RSUs(in dollars per share) | $ / shares	12.87
Weighted average value, vested (in dollars per share) | $ / shares	28.29
Weighted average value, forfeited (in dollars per share) | $ / shares	22.73
Weighted average grant date fair value - ending balance (in dollars per share) | $ / shares	$ 18.25

XML

Shareholders' Equity - Summary of the Weighted-Average Assumptions for the PSUs Granted (Details)	9 Months Ended
	Feb. 01, 2025 $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected volatility	52.40%
Risk free interest rate	4.07%
Expected term (in years)	2 years 8 months 19 days
Grant date fair value	$ 14.09

XML

Shareholders' Equity - Summary of PSU Activity (Details) - PSUs	9 Months Ended
	Feb. 01, 2025 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested Outstanding beginning balance (in shares) | shares	0
Awarded (in shares) | shares	208,661
Vested (in shares) | shares	0
Forfeited (in shares) | shares	0
Non-vested Outstanding ending balance (in shares) | shares	208,661
Weighted average grant date fair value
Weighted average grant date fair value - beginning balance (in dollars per share) | $ / shares	$ 0
Weighted average value, awarded (in dollars per share) | $ / shares	14.09
Weighted average value, vested (in dollars per share) | $ / shares	0
Weighted average value, forfeited (in dollars per share) | $ / shares	0
Weighted average grant date fair value - ending balance (in dollars per share) | $ / shares	$ 14.09

XML

Shareholders' Equity - Summary of Awards Granted to Non-employee Directors (Details) - Non-employee Directors	9 Months Ended
	Feb. 01, 2025 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested Outstanding beginning balance (in shares)	77,319
Awarded (in shares)	147,405
Issued (in shares)	(80,436)
Non-vested Outstanding ending balance (in shares)	144,288
Weighted average grant date fair value
Weighted average grant date fair value - beginning balance (in dollars per share) | $ / shares	$ 37.23
Weighted average grant date fair value, awarded (in dollars per share) | $ / shares	9.92
Weighted average grant date fair value, issued (in dollars per share) | $ / shares	10.49
Weighted average grant date fair value - ending balance (in dollars per share) | $ / shares	$ 22.8
Non-Employee Director Awards
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested Outstanding beginning balance (in shares)	0
Awarded (in shares)	56,680
Issued (in shares)	(56,680)
Non-vested Outstanding ending balance (in shares)	0
Deferred Non-Employee Director Awards
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested Outstanding beginning balance (in shares)	77,319
Awarded (in shares)	90,725
Issued (in shares)	(23,756)
Non-vested Outstanding ending balance (in shares)	144,288

XML

Shareholders' Equity - Summary of Combined Stock Option Activity and Related Information for Stock Options Granted (Details) - Employee Stock Option - USD ($) $ / shares in Units, $ in Millions	9 Months Ended	12 Months Ended
	Feb. 01, 2025	Apr. 27, 2024
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding [Roll Forward]
Outstanding - beginning balance (in shares)	8,000
Exercised (in shares)	0
Forfeited (in shares)	(8,000)
Outstanding - ending balance (in shares)	0	8,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted average exercise price, Outstanding - beginning balance (in dollars per share)	$ 37.01
Weighted average exercise price, Exercised (in dollars per share)	0
Weighted average exercise price, Forfeited (in dollars per share)	37.01
Weighted average exercise price, Outstanding - ending balance (in dollars per share)	$ 0	$ 37.01
Weighted-average life of outstanding options	0 years	2 months 12 days
Intrinsic value of outstanding options	$ 0.0	$ 0.0

XML

Shareholders' Equity - Stock-based Compensation Expense (Details) - 2014 Incentive Plan - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 1.8	$ (2.1)	$ 5.5	$ 1.8
RSUs | Management
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	1.5	(2.1)	3.5	0.2
RSUs | Deferred Non-Employee Director Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	0.0	0.0	0.9	1.0
RSUs | Non-Employee Director Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	0.0	0.0	0.6	0.6
PSUs | Management
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 0.3	$ 0.0	$ 0.5	$ 0.0

XML

Loss per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024
Earnings Per Share [Abstract]
Net loss	$ (14.4)	$ (11.6)	$ (34.3)	$ (66.0)
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Denominator for basic loss per share - weighted average shares outstanding and vested/unissued restricted stock units	35,182,166	35,327,995	35,370,099	35,562,513
Dilutive potential common shares	0	0	0	0
Denominator for diluted loss per share	35,182,166	35,327,995	35,370,099	35,562,513
Loss per share:
Basic	$ (0.41)	$ (0.33)	$ (0.97)	$ (1.86)
Loss per share:
Diluted	$ (0.41)	$ (0.33)	$ (0.97)	$ (1.86)
Number of anti-dilutive potentially issuable shares excluded from diluted common shares outstanding	1,303,187	1,319,577	1,176,069	1,463,996

XML

Loss per Share - Narrative (Details) - shares	3 Months Ended		9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024
Earnings Per Share [Abstract]
Dilutive effect of potential common shares	362,000	503,000	221,000	560,000

XML

Segment Information - Schedule of Segment Reporting Information, by Segment (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Oct. 28, 2023	Feb. 01, 2025	Jan. 27, 2024	Apr. 27, 2024
Segment Reporting Information [Line Items]
Net sales	$ 239.9	$ 259.5		$ 791.0	$ 837.2
Income (loss) from operations	(2.2)	(3.0)		(0.3)	(50.5)
Interest expense, net	5.5	5.0		16.5	12.2
Other expense (income), net	0.5	2.5		2.9	2.3
Pre-tax loss	(8.2)	(10.5)		(19.7)	(65.0)
Goodwill impairment					56.5
Identifiable assets	1,304.6			1,304.6		$ 1,403.5
Automotive
Segment Reporting Information [Line Items]
Net sales	115.7	139.7		396.0	452.3
Income (loss) from operations	(9.0)	(11.0)		(14.0)	(75.3)
Goodwill impairment			$ 56.5		56.5
Identifiable assets	592.9			592.9		592.7
Industrial
Segment Reporting Information [Line Items]
Net sales	111.9	107.1		354.8	342.9
Income (loss) from operations	22.6	18.9		63.8	68.8
Goodwill impairment					0.0
Identifiable assets	583.4			583.4		604.5
Interface
Segment Reporting Information [Line Items]
Net sales	12.3	12.7		40.2	39.6
Income (loss) from operations	2.2	1.5		8.8	5.4
Goodwill impairment					0.0
Identifiable assets	66.6			66.6		67.1
Medical
Segment Reporting Information [Line Items]
Net sales	0.0	0.0		0.0	2.4
Income (loss) from operations	0.0	(0.1)		0.0	(3.0)
Goodwill impairment					0.0
Identifiable assets	0.0			0.0		0.2
Eliminations/Corporate
Segment Reporting Information [Line Items]
Net sales	0.0	0.0		0.0	0.0
Income (loss) from operations	(18.0)	(12.3)		(58.9)	(46.4)
Goodwill impairment					0.0
Identifiable assets	61.7			61.7		$ 139.0
Operating Segments
Segment Reporting Information [Line Items]
Net sales	239.9	259.5		791.0	837.2
Operating Segments | Automotive
Segment Reporting Information [Line Items]
Net sales	120.1	142.4		404.9	461.5
Operating Segments | Industrial
Segment Reporting Information [Line Items]
Net sales	119.3	117.1		375.8	367.7
Operating Segments | Interface
Segment Reporting Information [Line Items]
Net sales	12.3	12.7		40.2	39.7
Operating Segments | Medical
Segment Reporting Information [Line Items]
Net sales	0.0	0.0		0.0	2.4
Operating Segments | Eliminations/Corporate
Segment Reporting Information [Line Items]
Net sales	(11.8)	(12.7)		(29.9)	(34.1)
Transfers between Segments
Segment Reporting Information [Line Items]
Net sales	0.0	0.0		0.0	0.0
Transfers between Segments | Automotive
Segment Reporting Information [Line Items]
Net sales	(4.4)	(2.7)		(8.9)	(9.2)
Transfers between Segments | Industrial
Segment Reporting Information [Line Items]
Net sales	(7.4)	(10.0)		(21.0)	(24.8)
Transfers between Segments | Interface
Segment Reporting Information [Line Items]
Net sales	0.0	0.0		0.0	(0.1)
Transfers between Segments | Medical
Segment Reporting Information [Line Items]
Net sales	0.0	0.0		0.0	0.0
Transfers between Segments | Eliminations/Corporate
Segment Reporting Information [Line Items]
Net sales	$ 11.8	$ 12.7		$ 29.9	$ 34.1

XML

Contingencies - Narrative (Details) - USD ($) $ in Millions	Aug. 05, 2024	Apr. 23, 2024	Mar. 02, 2020
Loss Contingencies [Line Items]
Affirmed final judgment amount	$ 22.5	$ 22.5
Infringing U S Sales under the Lanham Act [Member]
Loss Contingencies [Line Items]
Affirmed final judgment amount	$ 0.3
Settled Litigation [Member]
Loss Contingencies [Line Items]
Affirmed final judgment amount		$ 113.0
Compensatory Damages
Loss Contingencies [Line Items]
Gain Contingency, Unrecorded Amount			$ 102.0
Punitive Damages
Loss Contingencies [Line Items]
Gain Contingency, Unrecorded Amount			$ 11.0

XML

Restructuring and Asset Impairment Charges - Schedule of Components of Restructuring and Asset Impairment Charges (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024
Restructuring Cost And Reserve [Line Items]
Restructuring and asset impairment charges	$ 0.0	$ 0.1	$ 0.7	$ 1.4
Employee Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring and asset impairment charges	0.0	0.0	0.3	0.7
Asset Impairment Charges
Restructuring Cost And Reserve [Line Items]
Restructuring and asset impairment charges	$ 0.0	$ 0.1	$ 0.4	$ 0.7

XML

Restructuring and Asset Impairment Charges - Schedule of Restructuring and Asset Impairment Charges by Reportable Segment (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Feb. 01, 2025	Jan. 27, 2024	Feb. 01, 2025	Jan. 27, 2024
Restructuring Cost And Reserve [Line Items]
Restructuring and asset impairment charges	$ 0.0	$ 0.1	$ 0.7	$ 1.4
Cost of Products Sold
Restructuring Cost And Reserve [Line Items]
Restructuring and asset impairment charges	0.0	0.1	0.4	0.9
Selling and Administrative Expenses
Restructuring Cost And Reserve [Line Items]
Restructuring and asset impairment charges	0.0	0.0	0.3	0.5
Automotive
Restructuring Cost And Reserve [Line Items]
Restructuring and asset impairment charges	0.0	0.0	0.3	0.2
Industrial
Restructuring Cost And Reserve [Line Items]
Restructuring and asset impairment charges	0.0	0.1	0.1	0.1
Interface
Restructuring Cost And Reserve [Line Items]
Restructuring and asset impairment charges	0.0	0.0	0.0	0.0
Medical
Restructuring Cost And Reserve [Line Items]
Restructuring and asset impairment charges	0.0	0.0	0.0	1.1
Eliminations/Corporate
Restructuring Cost And Reserve [Line Items]
Restructuring and asset impairment charges	$ 0.0	$ 0.0	$ 0.3	$ 0.0

XML

Restructuring and Asset Impairment Charges - Narrative (Details) - USD ($) $ in Millions	Feb. 01, 2025	Apr. 27, 2024
Restructuring and Related Activities [Abstract]
Restructuring liability	$ 0.0	$ 0.7

XML

Related Party Transactions - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Feb. 01, 2025	Feb. 01, 2025	Apr. 27, 2024
Related Party Transaction [Line Items]
Other accrued liabilities	$ 42.3	$ 42.3	$ 46.0
Accounts payable	107.7	107.7	132.4
Alix Partners
Related Party Transaction [Line Items]
Consulting services expenses	0.9	9.8
Other accrued liabilities and accounts payable	$ 0.4	$ 0.4
Other accrued liabilities			$ 1.4